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SUMMARY
Arachidonic acid (AA), after it is released from cell membrane phospholipids, 
may be metabolized by the cyclo-oxygenase (CO) enzyme leading to formation of the 
prostaglandins (PG’s) and thromboxanes (TX’s) or by the 5-lipoxygenase (5-LO) leading 
to formation of the leukotrienes (LT’s). These metabolites are collectively known as 
eicosanoids. The PG’s,especially PGE2 and PGI2 (prostacyclin) have important roles in 
the development of the cardinal signs of inflammation including erythema, oedema and 
pain. However, PGE2 and PGI2 can also have anti-inflammatory actions.
Thromboxane A2 (TXA2 ) is a vasoconstrictor and a potent inducer of platelet 
aggregation while PGI2 is a vasodilator and a potent inhibitor of platelet aggregation. The 
balance between TXA2 synthesis by platelets and PGI2 synthesis by vascular 
endothelium is thought to be an important mechanism in haemostasis while an imbalance 
is thought to play a role in the development of some disease states.
Leukotriene B4 (LTB4 ) is thought to mediate leukocyte behaviour during the 
inflammatory response since it is a potent chemokinetic and chemotactic agent for 
polymorphonuclear leukocytes (PMN’s) and also induces adhesion, aggregation and 
degranulation of PMN’s.
Although the individual properties of PGI2 , TXA2 and LTB4 are well recognized, 
their precise role in specific inflammatory diseases is often not known, although such 
information may facilitate the development of effective treatments. The remit of this 
thesis was to use available methodology (although not uncritically), to measure levels of 
these mediators in several inflammatory disease states and to examine some other aspects 
of their participation, with a view to assessing their role in these conditions. The effect of 
various therapies on production of these mediators, both in vitro and ex vivo was also 
examined.
The studies reported in Chapter 5 looked at the role of eicosanoids in some 
inflammatory vascular diseases. Theories regarding the pathogenesis of Raynaud’s 
phenomenon (RP) and approaches to it’s treatment have been numerous. This work has
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shown that in RP secondary to progressive systemic sclerosis (PSS), plasma levels of 
PGl2-metabolites were unexpectedly elevated. Furthermore, the platelet sensitivity to 
iloprost (a stable analogue of PGI2) in these patients was shown to be decreased, but was 
normalized after PG therapy. The beneficial effect of PGl2/iloprost infusion in PSS may 
therefore be considered as overcoming platelet resistance to PGI2 rather than 
supplementing an inadequate production of PGI2 .
The production of LTB4 from stimulated PMN’s of patients with RP secondary to 
PSS and vibration-induced white finger (VWF) was also shown to be increased. The 
relevance of this observation to the development of vasospasm and vascular occlusion is 
discussed. The observation of increased levels in VWF supports the growing opinion 
that this condition is a true secondary Raynaud’s syndrome. The finding of increased 
LTB4 production in PSS suggests that cellular resistance to the inhibitory effects of PGI2 
may be a generalized phenomenon in this condition.
A recent advent in the treatment of RP has been the use of iloprost. The effect of 
transdermal iloprost on LTB4 production from PMN’s of normal volunteers and 
Raynaud’s patients was investigated. It was concluded that iloprost had some inhibitory 
effect on LTB4 production, but that it’s anti-platelet and vasodilatory effects may be more 
important in RP. The possibility that some of the beneficial effects of ketanserin (a 
serotonin antagonist) and stanozalol (an enhancer of fibrinolysis) in RP could be due to 
an effect on PMN LTB4 production was also examined.
Henoch-Schonlein purpura (HSP) is a type of childhood vasculitis. Results are 
presented which show that plasma from these patients has a diminished or absent ability 
to support vascular PGI2 generation. Further experiments were undertaken to determine 
whether this was due to reduced stimulation of PGI2 synthesis or active inhibition.
Chapter 6  examined LTB4 production in rheumatoid arthritis (RA) and psoriatic 
arthritis (PA). It was found that isolated PMN’s from RA patients had an increased 
capacity to produce LTB4 and that this was not secondary to non-steroidal anti­
inflammatory drug (NSAID) therapy. Weak but significant correlations were found
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between LTB4 and markers for joint disease activity. Likewise, an increased capacity for 
LTB4 production was observed in PMN’s from PA patients. The relevance of this to 
both the skin and joint manifestations of the disease is discussed. No significant 
correlation of LTB4 with either skin of joint indices of disease activity was observed. It 
was concluded from these observations that LTB4 is unlikely to be an initiating, causal 
factor in chronic inflammatory conditions, but that it’s inhibition could, nevertheless 
produce an improvement in inflammatory symptoms.
A relatively new approach to anti-inflammatory therapy is the dietary manipulation 
of essential fatty acid (EFA’s) leading to the endogenous production of PG and LT 
analogues with diminished inflammatory activity. Results of two double-blind, placebo- 
controlled studies with Evening primrose oil (EPO) (a source of di-homo-y-linolenic acid) 
and fish oil (a source of eicosapentaenoic acid) in the treatment of RA and PA are 
presented in Chapter 7. These dietary supplements enabled RA patients to decrease or 
stop their NS AID therapy with no deterioration in objective markers of disease activity. 
In addition, the effect of EPO and EPO/fish oil on LTB4 production from PMN’s in these 
patients was investigated. In contrast, PA patients receiving EPO/fish oil were not very 
successful in discontinuing NSAID’s although inhibitory effects on LTB4 production and 
a stabilizing effect on PGI2 and TXA2 production during attempts at NSAID withdrawal 
were observed. The potential for the treatment of chronic inflammatory disease by EFA 
manipulation, is discussed.
The statistical analyses for this thesis were carried out using “STATGRAPHICS” 
computer package on an Amstrad PC-MD computer. The tests used were the Mann- 
Whitney U test (unpaired data) and the two-tailed paired Wilcoxon test (paired data). 
Correlations were carried out using Spearman rank correlation or linear regression 
analysis. Only ‘p ’ values less than 0.05 were regarded as statistically significant.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 The Inflammatory Response
Inflammation is a complex biological process which occurs in tissues as a 
result of irritation and injury. The stimulus for this response may be chemical (for 
example, urate crystals), biological (microbial invasion) or direct physical trauma. It is 
primarily a defense mechanism, enabling fluid and white blood cells (leukocytes) to 
accumulate at the site of injury in order that the stimulus be eliminated and the tissue 
repaired. In certain circumstances however, inflammation can persist even though the 
initiating stimulus has disappeared and this can lead to tissue destruction.
The clinical features or "cardinal signs" of inflammation which were first 
noted by Celsus as early as 1 AD (Ryan & Majno, 1977) are redness, swelling, heat, pain 
and ultimately, loss of function (Table 1.1). These are the result of several underlying 
processes occurring in the soft tissue which can be divided into three major events:
(1) changes in vascular calibre and blood flow (hyperaemia), (2) increased 
vascular permeability and (3) infiltration of the tissues by polymorphonuclear leukocytes 
(PMN’s), mainly neutrophils (Wedmore and Williams, 1981).
The two vascular changes which are the hallmarks of inflammation are thus 
hyperaemia and increased vascular permeability (Walter & Israel, 1979). Arteriolar 
relaxation, mediated mainly by locally acting biochemical factors, causes blood flow to 
increase and the tissues become engorged with blood, producing redness and heat. In the 
post capillary venule, the main site of permeability change in the inflammatory response,, 
dilation is accompanied by the formation of inter-endothelial cell gaps resulting in greatly 
increased permeability to plasma and plasma proteins (Ryan & Majno, 1977). This is 
responsible for the oedema seen at inflammatory loci, the resulting increase in tissue 
tension contributing to pain at the site (Table 1.1).
26
1. REDNESS
(Rubor)
hyperaemia
2 . HEAT
(Calor)
hyperaemia
3. OEDEMA
(Tumor)
increased vascular permeability
4. PAIN
(Dolor)
irritation of pain sensitive nerve endings
5. LOSS OF FUNCTION
(Functio laesia)
Table 1.1 The cardinal signs of inflammation and their underlying causes
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The primary cellular response is the emigration of leukocytes, mainly PMN’s, 
from the small blood vessels to accumulate at the site of inflammation. Thus, after an 
initial period of increased blood flow, the flow slows and PMN's pass to the periphery of 
the stream making contact with and adhering to the vascular endothelium and each other 
(aggregation). These marginated cells extend pseudopodia which are able to disrupt the 
junction between adjacent endothelial cells enabling the leukocytes to squeeze through 
(Walter & Israel, 1979). This migration occurs by an active process known as 
chemotaxis whereby the cells are attracted across a chemical gradient by factors released 
during the course of the reaction.
On arrival at the inflammatory locus, these PMN's actively phagocytose and 
digest bacteria, damaged cells and fibrin, as well as releasing further chemotactic factors 
to recruit more leukocytes (Ryan & Majno, 1977). During phagocytic activity, 
lysosomal enzymes and toxic oxygen metabolites are released into the surrounding tissue 
fluid where they are believed to contribute to the inflammatory process (Henson & 
Johnston, 1987). Furthermore, mediators produced at the inflammatory locus enter the 
circulation to reach the haemopoetic tissues where they stimulate the proliferation and 
release of further leukocytes which, in turn, are carried to the inflamed area (Ryan & 
Majno, 1977). This process can be detected clinically as a peripheral blood leukocytosis 
showing a higher proportion of immature cells.
1.2  Pathological Inflammation
The inflammatory reaction is initiated, amplified, perpetuated and finally 
resolved by a complex series of events in the micro-environment of tissues. This process 
is regulated by a variety of chemical mediators, some derived from the circulation and 
some produced by endogenous tissue or inflammatory cells. It is evident that such a 
process must be carefully regulated; if the initiating stimulus cannot be eliminated or if the 
response persists despite elimination of the stimulus, then, mechanisms originally 
designed for host defense may themselves cause disease. This is thought to be the basis
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for the development of a chronic or pathological inflammation such as that seen in the 
rheumatoid joint (Currey, 1978).
Chronic inflammation is associated with a different cellular infiltrate than that 
seen in acute inflammation; mononuclear cells (lymphocytes and macrophages) are 
present along with the PMN's. The chronic picture is also one of more extensive tissue 
damage with resultant fibrosis and it may span a period of months or even years. The 
outcome is frequently permanent loss of function.
1.3  Inflammatory Mediators
1.3(a) General concept
Regardless of the inflammatory stimulus, the sequence of events which follow 
are always similar to the cardinal signs. This led to the realization that following injury, 
there was probably a release of endogenous substances which produced these effects.
One of the earliest mediators described was the vasoactive amine, histamine. 
Discovered by Barger and Dale in 1918, this was shown to be associated with 
anaphylactic shock (Owen, 1987). Subsequently, in 1929, Sir Thomas Lewis showed 
that injections of histamine could produce many of the features of acute inflammation and 
speculated that it could be one of the substances involved in the inflammatory process 
(Walter & Israel, 1979).
Since then, numerous factors, of diverse chemical nature, have been proposed 
as inflammatory mediators and, at present, there are around one hundred molecules which 
are claimed to influence some element(s) of inflammation. The following sections are a 
brief review of the major classes of inflammatory mediators and some of the more 
prominent mediators within them. Although the individual properties and characteristics 
of many mediators have been well elucidated, their contribution to, and precise role in 
specific inflammatory diseases is often not known. It is also important to realize that
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mediators do not work in isolation; it is their interaction which leads to the fine-tuning of 
the inflammatory process and also makes it's study so complex.
1.3 (b) Vasoactive amines
The most studied inflammatory amine is histamine. Formed by the 
decarboxylation of the amino acid histidine, it is present throughout body tissues, but is 
stored primarily in mast cells and circulating basophils (Owen, 1987). It is released in 
response to a number of stimuli including immunoglobulin E (IgE) (Austen, 1974), 
complement-derived factors C3a and C5a (Hook, Siraganian & Wahl, 1975) and direct 
physical trauma typified by the flare and weal of Lewis's triple response (Ryan & Majno,
1977).
Local administration of histamine elicits the classical vascular responses of 
acute inflammation namely, increased blood flow and content, increased vascular 
permeability and oedema formation (Owen, 1987). Although it does not have general 
leukocyte chemotactic activity it appears to be selectively chemotactic for eosinophils in 
low doses (Clark, Gallin & Kaplan, 1975).
Elucidation of the role of histamine has led to the clinical use of histamine 
antagonists to suppress inflammation associated with mast cell degranulation e.g. allergic 
rhinitis, the urticarias and asthma (Owen, 1987). However, the transient nature of the 
histamine response (Di Rosa, Giroud & Willoughby, 1971), makes it unlikely that it is 
involved in chronic inflammation.
1.3 (c) Kinins
The kinins are a family of small peptides formed in blood and body fluids by 
the action of the kallikreins on large, inactive protein precursors, the kininogens; the 
kallikreins themselves being formed from pre-kallikreins following the appropriate 
stimulus (Regoli, 1987). The concentration of kinins in blood therefore, is normally low.
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The kinins are among the most potent naturally occurring peptides and exert a 
variety of biological actions in vivo and in vitro. The best known of the kinins is the 
nonapeptide bradykinin; this causes extravascular smooth muscle contraction, 
vasodilatation, increased vascular permeability and pain (Regoli, 1987). More recently, 
kinins have been shown to stimulate collagen synthesis and proliferation of human 
fibroblasts (Goldstein & Wall, 1984). Thus, evidence is accumulating that they could be 
involved in both the acute and chronic phases of inflammation.
1.3 (d) Complement-derived peptides
The complement system consists of about twenty different proteins which, 
once the system is activated, interact in a sequential and carefully regulated series of 
reactions. Activation of this complement "cascade" can occur via two different pathways, 
the classical pathway being initiated by the binding of immunoglobulin G (IgG) and 
immunoglobulin M (IgM) to antigen (Muller-Eberhard, 1975). However, it was 
discovered at a later date that other substances, typically polysaccharides such as those 
found in yeast cell walls, could activate the so-called “alternative" pathway (Muller- 
Eberhard, 1975). It was thus realized that complement could be involved in non-immune 
inflammation and the cascade is now known to give rise to a range of vascular mediators 
and chemotactic factors (Jose, 1987).
A central event in complement activation is cleavage of fragment C3 into two 
peptide fragments C3a and C3b and, similarly, activation of the fifth component results in 
the formation of C5a and C5b (Cochrane & Muller-Eberhard, 1968). Fragments C3a and 
C5a are both anaphylatoxins since they cause mast cell degranulation with release of 
histamine and stimulate smooth muscle contraction (Hook, Siraganian & Wahl, 1975). 
In addition, the C5 fragments have potent effects on leukocytes. In vitro these include 
stimulation of aggregation, degranulation and enzyme release, chemokinesis (random 
movement) and chemotaxis (Jose, 1987). In vivo, C5 factors promote neutrophil- 
endothelial adherence and increase microvascular permeability (Williams & Jose, 1981), 
two events which are known to be closely linked (Wedmore & Williams, 1981).
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Fragment C3b is important for immune adherence and facilitates phagocytosis 
by opsonization of the pathogen (Jose, 1987). Furthermore, it increases oxidative 
metabolism and lysosomal enzyme secretion by phagocytes, thereby further enhancing 
their phagocytic and killing ability (Erhardt, 1983).
Complement is considered to be a potentially important mediator in chronic 
inflammation and complement-derived chemotactic factors have been reported in 
rheumatoid synovial fluids (Ward & Zvaiffler, 1971).
1.3(e) Reactive metabolites of oxygen
PMN's and macrophages show rapid oxygen uptake when stimulated by 
phagocytosis and when they interact with immune complexes C5a and cytokines (Blake 
et al, 1987). This "respiratory burst" is a major source of highly reactive oxygen 
metabolites including hydrogen peroxide (H2O2), superoxide anion (O2 “ ) and hydroxyl 
radical (OH*) (Babior, 1978). These unstable metabolites, which are capable of causing 
breakdown of proteins, nucleic acids and other cell components (Blake, et al, 1987) are 
presumably important for bacterial killing as part of the normal defense mechanism. 
However, tissues at sites of PMN accumulation can become targets for inappropriate free 
radical attack and radical damage has been implicated in tissue injury during inflammation 
(Henson & Johnston, 1987).
The damaging potential of these species is related to their rate of production 
and their inactivation by enzymes such as superoxide dismutase (SOD) and glutathione 
peroxidase (Dormandy, 1978). In addition, free radical "scavengers" such as vitamin E 
and thiol-containing compounds such as cysteine-rich proteins (e.g. penicillamine), have 
the potential to react with these metabolites to form a less reactive species (Blake, Allen & 
Lunec, 1987).
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1.3 (f) Cytokines
The cytokines are a group of polypeptides secreted mainly by monocytes and 
macrophages (Billingham, 1987) and have recently attracted much attention as mediators 
of inflammation and for their role in defense mechanisms in general. Many cytokine 
activities which have been independently studied for years, for example, mononuclear cell 
factor (MCF), lymphocyte activating factor (LAF) and endogenous pyrogen (EP), have 
now been shown to have overlapping chemical, physical and biological properties and are 
believed to be due to the same molecule or family of closely related molecules (Dinarello, 
1984). At a specially convened workshop in 1979 the name interleukin-1 (IL-1) was 
adopted to cover these activities and to distinguish it from another soluble product 
secreted by T-lymphocytes and named interleukin-2 (IL-2) (Aarden et a l , 1979). A vast 
literature on IL-1 has arisen in the past few years and the following review is a brief 
summary.
IL-1 is a 15,000 dalton polypeptide produced predominantly by mononuclear 
leukocytes, but also by many other cell types (Dinarello, 1984). It's synthesis requires 
appropriate cell activation and there are numerous stimuli including bacterial endotoxin, 
immune complexes and phagocytosis. The IL-1 thus secreted is made by de novo 
protein synthesis (Nordlund, Root & Wolff, 1970; Windle, Shin & Morrow, 1984) and 
has effects on a wide range of target tissues.
The list of biological properties of IL-1 is extensive (Table 1.2). It appears to 
be the initiating mediator in many host responses to infection and injury and many of its 
activities account for several aspects of the so-called "acute phase response". Thus IL-1 
induces hypoferraemia, proteinuria, increased synthesis of hepatic acute phase proteins 
and fever (Dinarello, 1984). There is evidence to suggest that IL-1 is, in fact, more 
activeat febrile temperatures (Duff, 1985). In addition, EL-1 has neutrophilia - inducing 
properties and seems likely to stimulate direct release of neutrophils from the bone 
marrow (Dale et al, 1975).
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BIOLOGICAL ACTIONS OF INTERLEUKIN-1
Fever
Hypozincaemia/hypoferraemia
Increased:
Blood neutrophils 
Hepatic acute phase proteins 
Bone resorption 
Endothelial procoagulant 
Muscle proteolysis 
Slow wave sleep
Proliferation of:
Fibroblasts 
Glial cells 
Mesangial cells
Increased:
IL-2 production 
EL-2 receptors 
Lymphokine production
Chemotaxis of neutrophils, 
monocytes and lymphocytes
Stimulation of PGE2  in: 
Hypothalamus 
Cerebral cortex 
Skeletal muscle 
Dermal fibroblast 
Synovial fibroblast 
Monocytes
Augmentation of:
T-cell responses 
B-cell responses 
NK cells
Increases in neutrophil 
enzyme release and O2
Collagenase production
Table 1.2 Biological activities attributed to interleukin - 1
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To date, there is however, limited evidence that IL-1 can induce the vascular 
permeability changes of acute inflammation. In any case, the time taken for synthesis and 
release of IL-1 (about 6  hours) precludes its involvement in early oedema formation. It 
does, however, have a chemotactic effect on both PMN and mononuclear cells (Luger et 
al, 1983) and appears to enhance adherence of PMN’s to vascular endothelium (Pohlman 
et al., 1986).
EL-1 also seems to have a role in the repair processes which accompany many 
inflammatory and infectious diseases; these include the cleaning up of dead cells and 
debris and the replacement of lost tissue. Thus, the production of degradative enzymes 
such as collagenase is stimulated (Postlethwaite et al, 1983), as is bone resorption by 
osteoclasts (Gowen et al, 1983). Fibroblast proliferation and collagen production are also 
enhanced by EL-1 (Wahl, Wahl & McCarthy, 1978). However, these properties also give 
EL-1 the potential to mediate inappropriate tissue destruction in chronic inflammatory 
disease.
Finally, IL-1 appears also to have immuno-regulatory properties and can 
augment both T and B - lymphocyte responses (Maizel et al, 1981; Falkoff et al, 1983). 
The ability of EL-1 to stimulate the proliferation response of murine thymocytes to sub- 
optimal concentrations of plant lectins is still the basis for the quantitative assay of IL-1 
and seems to occur indirectly via the production of EL-2 (Smith et al, 1980).
1.4 Arachidonic Acid as a Source of Inflammatory Mediators
The essential fatty acid (EFA), arachidonic acid (AA), is quite unique in that it 
serves as precursor for a plethora of often potent inflammatory mediators with wide- 
ranging effects, namely, the prostaglandins (PG's) and thromboxanes (TX's), 
(collectively known as prostanoids) and the leukotrienes (LT's). In 1980 the term 
"eicosanoid" was introduced (Corey et al, 1980) to cover all products of AA metabolism, 
the systemic name for AA being 5,8,11,14 eicosatetraenoic acid.
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Eicosanoids are released by mammalian cells in response to physiological, 
pharmacological or pathological stimuli and, since they are not stored within cells, 
release is immediately preceded by biosynthesis. In most tissues, fatty acids are 
incorporated into complex lipids which perform a structural role in cell membranes. In 
mammals, the bulk of AA (and other EFA's) is esterified in the fatty-acyl chains of the 
membrane phospholipid fraction (Flower & Blackwell, 1976), almost exclusively in the 
2-acyl position (Blackwell & Flower, 1983). Synthesis of eicosanoids must therefore be 
preceded by liberation of AA by the calcium-dependent enzyme phospholipase A2 (PLA2 ) 
(Flower & Blackwell, 1976), which cleaves at this position (Fig. 1.1). PLA2  thus 
becomes a potentially important regulatory enzyme for the entire eicosanoid cascade. 
Evidence for the existence of an arachidonyl-specific phospholipase however, remains 
inconclusive (Irvine, 1982).
The enzyme systems for metabolism of EFA's are, in general, shared. This 
means that the different EFA's will compete with each other (the subject of chapter 7), 
(Crawford, 1983). Three naturally occurring eicosapolyenoic acids, with increasing 
degrees of desaturation, are substrates for conversion to eicosanoids; the trienoic 
(dihomo-y-linolenic) acid, the tetraenoic (arachidonic) acid and the pentaenoic 
(eicosapentaenoic) acid. However, in most species, including man, AA is the commonest 
dietary EFA (red meat has a high content) and so its products, the dienoic PG's and the 
tetraenoic LT's usually dominate (Willis, 1981). An alternative source of AA is from 
anabolic desaturation and chain elongation of another EFA, linoleic acid, but it is now 
known that this conversion is severely rate-limited in vivo (Crawford, 1983).
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As a consequence of its predominance in mammalian biochemistry, AA and its 
metabolites are the most biologically significant and have therefore been the most studied. 
In animals, A A is metabolized by two distinct oxygenase pathways (Fig. 1.2) (Higgs et 
al, 1981). The cyclo-oxygenase (CO), which is widely distributed in mammalian cells 
(Higgs & Vane, 1983) converts AA into two cyclic endoperoxides, prostaglandin G2  
(PGG2 ) and prostaglandin H2 (PGH2 ), which serve as precursors for the formation of 
the PG's and TX's. Alternatively, AA can be metabolized by certain lipoxygenases to 
generate non-cyclised hydroperoxy derivatives. In the case of the 5-lipoxygenase (5- 
LO), the 5-hydroperoxy derivative may be further metabolized to form the LT's. Unlike 
the CO, the 5-LO is restricted mainly, but not exclusively, to inflammatory cells (Lewis & 
Austen, 1984).
The metabolites formed vary from cell to cell, depending on the distribution of 
the various enzymes involved. Thus, in platelets, AA is converted mainly to 
thromboxane A2 (TXA2 ), while in vascular endothelium, prostacyclin (PGI2 ), is the 
main metabolite. In neutrophils, leukotriene B4  (LTB4 ) is formed via the action of the 5- 
LO, although CO products such as PGI2  and TXA2  are also formed. A more detailed 
description of these pathways is given in chapters 2 and 3.
It is now known that many of the products of AA metabolism are intimately 
involved in the inflammatory process; all the PG's, TX's and LT's play a part. 
However, as this thesis specifically relates to TXA2 , PGI2  and LTB4 , emphasis has been 
given to these three substances in the following review.
1.5  Discovery of the Prostanoids
1.5(a) The classical prostaglandins
In 1930 Burr and Burr published their classic paper introducing the concept of 
the EFA's - those which had to be provided in the diet for the normal physiological 
functioning of animals and man. At around the same time, Kurzrok, a gynaecologist 
interested in artificial insemination, discovered that lipid fractions isolated from human
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semen increased uterine contraction (Kurzrok & Lieb, 1930). Unknown to the 
researchers at the time, these two areas of work were eventually to converge.
In 1935, Goldblatt attributed the biological activity in seminal plasma to a lipid 
or lipid-like substance. Von Euler (1936), who had also joined the search for the active 
principle, named it 'prostaglandin' supposing, wrongly, that it was produced by the 
prostate gland. He also reported similar activity in extracts from sheep seminal vesicles 
and proposed that the active component had the properties of a fatty acid.
It was some twenty years later (Bergstrom & Sjovali, 1957) that the first 
PG's, PGEi and P G F ia were isolated from sheep vesicular gland. However, it was
not until the advent of gas-liquid chromatography/mass spectrometry (GCMS) that their 
structure was elucidated (Bergstrom, Danielsson & Samuelsson, 1964; Van Dorp et al, 
1964). The presence of cis double bonds in the PG's led these two groups to 
simultaneously suspect and subsequently confirm, with the use of radiolabelled AA, the 
origin of the PG's in the EFA's (Bergstrom et al, 1964; Van Dorp et al, 1964).
1.5(b) Thromboxane
In 1969 Piper and Vane demonstrated the release of a previously unknown 
substance from perfused guinea-pig lungs during anaphylaxis and after infusion with AA. 
This unstable substance was potent in causing contractions of rabbit aorta and other 
smooth muscle preparations and was originally known as rabbit aorta-contracting 
substance (RCS). Since the PG endoperoxides are also unstable and contract rabbit 
aorta, it was first suggested that RCS was an endoperoxide. However, this could not 
account for all the contractile activity observed and, moreover, the endoperoxides had a 
significantly longer half-life (>5 minutes) than that of RCS (<2 minutes).
These discrepancies were resolved in 1975 with the identification of an 
extremely labile substance released from aggregating platelets (Hamberg, Svensson & 
Samuelsson, 1975). This substance had a half-life of about 30 seconds at 37°C and was 
more active than the endoperoxides in contracting rabbit aorta. It was concluded that this
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was the major constituent of RCS and, due to its ability to aggregate platelets and since its 
structure contained an oxane ring, it was named thromboxane. The unstable 
thromboxane and its stable metabolite are now known as TXA2  and TXB2  respectively.
1.5(c) Prostacyclin
Prostacyclin (PGI2 ) was first described by Moncada and Vane (1976). The 
discovery arose from experiments designed to investigate the theory that damaged blood 
vessels might produce TXA2  which could act synergistically with that produced by 
platelets. They found, however, that when microsomes from rabbit or pig aorta were 
incubated with PG endoperoxides an unstable substance was formed which inhibited 
platelet aggregation and relaxed smooth muscle, properties opposite to those of TXA2 . 
This substance was named PGX until its structure was elucidated (Johnson et al, 1976) 
when it was renamed prostacyclin. The discovery of PGI2  led Moncada & Vane to 
speculate that this substance could be responsible for the unique ability of vascular 
endothelium to resist platelet adhesion and that the TXA2 /PGI2  balance could be 
important for haemostasis in general (see chapter 2 ).
1.6  Structure and Nomenclature of the Prostanoids
The structures of some of the prostanoids are shown in Fig. 1.3. All 
prostanoids contain twenty carbon atoms arranged in a (bi) cyclic structure with two side 
chains, giving rise to the well-known "hairpin" configuration. One of these chains is 
terminated by a carboxyl group and the other by a methyl group which effectively means 
that they are cyclic fatty acids. The TX's have an oxacylohexane ring in place of the 
cyclopentane ring of the PG's and PGI2  has a double ring structure.
Depending on the configuration of this cyclic part of the molecule, prostanoids 
are divided into various PG "families", indicated by the letters A to I, and into 
thromboxanes A and B. Each of these prostanoid families consists of a 1-, a 2- and a 3- 
series, depending on the number of double bonds in their side chains. AA gives rise to 
the 2 -series (or dienoic) prostanoids.
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1.7 Discovery of the Leukotrienes
1.7(a) Leukotriene B4
The discovery of the LT's sprung from studies of the metabolism of AA in 
leukocytes. In 1976, Samuelsson and colleagues incubated ^C-labelled A A with rabbit 
peritoneal PMN’s and found that the major metabolite formed was a new lipoxygenase 
product namely, 5(S)-hydroxy-6,8,ll,14-eicosatetraenoic acid (5-HETE) (Borgeat, 
Hamburg & Samuelsson, 1976). Further studies with rabbit PMN’s showed that a 
number of other metabolites were formed, one of which was 5(S)-12(R)-dihydroxy- 
6,14-cis-8,10-trans-eicosatetraenoic acid (5,12 di-HETE) (Borgeat & Samuelsson, 
1979a). At the same time, work with human peripheral blood PMN’s showed a similar 
profile of metabolites and, furthermore, the biosynthesis of the 5,12 di-HETE was shown 
to increase dramatically when the cells were treated with the divalent cation ionophore 
A23187 (Borgeat & Samuelsson, 1979b).
Mechanistic studies and analysis of the stereochemistry involved, led to the 
hypothesis that the 5,12 di-HETE was formed via an unstable epoxide intermediate; the 
structure 5,6 oxido-7,9,ll,14-eicosatetraenoic acid was proposed and confirmed by 
chemical synthesis (Borgeat & Samuelsson, 1979c). The 5,12 di-HETE and its epoxide 
precursor were later to be known as LTB4  and leukotriene A4  (LTA4 ), respectively (Fig. 
1.2) (Samuelsson & Hammarstrom, 1980).
In 1980, a newly discovered chemotactic and cell-aggregating substance 
generated by PMN’s on stimulation with A23187 was shown to be identical to LTB4  
(Ford-Hutchison et al, 1980) and has since been shown to possess a wide range of 
biological activities (see chapter 3).
1.7 (b) Leukotrienes C4 , D4 , E4  and F4
These LT's constitute a separate class from that of LTB4 . They are, in fact, 
peptido-LT's, having one or more amino acids linked to their FA chains via a thioether
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bond at C-6 . Various mixtures of these LT's are now known to make up the so-called 
slow-reacting substance of anaphylaxis (SRS-A).
SRS-A has been recognized as a biological activity since the work of Feldberg 
& Kellaway in 1938, who identified it as a smooth muscle contracting factor secreted by 
perfused guinea-pig lung treated with cobra venom. It is now thought that SRS-A has an 
important role in asthma and other types of immediate hypersensitivity reactions (Morris 
eta l, 1980).
Structural elucidation of SRS-A had been limited due to lack of pure 
preparations. However, it had been characterized using ultraviolet (UV) absorption as a 
sulphur-containing polar lipid and radio-labelling experiments had suggested that it was 
derived from AA. In addition, the ionophore A23187 stimulated release of SRS-A from 
leukocytes. These observations led Samuelsson and colleagues to hypothesistthat there 
was a relationship between SRS-A and the lipoxygenase products formed from A A in 
leukocytes (Samuelsson, 1983). Using mouse mastocytoma cells, which they had found 
to be a good source of SRS-A and a combination of chemical derivatization, high 
performance liquid chromatography (HPLC), UV spectroscopy and amino acid sequence 
analysis, they were able to make the first complete structural determination of SRS-A 
(Murphy, Hammarstrom & Samuelsson, 1979; Hammarstrom et al, 1979). The structure 
of SRS-A from mouse mastocytoma cells was 5-hydroxy-6-S-glutathionyl-7,9,ll,14 
eicosatetraenoic acid, glutathione being a tripeptide consisting of cysteine, glycine and 
glutamic acid. This substance is now known as leukotriene C4  (LTC4 ) (Samuelsson & 
Hammarstrom, 1980).
In the same year, Morris et al (1980) identified the corresponding 
cysteinylglycine derivative, later termed leukotriene D4  (LTD4 ), as the SRS product from 
immunologically challenged guinea-pig lung. They also showed that the structure 
determined was identical to that obtained non-immunologically from rat basophil 
leukaemia (RBL-1) cells. The cysteinyl derivative, termed leukotriene E4  (LTE4 ) was
identified by Lewis et al (1980a) (Fig 1.2).
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The cysteine-containing LT's are now known to occur in a variety of different 
biological samples in various mixtures (Samuelsson, 1983) and the original premise that 
the unstable epoxide intermediate LTA4  is also the precursor of LTC4 , has been 
confirmed (Hammarstrom & Samuelsson, 1980). More recently, it has been found that 
LTE4  can function as an acceptor of y-glutamic acid forming a y-glutamyl cysteinyl 
derivative, named leukotriene F4  (LTF4 ) (Anderson, Allison & Meister, 1982).
1.8  Structure and Nomenclature of the Leukotrienes
The term "leukotriene" was first introduced in 1979 for compounds which are 
non-cyclized, C-20 carboxylic acids with one or two oxygen substituents and three 
conjugated double bonds (a conjugated triene) (Samuelsson et al, 1979). It was 
suggested at the same time that structurally different members of this group be 
distinguished by the letters A, B, C etc. LT's C to F have one or more amino acids 
linked via a thioether bond as described in the previous section.
Since other eicosapolyenoic acids (besides AA) are transformed into 
analogous structures, subscript numbers were introduced to denote the number of double 
bonds in the molecule (Samuelsson & Hammarstrom, 1980). AA gives rise to the 4- 
series or tetraenoic LT's, containing three conjugated double bonds and one isolated 
double bond (Fig 1.4). These compounds are now known, therefore, as LTB4 , C4  and
so on.
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CHAPTER 2
THE PROSTANOIDS
2.1  Biosynthesis
The first step in the biosynthesis of the prostanoids from AA is the formation, 
by the CO enzyme system, of two short-lived intermediaries, the endoperoxides, PGG2  
and PGH2 - The initial CO transformation is the insertion of two molecules of oxygen 
into the fatty acid chain forming the bicyclic endoperoxide PGG2  (Bakhle, 1983). 
However, many CO preparations contain a peroxidase activity which rapidly converts 
PGG2  to PGH2  by cleavage of the C-15 hydroperoxy group to form a hydroxyl group 
(Bakhle, 1983). This two step process was proved by Hamber g e t al., (1974) with the 
isolation, from platelets, of the two endoperoxides. The activity of the CO is dependent 
on the provision of non-esterified AA by the enzyme PLA2 . It has also been proposed 
that CO activity is sustained by the continual presence of low levels of lipid peroxide 
which act as an enzyme "promoter" (Warso & Lands, 1983).
The two endoperoxides thus formed by the CO serve as substrate for 
subsequent transformations, via various synthetase enzymes to the primary PG's (PGD2 , 
PGE2 , PGF2 a)> PGI2  and TXA2  (Fig. 2 .1). PGF2 a  however, is suspected to be a 
non-enzymatic product (Bakhle, 1983). PGI2  and TXA2  are unstable and are rapidly 
converted to the stable 6 -keto-prostaglandin F la  (6 -keto-PGFia ) and TXB2  respectively
(Johnson et a l, 1976; Hamberg et a l, 1975); these are the metabolites most commonly 
used as indices of PGI2  and TXA2  production. The endoperoxides can also be 
metabolized to a 17-carbon hydroxy acid (HHT) with the concomitant release of 
malondialdehyde (MDA).
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Fig. 2.1 Metabolism of arachidonic acid via the cyclo-oxygenase pathway : detailed 
structures and enzymes.
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2 .2  Sites of Synthesis
The CO enzyme seems to be ubiquitous, PG's being synthesized in every 
mammalian tissue with the exception of red blood cells (Samuelsson et al., 1978; Sun, 
Chapman & McGuire, 1977). Subcellularly, CO is located in the microsomes 
(Samuelsson et al., 1978). In most biological systems, more than one PG together with 
TXA2  is the normal mixture of CO products, the exact composition of the mixture 
depending on cell or tissue type and species. The best example is the synthesis of PGI2  
by vascular endothelium and TXA2  by platelets. PGI2  is the main CO product in all 
vascular preparations so far tested (Samuelsson et al., 1978). In contrast, platelets do not 
contain PGI2  synthetase and are therefore incapable of producing PGI2  (Bakhle, 1983). 
It should be noted however, that some vascular preparations such as human umbilical 
artery (Tuvemo, 1980) and cultured bovine endothelial cells (Ingerman-Wojenski et al.,
1981) can produce TXA2 .
Species differences also exist. In rat, rabbit and human lung the major CO 
product is PGI2  (Alabaster, 1980; Al-Ubaidi & Bakhle, 1980) whereas in guinea-pig 
lung it is TXA2  (Alabaster, 1980). Clearly, therefore, work done on animal models 
(guinea-pig lung has been used most frequently to study pulmonary metabolism of AA) 
cannot always be extrapolated to the human situation. Moreover, the profile of CO 
products generated in tissues is not rigid and in some cases can be changed by simply 
altering the substrate concentration. A low substrate concentration seems to favour 
production of PGI2 , whereas a high substrate concentration favours synthesis of TXA2  
(Sun etal., 1977; She etal., 1981).
All the major immuno-inflammatory cells (PMN's, monocytes, macrophages 
and lymphocytes) appear to be able to synthesize prostanoids although macrophages 
appear to be the major source (Humes et al., 1977; Morley et al., 1979). The most 
predominant products generated are TXA2  and PGE2  (Morley et al., 1979). PGI2  has 
been detected in macrophages and mast cells, but does not seem to be a significant 
product in circulating leukocytes. Stimuli for the release of PG's from leukocytes are
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many and include phagocytosis, cytokines and complement (Humes et al., 1977; Conti et 
al., 1986; Clancy & Hugli, 1985).
2 .3  Metabolism
The metabolism of CO products is usually through further oxidation and 
almost always results in marked loss of biological activity (Crutchley & Piper, 1975). 
The main deactivation enzymes are 15-hydroxyprostaglandin dehydrogenase (PGDH) 
and A*3 prostaglandin reductase which catalyse the formation of dihydro-PG's (Bakhle, 
1983). PGDH is an intracellular enzyme and extracellular substrate must pass across the 
cell membrane before inactivation can occur (Bakhle, 1983). PG metabolism is rapid, 
more than 90% of PGE2  and PGF2a being inactivated in a single passage through the
pulmonary circulation (Ferreira & Vane, 1967).
PGI2 is a short-lived metabolite with a half-life of 2-3 minutes at
physiological temperature and pH (Dusting et al., 1978a), being rapidly hydrolysed to 6 - 
keto-PGFioc- However, local biological inactivation by PGDH o r  p g  reductase
may be a mechanism in vivo, the metabolites formed again being considerably less active 
than PGI2  (Whittle & Moncada, 1983). The exception is that formed in hepatic tissue, 6 - 
keto-PGEi, which possesses anti-aggregatory activity almost equipotent with that of 
PGI2  (Quilley et al., 1980).
In contrast to the primary PG's PGI2  is not inactivated in the lungs, since it is 
not a substrate for the membrane transfer process (Dusting et al., 1978b). Furthermore, 
the lung has been found by some workers to continuously release PGI2  into the arterial 
circulation (Gryglewski, Korbut & Ocetkiewicz, 1978; Hensby et al., 1979). This, 
together with the lack of pulmonary inactivation, led to the suggestion that PGI2  is a 
circulating hormone (Moncada et a l, 1978). However, other workers failed to obtain 
evidence of pulmonary production (Smith et al., 1978; Pace-Asciak et al., 1980) and in 
addition, Blair et al. (1982) have suggested that human plasma levels of PGI2  are too low 
for it to function as a circulating hormone. It is now generally accepted that PGI2  falls
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instead into the category of "local hormone", being synthesized and inactivated in the 
same tissue or group of cells.
TXA2  is also short-lived, having a half-life at body pH and temperature of 
around 30 seconds (Hamberg, Svensson & Samuelsson, 1975). Hydrolysis to the stable 
and inactive TXB2  occurs spontaneously, but may be enzyme assisted in vivo (Bakhle, 
1983). In man, 6 -oxidation is the main mechanism for TXB2  degradation, 2,3-dinor- 
TXB2  being the major urinary metabolite (Roberts et al., 1981).
2 .4  Inhibition by Aspirin
A key discovery in PG research was the finding in 1971 that drugs such as 
aspirin and indomethacin, which had been used empirically as anti-inflammatory drugs 
for many years, could selectively inhibit PG synthesis (Vane; Smith & Willis; Ferreira, 
Moncada & Vane). It was therefore proposed that this was the mode of action of these 
compounds. The mechanism of inhibition by aspirin was later shown to be the covalent 
acetylation of a lysine residue at the active site of the CO enzyme (Roth et al., 1978). 
This means that aspirin has a longer lasting effect on platelets (which cannot synthesize 
new enzyme) than on endothelial cells, which have been shown to quickly recover their 
CO activity after treatment with low dose aspirin (Jaffe & Weksler, 1979). The link 
between aspirin and the PG's has also provided a useful research tool to help elucidate the 
role of PG's in vivo.
2 .5  Biological Actions
2.5 (a) Development of the cardinal signs of inflammation.
Over the years, a substantial amount of evidence has arisen to support a role 
for the PG's in the development and maintenance of the signs and symptoms of 
inflammation. They have been demonstrated to have potent vasodilatory and hyperalgesic 
actions and, moreover, have been detected at inflammatory loci in sufficient concentration 
to cause these effects.
51
The vascular elements of the inflammatory response are hyperaemia and 
increased permeability producing redness and oedema. The E-type PG's are powerful 
vasodilators and give a long-lasting erythema following intra-dermal injection into human 
skin (Solomon, Juhlin & Kirschenbaum, 1968). PGI2  is also a potent vasodilator with 
comparable potency to PGE2  (Williams, 1979). Although PGE2  and PGI2  increase 
blood flow, PG's by themselves are poor inducers of oedema (Williams, 1979). 
However, they have been shown to potentiate the oedema-producing activity of 
bradykinin and histamine (Williams & Peck, 1977; Williams & Morley, 1973). Since 
these increase vascular permeability by contracting venular endothelial cells (Williams, 
1983), their activity is greatly enhanced by vasodilators such as PGI2 . In addition, PG's 
can synergise with other mediators of increased permeability such as complement 
fragment C5a, to cause oedema (Williams & Jose, 1981). However, C5a has a different 
mechanism of action for inducing increased vascular permeability and although the exact 
mechanism is not known, it requires the presence of PMN's. It has been shown that 
increased permeability cannot be induced by C5a in animals depleted of circulating 
PMN’s, but that responses to histamine and bradykinin remain unchanged (Wedmore & 
Williams, 1981).
The role of PG's in the provocation of pain also involves mediator synergism; 
PG's by themselves do not cause overt pain. The application of PGEi to a blister base 
(Horton, 1963) or the intradermal injection of PGE's or PGF's, both in human skin 
(Crunkhom & Willis, 1971) merely induced an area which was hyperalgesic i.e. sensitive 
to touch. However, Ferreira (1972) found that if PGEi was given before sub-dermal 
infusion of histamine or bradykinin, overt pain resulted. Histamine and bradykinin 
together could not reproduce this effect, nor could they potentiate the subsequent infusion 
of PGEi. Ferreira suggests that the sensitization of afferent pain receptors by PG's is 
responsible for this pain enhancement.
More recently, PGI2  has also been shown to invoke hyperalgesia, being 
approximately five times more potent than PGE2  in producing increased sensitivity
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following injection into rat paws (Higgs, Moncada & Vane, 1978a). However, in 
contrast to the effects of the stable PG's which produce a cumulative, long-lasting 
hyperalgesia, the effect of PGI2  is short-lived (Ferreira, Nakamura & de Abreu Castro,
1978).
Inhibition of synthesis of PG's such as PGE2  and PGI2  thus accounts for the 
reduction in erythema, oedema and hyperalgesia seen with the aspirin-like drugs 
(Moncada, Ferreira & Vane, 1973). In addition, because the PG's potentiate the actions 
of other mediators such as histamine and bradykinin, their actions are attenuated also.
Another characteristic of acute inflammation in which PG's are involved is 
elevated temperature, or fever. In this respect also, the PGE's are the most active. PGE2  
is a potent pyrogenic agent and elevated levels of PGE2  have been detected in the cerebro­
spinal fluid (CSF) taken from pyrexic patients (Saxena et al., 1979). Production of 
PGE2  is thought to account for the fever induced by IL-1  (endogenous pyrogen) and 
some anti-pyretics appear to work by preventing PG synthesis (Dinarello & Wolff,
1982).
2.5 (b) Effect on Polymorphonuclear Leukocytes
Since one of the earliest responses to tissue injury is the influx of PMN's, the 
effect of AA metabolites on PMN function has received considerable attention. Reports 
of the effects of CO products on PMN chemotaxis have often been conflicting. 
However, on the whole, any effects which have been observed are weak and species 
specific. TXB2  is chemotactic for mouse PMN's, but not for human cells (Kitchen, Boot 
& Dawson, 1978). PGEi is mildly chemotactic for rabbit PMN's (Kaley & Weiner, 
1971) and PGF2 a> although not itself chemotactic, enhances the chemotactic
responsiveness of PMN’s to other stimuli (Diaz-Perez, Goldyne & Winkelmann, 1976). 
PGE2  actually inhibits both chemotaxis and chemokinesis of human PMN’s (Goetzl & 
Gorman, 1978).
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It can be seen therefore, that the effects of PG's on cell movement in vitro are 
varied. Moreover, inhibition of PG production does not correlate with a reduction of 
leukocyte migration in vivo (Higgs et al., 1981). Indeed, in contrast to the pro- 
inflammatory effects of PG's on development of the vascular responses of inflammation, 
their effects on leukocytes seem to be mainly inhibitory. It has therefore been suggested 
that the PG's could have a negative feedback role in chronic inflammation, initially aiding 
the development of the cardinal signs followed by a later suppressant effect (Bonta & 
Pamham, 1978a).
Many reports in the early 1970's indicated that the intra-cellular concentration 
of adenosine 3’-, 5’-monophosphate (cyclic AMP; cAMP) influences leukocyte function, 
an elevation in cAMP having a generally inhibitory effect (Bourne et al., 1974). It has 
been suggested therefore, that this is the mechanism whereby E-type PG's suppress 
PMN activity and indeed, some of the effects of the PGE's can be mimicked by treating 
the cells with exogenous cAMP (Rivkin, Rosenblatt & Becker, 1975). PGI2  is a 
particularly potent stimulator of adenylate cyclase (the enzyme catalyzing the formation of 
cAMP) at low concentration (Gorman, Bunting & Miller, 1977; Tateson, Moncada & 
Vane, 1977) and has been shown to prevent PMN chemotaxis in vitro, also at low 
concentration (Weksler, Knapp & Jaffe, 1977). In addition, PGI2  prevents margination 
and adherence of PMN’s in hamster check pouch venules (Higgs, Moncada & Vane, 
1978b) and in vitro reduces PMN adherence to nylon fibres and cultured endothelial cells 
(Boxer et al., 1980). Total leukocyte numbers in inflammatory exudates are at then- 
highest when PGI2  production is at it's lowest (Higgs & Salmon, 1979), suggesting that 
PGI2  may be the most likely CO product to modulate leukocyte function.
Lysosomal enzyme release is yet another PMN function which appears to be 
inhibited by the PGE's and PGI2  via an increase in cAMP (Weissmann, Dukor & Zurier, 
1971). PGEi appears to inhibit the release of these potentially damaging enzymes both 
during phagocytosis and during PMN adherence to non-phagocytosable surfaces such as 
cartilage (Lewis, 1983). Since the PGE's and PGI2  are found in inflammatory sites in
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high enough concentration to elicit these effects, they may well modulate lysosomal 
enzyme release in vivo.
2.5 (c) Effects on Lymphocytes
A characteristic of chronic inflammation is the involvement of several different 
types of white blood cells including PMN's, macrophages and lymphocytes. In RA, for 
example, both B lymphocytes (producing antibodies) and T lymphocytes (involved in 
cell-mediated immune mechanisms) have been implicated in the pathogenesis.
As with PMN's, the effects of the PGE's and PGI2  on lymphocytes is mainly 
inhibitory. In vitro, the PGE's and PGI2  inhibit PHA-stimulated mitogenesis in 
lymphocytes (Smith, Steiner & Parker, 1971; Gordon, Henderson & Westwick, 1979). 
The E-type PG's are also recognized as inhibitors of cytokine secretion and indomethacin 
has been shown to enhance antigen-induced cytokine production from T-cells (Gordon, 
Bray & Morley, 1976).
There has been some controversy in the literature as to whether the relatively 
high doses of PG's used to achieve inhibition of lymphocyte function in vitro are 
physiologically unrealistic. As reflected by their concentration in inflammatory exudates 
however, PG's are produced locally in high concentration and may well therefore, have 
inhibitory effects on lymphocytes in vivo. In contrast, PGI2  at high concentration may 
elevate cyclic guanosine monophosphate (cGMP) rather than cAMP which would result 
in stimulatory effects (Gordon et al., 1979).
Knowledge of the PG-mediated regulation of B-lymphocyte function is 
limited. Some experiments indicate that certain concentrations of E-type PG's will 
inhibit generation of IgG and IgM antibodies (Zurier & Quagliata, 1971) while at "lower" 
doses they may stimulate production (Staite & Panayi, 1984).
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2 . 6  PGI2 /TXA2 Interaction
2.6 (a) General Concept
Since the discovery of PGI2  and TXA2 , evidence has accumulated that these 
CO products, rather than the classical PG's, may be of physiological and pathological 
importance. TXA2 , produced by platelets, is a strong contractor of large blood vessels 
and induces platelet aggregation (Hamberg et al., 1975). PGI2 , produced by vascular 
endothelium, is a strong vasodilator and the most potent inhibitor of platelet aggregation 
known (Bunting et al., 1976). Indeed, these two compounds appear to have directly 
opposing actions in many systems (Table 2 .1) and the PGI2 /TXA2  ratio is thought to be 
a potential control mechanism for both normal haemostasis and the development of some 
disease states. In particular, the PGI2/TXA2  balance has been implicated as an important 
factor in the development of various thrombotic conditions in which increased platelet 
aggregability plays a role (see section 2 .6  (f)).
PROSTACYCLIN THROMBOXANE A2
Anti-aggregatory Pro-aggregatory
Vasodilator Vasoconstrictor
Bronchodilator Bronchoconstrictor
Cytoprotective Cytodestructive
Table 2.1 Opposing actions of prostacyclin and thromboxane A2
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Fig. 2.2 Theory of Moncada and Vane.
57
2.6 (b) Effect on Platelets
In 1975, Hamberg et al. proposed that the newly discovered TXA2 , rather 
than the endoperoxides, was the platelet aggregating material contained in 'RCS'. TXA2  
is now known to be the main AA metabolite which mediates platelet aggregation and 
release. It should be noted however, that TXA2 -induced aggregation represents only one 
mechanism of platelet aggregation. Other stimulants include ADP, thrombin and collagen 
(de Gaetano, Bertele & Cerletti, 1987) each of which may be relevant in different in vivo 
situations.
In contrast, PGI2  is the most potent platelet anti-aggregating agent described, 
being more active than either PGEi or PGD2  (Gryglewski et al., 1976). In addition, 
PGI2  is capable of disaggregating platelet clumps in plasma, in vitro (Bunting et al.,
1976) and on collagen strips (Gryglewski et al., 1978).
Moncada et al. (1976) have proposed that the balance between TXA2  
synthesis in platelets and PGI2  synthesis by vascular endothelium is an important 
mechanism in haemostasis and that PGI2  enables arteries to resist platelet adhesion and 
hence, thrombus formation (Fig. 2.2). It has been demonstrated that endothelial cells 
can, in fact, utilize PG endoperoxides from platelets for PGI2  synthesis (Bunting et al.,
1976). However, this mechanism is probably not relevant under normal circumstances 
although it may play a role when the vessel wall is damaged (Needleman et al., 1978).
2.6 (c) Effect on vascular tone
As with platelet function, the directly opposing vasoactive properties of TXA2  
and PGI2  are relevant to the understanding of vascular tone and blood flow both in 
normal and pathological situations.
TXA2  is highly unstable and its vascular actions can be difficult to study. It is 
therefore usually generated when required by rapid incubation of PGH2  with platelet 
microsomes (Moncada et al., 1976). TXA2  generated in this way has been shown to
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contract numerous isolated arteries including rabbit aorta, rabbit coronary arteries, human 
umbilical artery and bovine coronary artery (Whittle & Moncada, 1983a). Studies on 
perfused vascular beds in vivo (e.g. perfused canine mesenteric and femoral vascular 
beds) have demonstrated that TXA2  causes an immediate and short-lasting 
vasoconstriction (Dusting etal., 1978).
In contrast, PGI2  relaxes most isolated vascular strips including rabbit coeliac 
and mesenteric arteries, bovine coronary artery, human and baboon cerebral arteries and 
lamb ductus arteriosus (Moncada & Vane, 1978). It is also a potent vasodilator in 
isolated perfused hearts of guinea-pig, rabbit and rat (Moncada & Vane, 1978). Because 
of its strong vasodilatory activity in many microvascular beds, PGI2  is thought to be 
involved in the control of local blood flow and in the hyperaemic responses of tissues 
such as the gastric mucosa [see section 2 .6  (e)]. The vasodilatory activity of PGI2  is also 
evident in the pulmonary and renal circulations (Moncada & Vane, 1978).
2.6 (d) Effect on the bronchopulmonary system
TXA 2  readily contracts guinea-pig airway smooth muscle in vitro and 
following intravenous administration to the anaesthetised guinea-pig (Svensson et al.,
1977). Intravenous administration of a thromboxane synthetase inhibitor or thromboxane 
receptor antagonist in guinea-pig inhibits bronchoconstriction induced by AA or 
bradykinin, but not histamine or antigen-induced constriction (Greenberg, Antonaccio & 
Steinbacher, 1982). TX's also appear to mediate a substantial component of the 
bronchoconstrictor action of SRS-A in guinea-pig lung (Piper & Samhoun, 1981). In 
human lungs however, TXA2  does not appear to be a significant CO product and 
although most work has been done on guinea-pig lung, this may not be a good model for 
pulmonary AA metabolism in humans (Al-Ubaidi & Bakhle, 1980).
PGI2  is potentially able to oppose the actions of TXA2  in the broncho­
pulmonary system both by its actions on the pulmonary vasculature and bronchial smooth
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muscle since it has been shown to relax isolated strips of tracheal, bronchial and 
bronchiolar smooth muscle (Whittle & Moncada, 1983a).
2.6 (e) Cytoprotection
PGI2  and its analogues have the ability to protect the gastro-intestinal tract 
from damage induced by noxious agents, typically the non-steroidal anti-inflammatory 
drugs (NSAID's). Although PGI2  and its analogues are potent inhibitors of gastric acid 
secretion (Whittle, 1980), the anti-ulcer properties are separate since certain PG's at doses 
which have minimal anti-secretory activity can still protect in the rat stomach (Robert et 
al., 1979). The term "cytoprotection" has thus been introduced to describe this protective 
role.
The mechanism of action of this effect is not precisely known. However, it 
seems to be related to the vasodilatory action of certain PG's in the gastric mucosa. Loss 
of this action following CO inhibition may lead to areas of local ischaemia which would 
then have lowered resistance to gastric acid and digestive enzymes leading potentially to 
ulcer formation (Whittle, 1980). The inhibition of gastric CO by NSAID's correlates 
closely with their ulcerogenicity (Whittle et al., 1980).
These effects are, again, in contrast to those of TXA2  which is pro- 
ulcerogenic. TXA2  generated in gastric arterial blood in situ in the dog is a potent 
vasoconstrictor and, in the presence of a weak topical irritant such as taurocholate (a bile 
salt), causes extensive mucosal damage and ulceration within 30 minutes exposure 
(Whittle, Kauffman & Moncada, 1981). Likewise, the TX mimetic, epoxy-methano 
endoperoxide analogue, is a potent gastric vasoconstrictor and pro-ulcerogenic agent in 
the dog (Whittle & Moncada, 1983b).
Although the cytoprotective effect of PGI2  in the gastric mucosa is the best 
documented, other areas are being explored. For example, in experimental canine liver 
transplantation, storage with PGI2  has been shown to help prevent ischaemic damage 
(Monden & Fortner, 1982). Other studies, with platelets, indicate that PGI2  stabilizes
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cell membrane phospholipids and prolongs viability during storage (Blackwell et al., 
1982).
2 .6  (f) PGI2 /TXA2  Balance in pathological conditions
Several diseases have now been related to an imbalance in the PGI2 /TXA2  
ratio. In general, in diseases where there is a tendancy for thrombosis to develop, TXA2  
is raised or PGI2  is decreased or both. The opposite is found in diseases associated with 
an increased bleeding tendancy. However, this classical picture is not always observed 
and in some types of vascular disease where inadequate production of PGI2  might have 
been predicted, increased production has been found (see section 5 .1).
In 1977 Lagarde and Dechavanne showed that platelets from patients with 
arterial thrombosis, deep vein thrombosis or recurrent venous thrombosis produce more 
PG endoperoxides and have a shortened survival time compared to normal platelets. 
Shimamoto et al. (1978) have found that platelets from rabbits made atherosclerotic 
produce more TXA2  and are more sensitive to aggregating agents than controls. Similar 
observations have been made in platelets from patients who have survived myocardial 
infarction (Szczeklik et al., 1978). Hirsh et al. (1981) have reported an increase in 
coronary sinus levels of TXA2  in patients studied within 24 hours of ischaemic chest pain 
(angina), although it is not clear whether this is cause or effect.
Diabetes, a disease associated with formation of microvascular thrombo- 
emboli, has also been studied. Harrison, Reece & Johnson (1978) have reported reduced 
PGI2  release from the aortas of diabetic rats. PGI2  production from arteries of diabetic 
patients (obtained at operation) has also been measured and is said to be lowered 
compared to non-diabetic controls (Johnson et al., 1979). In addition, Dollery et al. 
(1979) have reported that circulating levels of 6 -keto-PGFia are reduced in diabetic 
patients with proliferative retinopathy. However, there is some controversy in this area 
and other workers have shown increased circulating levels of 6 -keto-PGFia (McLaren, 
1986) and decreased plasma TXB2  in diabetics (McLaren, 1986; Carter & Jones, 1986).
61
In uraemic patients, PGI2  production from blood vessels is increased 
(Remuzzi et al., 1977). This is attributed to an increase in the uncharacterized "plasma 
factor" which stimulates vascular PGI2  synthesis and is postulated to contribute to the 
bleeding tendancy in these patients (MacIntyre, Pearson & Gordon, 1978). Conversely, 
a deficiency in this PGI2 -stimulating factor has been reported in haemolytic uraemic 
syndrome which is characterized by widespread thrombotic occlusions (Remuzzi et al., 
1978a).
Defreyn et al. (1981) have shown a link between a familial bleeding tendancy 
and a partial deficiency of platelet thromboxane synthetase. The prolonged bleeding time 
in this case seems to have occurred due to a combination of decreased TXA2  formation 
and increased PGI2  formation.
The PGI2 /TX A 2  balance also appears to have significance in various 
pathological conditions of pregnancy. For instance, reduced umbilical and placental 
vascular PGI2  has been observed in patients with severe pre-eclampsia (Remuzzi et al., 
1980) and Greer et al (1985) found that maternal plasma PGI2 -M levels dropped to 
unrecordable levels as pregnancy-induced hypertension developed.
2 .7  Interaction with other Inflammatory Mediators
2.7 (a) Introduction
Many interactions between PG's and other substances have been observed 
and several are believed to be important in the context of the inflammatory response. The 
synergism between the PG's and histamine, bradykinin and C5a and its role in the 
potentiation of oedema and pain has already been described in section 2.5(a). Interaction 
of the PG's with LT's is discussed in chapter 3.
2.7 (b) Prostaglandins and cyclic AMP
Specific binding of PG's to various cells and tissues has been correlated with 
the activation of adenylate cyclase and an increase in cAMP (Samuelsson et al., 1978).
62
Many PG effects appear to be mediated by cAMP, particularly in the case of the PGE’s 
and PGI2  (Lewis, 1983). In turn, cAMP is able to stimulate biosynthesis of PGE which 
seems to suggest a positive feedback system. The “stop” signal in this system may be the 
desensitization of adenylate cyclase to specific agonists (Samuelsson et al, 1978). Many 
PG effects appear to be mediated by cAMP, particularly in the case of the PGE's and 
PGI2  (Lewis, 1983). However, PGE actions on cell function (e.g. haemopoietic stem 
cell proliferation) which do not appear to be accompanied by alteration in cAMP levels 
have also been described (Feher & Gidali, 1974).
In platelets, inhibition of aggregation by PGI2  has been correlated with an 
activation of adenylate cyclase leading to a rise in intracellular cAMP. As the most potent 
anti-aggregator of platelets, PGI2  is also the most potent endogenous stimulator of 
adenylate cyclase (Gorman, Bunting & Miller, 1977; Tateson, Moncada & Vane, 1977) 
It is thought that elevated cAMP levels reduce platelet cytoplasmic calcium concentration 
(by stimulating removal of calcium by the dense tubular membrane system) upon which 
platelet shape change, aggregation and release reaction depend (Kaser-Glanzmann et al.,
1977).
Conversely, TXA2  and PGH2  reduce platelet intracellular cAMP levels, but 
only when these have already been raised by an adenylate cyclase stimulant such as PGEi 
(Miller, Johnson & Gorman, 1977). Basal levels of cAMP are not lowered by TXA2 .
It has also been suggested that cAMP is able to inhibit the availability of 
endogenous AA to CO in cultured cells (Hassid, 1982), providing a possible mechanism 
for negative feedback control of PGI2  synthesis.
2.7 (c) Prostaglandins and interleukin -1
The exact nature of the mechanism of action of IL-1 is unclear. However, it 
does seem to be involved with membrane perturbation and the release of AA. Chang, 
Gilman and Lewis (1986) have shown that IL-1 activates PLA2  in rabbit chondrocytes 
and that this correlates with an increase in PGE2  production. Similarly, Bemheim and
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Dinarello (1985) have shown that IL-1 can stimulate the release of PGE2  from human 
fibroblasts and Rossi et al., (1985) have demonstrated an IL-1 induced production of 
PGI2  in endothelial and vascular smooth muscle cells. Release of TXB2  by human 
PMN’s and rabbit peritoneal macrophages in response to IL-1 has also been demonstrated 
(Conti et al., 1986).
The role of CO- derived metabolites of A A in the regulation of IL-1 
production has also been examined. Kunkel and Chensue (1986) have shown that 
indomethacin causes a dose-dependent increase in IL-1 production in lipopolysaccharide 
(LPS) - stimulated murine peritoneal macrophages. In addition, a direct suppression of 
IL-1 was observed when exogenous PGE2  was added.
These findings suggest a model in which the PG’s may act as regulators of 
IL-1 production by a negative feedback mechanism. Furthermore, since macrophages 
produce both PG’s and IL-1, they may, conceivably, control lymphocyte function by 
regulating their IL-1 production via the PG’s.
2.7 (d) Prostaglandins and reactive metabolites of oxygen
Oxygen radicals are produced by the AA pathway, especially during the 
PGG2  peroxidase step. The free radical product of this reaction, probably OH’, appears 
to inactivate the CO and may therefore provide an important negative feedback role for 
PG synthesis (Blake et al., 1987). In turn, the oxidative products of free radical reaction 
with lipids, lipid peroxides, are necessary at low level to activate the CO and are therefore 
promoters of PG production (Warso & Lands, 1983). In addition, peroxides are 
important in influencing whether PGI2  or TXA2  will predominate; high peroxide levels 
selectively enhance TXA2  production by their ability to inactivate PGI2  synthetase 
(Warso & Lands, 1983).
It has recently been demonstrated however, that the PGE’s and PGI2  are able 
to inhibit radical production in stimulated neutrophils (Szezeklik et al., 1987), again
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supporting the hypothesis that the PG’s are initially pro-inflammatory, allowing increased 
radical production with later anti-inflammatory, free radical scavenging effects.
2 .8  Prostanoid Receptors
Since the various prostanoids have distinct biological actions which are often 
observed at very low (nanomolar) concentrations, it has been hypothesized that they act 
via specific cell-surface receptors. As well as being specific, binding of prostanoid to 
receptor should be saturable, reversible and comparable in time-course and concentration 
to the effect produced. Using an experimental strategy of ligand-binding measurements, 
ranking of agonist potencies and the use of specific antagonists, many such receptors for 
the PG’s in various tissues have now been at least partially characterized (Samuelsson et 
al., 1975). The work carried out on PGI2  receptors is probably that most relevant to this 
thesis.
The stimulation of adenylate cyclase by PGI2  suggests that it interacts with a 
specific, membrane-bound receptor and attempts have been made to characterize those 
via which PGI2  elicits its anti-aggregatory and vasodilatory effects. Siegl et al., (1979) 
have identified selective binding sites of ^H-PGl2  on human platelets. This binding was 
observed to be rapid (80% of PGI2  bound in 1 minute) and is comparable to the time 
taken for cAMP elevation and aggregation. In accordance with other workers (Schillinger 
& Prior, 1980), Siegl et al., have identified two distinct sub-sets of PGI2  receptor; a 
small number of high affinity sites and a larger number of lower affinity sites. It has been 
suggested that binding to the lower affinity shows more correlation with cAMP elevation 
and is more likely to be the pharmacological receptor (Siegl, 1982). The relative abilities 
of PGI2 , PGEi, PGE2  and 6 -keto-PGFia to displace ^H-PGl2  reflects their potency as 
inhibitors of platelet aggregation in vitro (Siegl et al., 1979). PGI2 , PGEi and PGE2  
appear, therefore, to share a common receptor. The exception is PGD2  which seems to 
elicit its anti-aggregatory effect via a distinct receptor (Siegl, 1982).
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Town et al., (1982) have attempted to identify the receptors which mediate the 
vasodilatory effects of PGI2  using bovine coronary arteries and the stable PGI2  
analogue, iloprost. Results are similar to those found with platelets - two receptor sub­
sets, one high affinity and one low affinity have been identified. The dissociation 
constant for the high affinity site is within the concentration range in which PGI2  and 
iloprost relax coronary arteries in vitro.
2 .9  The role of the Prostanoids in Inflammatory Disease
The finding that the PG’s were involved in the development of the signs and 
symptoms of inflammation and the discovery that anti-inflammatory drugs worked by 
inhibiting PG formation, established a role for them in acute inflammation. However, 
there have also been reports of anti-inflammatory actions for PG’s, for instance, infusion 
of PGEi appears to prevent and suppress adjuvant arthritis in rats (Zurier & Quagliata, 
1971) and PGE2  inhibits cotton pellet granuloma formation in rats (Di Pasquale et al., 
1973). In addition, in EFA-deficient rats, where PG production is markedly reduced, the 
acute phase of inflammation is attenuated, but the chronic component (tissue proliferation) 
is enhanced (Bonta, Pamham & Adolfs, 1977). This suggests that although elevated PG 
levels would initially aid the development of the cardinal signs, they could, by their later 
suppressant effects on cellular function, help to terminate the inflammatory response. A 
breakdown in this mechanism could conceivably lead to the development of chronic 
inflammation.
The presence of PG’s has been demonstrated in a wide variety of 
inflammatory exudates. Initially, the most likely source of PG’s is the injured tissue 
itself, but as inflammation proceeds, infiltrating cells, especially macrophages, become an 
important source. However, the PG concentration in inflammatory exudates does not 
always increase in parallel with the accumulation of leukocytes and, in addition, there is 
no simple correlation between the severity of the inflammation and PG levels (Bonta & 
Pamham, 1978).
6 6
In 1969 Willis reported the presence of PGE2  in carrageenin-induced exudate 
from the rat. Much of the early work was concerned with detection of the stable PG’s, 
but it is now clear that PGI2  and TXA2  are also generated at inflammatory sites. 
Comparable concentrations of TXB2  and 6 -keto-PGFiot have since been detected in 
carrageenin-induced exudates in the rat (Higgs & Salmon, 1979).
Inflammatory joint disease, in particular RA, has been used extensively as a 
model of chronic inflammatory disease; joint inflammation seems to involve most of the 
mechanisms which have been proposed on the basis of experimental studies and its 
clinical course is fairly easy to follow. Many animal models of arthritis have been studied 
with respect to PG production. Dumonde and Glynn (1962) developed a model 
resembling RA by injecting antigen into a joint in sensitized rabbits. Using this model, 
Blackham et al., (1974) showed that levels of PGE in the synovium reached a peak after 
19 hours, declining again over a chronic phase of 46 days. Floman and Zor (1976) 
showed that synovial tissue from rats with a laboratory-induced mono-arthritis released 5- 
8 times as much PGE as synovium from non-arthritic rats.
Several studies have demonstrated the presence of PG’s in synovial fluid 
withdrawn from the joints of arthritic patients; PGE2  appears to be the most prominent 
although PGEi, PGF2 a  and TXB2  have also been detected (Sturge et al., 1978; Trang,
Granstrom & Lovgren, 1977). Again, however, the PG content of synovial fluid does 
not appear to correlate with leukocyte numbers in the synovium, nor does it seem to 
parallel the clinical course of RA (Bonta & Pamham, 1978). Moreover, measurement in 
synovial fluid is subject to error due to the necessarily invasive technique used for 
collection.
PG production by cultured synovial tissue has also been measured (Sturge et 
al., 1978; Dayer et al., 1976). PGE2  and PGF2 a have both been detected and Dayer et 
al., suggest that the main cellular source is most likely to be infiltrating macrophages or 
phagocytic type-A synovial lining cells which have macrophage-like properties. Bitensky 
et al., (1981) have looked at the production of PGE2 , 6 -keto-PGFioc and TXB2  from
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both rheumatoid and non-rheumatoid synovia. However, only the TXB2  production was 
significantly greater in rheumatoid tissue.
Two important aspects of chronic inflammatory joint disease are destruction of 
cartilage and resorption of bone. Cartilage consists mainly of glycosaminoglycan, 
proteoglycan and some collagen, while bone consists of collagen fibres in a mineral 
matrix (Lewis, 1983). Both tissues therefore, are affected by levels of the enzyme 
collagenase which plays a major role in the degradation of articular cartilage and other 
joint structures (Dayer et al., 1976). Wahl et al., (1977) have demonstrated that 
indomethacin inhibits endotoxin-stimulated collagen production from macrophages in 
culture and that this can be reversed by the addition of exogenous PGEi or PGE2 .
There are many other human inflammatory diseases besides RA, in which 
PG’s are thought to have a role. In psoriasis for example, levels of free AA, PGE2  and 
P G Fia have been shown to be significantly increased in lesional epidermis compared to
un-involved epidermis (Hammarstrom et al., 1975). In the case of ulcerative colitis, 
PGE2  levels in the rectal mucosa of patients is double that found in normal controls 
(Sharon et al., 1978). In most cases however, it is far from clear whether these increased 
levels are cause or consequence of the disease.
2 .10  Inhibition of the Prostanoids and Potential for Anti- 
Inflammatory Therapy
2.10(a) Introduction
There has been a search for many years for drugs which inhibit PG’s or 
antagonize their actions. All the enzymatic conversions in the AA cascade are, in theory, 
potential points for drug intervention (Fig. 2.3). Presently, however, the non-steroid 
anti-inflammatory drugs (NSAID’s) and the corticosteroids are the two main classes of 
drugs which are used in treatment of chronic inflammatory diseases, in particular RA .
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Fig. 2.3 Therapeutic manipulation of the arachidonic acid cascade.
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2.10 (b) The non-steroidal anti-inflammatory drugs
The discovery that several NSAID’s inhibit the formation of endogenous 
PG’s provided a plausible explanation for their anti-inflammatory action. It is now 
known that these drugs selectively inhibit the CO enzyme (see section 2.4). Drugs such 
as indomethacin and aspirin have both analgesic and anti-inflammatoiy properties and in 
general there is good correlation between the order of potency of PG inhibitors and their 
anti-inflammatory effect (Higgs & Flower, 1981). However, NSAID’s only provide 
symptomatic relief and do not reverse the underlying disease process in chronic 
conditions.
Since leukocytes are a major source of PG’s in the early stages of 
inflammation, drugs which inhibit leukocyte accumulation should help to reduce PG 
levels in inflammatory exudates. There have been conflicting reports on the effects of 
NSAID’s on leukocyte accumulation, but in general, drugs such as indomethacin and the 
salicylates enhance leukocyte migration at low doses but inhibit at high doses (Higgs et 
al., 1981). These observations can be explained by diversion of AA substrate towards 
the chemotactic LO products (see chapter 3) at low doses and a non-specific inhibition of 
AA peroxidation at high doses. Substrate diversion to the LT’s may also explain why 
NSAID’s do not seem to modify the disease process in inflammation; analgesia and 
decreased oedema would result from diminished PG levels but increased LT production 
would allow the more chronic PMN-mediated components of inflammation to proceed 
unchecked.
2.10 (c) The corticosteroids
In contrast to the NSAID’s, the anti-inflammatory properties of the 
corticosteroids (e.g. hydrocortisone, dexamethasone) cannot be explained by the 
inhibition of CO or any of the other PG-generating enzymes. Instead, these appear to 
work by preventing the release of A A from the cell membrane via the inhibition of PLA2  
and so do not work in cell-free systems (Blackwell et al., 1978; Nijkamp et al., 1976).
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The inhibition itself appears to occur indirectly via the action of intra-cellular proteins 
synthesized and released after binding of the corticosteroid to specific cell membrane 
receptors (Blackwell et al., 1980). Such inhibitory proteins have been isolated from 
perfused guinea-pig lung and rat peritoneal macrophages (macrocortin) and similarly from 
rabbit peritoneal neutrophils (lipomodulin) (Blackwell & Flower, 1983).
Effectively then, corticosteroids act as dual inhibitors, blocking both the CO 
and LO pathways, both of which depend on the provision of AA substrate. This explains 
why they are generally better anti-inflammatory agents than the NSAID’s, although the 
advantage is off-set by the fact that they also produce more serious side effects. 
Experimental dual CO and LO inhibitors such as BW755C are presently being tested as 
anti-inflammatory agents (Salmon, Simmons & Moncada, 1983). It is hoped that these 
will have the steroid-like therapeutic activity (PG inhibition without potentiation of 
leukocyte migration) without the toxic side-effects normally associated with steroid 
treatment.
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CHAPTER 3
THE LEUKOTRIENES
3.1 Biosynthesis
The leukotrienes (LT’s) are a family of biologically active compounds 
derived from A A via the action of a 5-lipoxygenase (5-LO) enzyme (Fig. 3.1). In the 
first step, A A undergoes hydroperoxidation by the 5-LO to form a 5-hydroperoxy- 
eicosatetraenoic acid (5-HPETE) (Taylor & Morris, 1983). This intermediate may be 
reduced to 5-hydroxyeicosatetraenoic acid (5-HETE) or alternatively may be converted by 
a dehydrase to the highly unstable 5,6 epoxide intermediate, LTA4  (Borgeat & 
Samuelsson, 1979c). Subsequently, LTA4  may be hydrolysed enzymatically by epoxide 
hydrolase to yield the 5,12-dihydroxy-eicosatetraenoic acid (5,12-di-HETE), LTB4  
(Borgeat & Samuelsson, 1979c); this is the rate-limiting step for the pathway (Jakschik & 
Kuo, 1983). Alternatively, non-enzymatic hydrolysis of LTA4  generates the less 
biologically active isomers of LTB4 , namely the 5,6-di-HETE’s and the 6 -trans LTB4  
diastereoisomers (Lewis & Austen, 1984), (Fig. 3.1).
LTA 4  is also the precursor for the formation of the cysteinyl-LT’s. 
Addition of glutathione via glutathione-S-transferase yields LTC4  (Murphy, 
Hammarstrom & Samuelsson, 1979), then, upon hydrolysis of its peptide side chain by 
y-glutamyl transferase (y-GT), LTC4  is converted to LTD4 . Further metabolism by a di­
peptidase cleaves glycine from the side chain to form LTE4  which then has a single amino 
acid residue (cysteine) at C-6  (Lewis and Austen, 1984). In the presence of glutathione, 
LTE4  can act as an acceptor of y-glutamic acid to form the y-glutamyl cysteinyl 
derivative, LTF4  (Anderson et al, 1982). However, LTF4  has not yet been detected in 
biological fluids.
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Fig. 3.1 Metabolism of arachidonic acid via the 5-lipoxygenase pathway: detailed 
structures and enzymes.
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3.2 Sites of Synthesis
Whereas the metabolism of AA to CO products is characteristic of most cell 
types, the 5-lipoxygenation of AA appears to be less widely distributed but is associated 
with all types of leukocytes. Cells such as PMN’s, monocytes and mast cells from 
several species release relatively large amounts of LT’s when appropriately stimulated 
(Lewis & Austen, 1984). However, there are distinct differences in the profile of LT’s 
formed in individual classes of leukocyte. For example, in peripheral blood PMN’s 
(mainly neutrophils) the amount of LTB4 produced by a given stimulus is some ten times 
greater than that of LTC4 . . In eosinophils however, the ratio is reversed and LTC4 is the 
major LT product (Lewis & Austen, 1984). In addition, there are many leukocytes in 
which a 12-lipoxygenase or 15-lipoxygenase is quantitatively more important (Brash, 
Murray & Oates, 1985). These enzymes lead to the formation of compounds such as 12- 
HETE and 15-HETE which may also be important in inflammation, but are largely 
outside the scope of this thesis.
Many other tissue types have the potential to generate LT’s, including 
human and guinea-pig lung and guinea-pig pulmonary and coronary arteries (Piper, 
1985). Piper & Galton (1984) have found that the main source of LT’s from stimulated 
porcine pulmonary artery is the adventitia. Johnson et al (1985) have reported that 
endothelial cells do not appear to synthesise LT’s, although they are able to metabolize 
them. Similarly, erythrocytes, which were thought to be metabolically inert in terms of 
eiconsanoid synthesis, have been shown to transform LTA4  into LTB4  (Fitzpatrick et al, 
1984).
The subcellular localization of enzymes in the LT pathway is quite complex 
and involves movement of intermediates between cell compartments. In RBL-1 cells for 
example, all the enzymes leading to the formation of LTB4  from AA are found in the 
cytosol whereas the enzymes converting LTA4  to LTC4 , D4 and E4 are located in the 
particulate fraction (Jakschik & Kuo, 1983). The exact subcellular locations have not 
been conclusively determined, but in a variety of cell types the y-glutamyl transpeptidase
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which converts LTC4  to LTD4  seems to be located in the plasma membrane (Anderson, 
Allison & Meister, 1982) and the dipeptidase converting LTD4  to LTE4  appears to be 
associated with the specific granules in human PMN’s (Lee et al, 1983a). The 
organization of enzymes therefore, means that AA, after it is released from 
phospholipids, can either be converted to the prostanoids via the CO, a microsomal 
enzyme or to 5-HPETE by the cytosolic 5-LO. Similarly, the LTA4  intermediate can 
either be a substrate for the soluble hydrolase to form LTB4  or the particulate glutathione- 
S-transferase to form LTC4 . The factors controlling the fate of substrate are not entirely 
understood but this may be partly dependent on the nature of the stimulus causing cell 
activation.
3 .3  Stimulation of Leukotriene Biosynthesis
Leukotrienes are not normally stored within cells but are synthesised and 
released after activation of the pathway by a variety of stimuli. The 5-LO is a calcium- 
dependent enzyme and for LT synthesis to occur therefore, there is not only a requirement 
for A A to be released, but also for the 5-LO to be activated (Parker & Aykent, 1982; Ochi 
et al, 1983). Hence, addition of AA to leukocytes is not usually sufficient to stimulate LT 
synthesis and a stiumulus such as the calcium ionophore A23187 is required to activate 
the pathway (Borgeat & Samuelsson, 1979b). This requirement for activation of 5-LO 
means that the LT pathway can be inhibited either by direct inhibition of the enzyme or by 
agents which block activation.
Much of the in vitro data on LTB4  generation have come from leukocytes 
stimulated with A23187. This agent is a microbial-derived carboxylic acid which is able 
to transport divalent cations across both cellular and intra-cellular membranes (Reed & 
Hardy, 1972). In leukocytes, therefore, it increases the cytosolic calcium concentration 
by causing an influx of extracellular calcium and also by mobilising intracellular stores of 
calcium.
75
Although A23187 is a potent stimulus for release of LT’s and is often used 
as a research tool, it is, however, non-physiological. Other, more physiological stimuli 
can be used, for example, the synthetic analogue of a bacterial chemotactic peptide, N- 
formyl-Met Leu Phe (FMLP), the complement anaphylatoxins C3a and C5a, the 
phagocytic stimulus zymosan and various antigens (Bray, 1983). However, the amounts 
of LT produced are much less than with A23187 and indeed, the generation of LT’s by 
many tissues would have remained elusive had A23187 not been used. It should be 
noted that in contrast to A23187 which activates both the PLA2  and the 5-LO, FMLP and 
C5a do not induce the mobilisation of AA and only stimulate LT biosynthesis when 
exogenous AA is provided (Clancy, Dahinden & Hugli, 1983).
3.4  Metabolism
3.4 (a) Leukotriene B4
The neutrophil-dependent inactivation of LTB4  is an intra-cellular process 
and occurs via co-oxidation to yeild 2 O-OH-LTB4  and subsequently, 2 O-COOH-LTB4  
(Ford-Hutchinson et al, 1983). This process is not observed with eosinophils or 
peripheral blood monocytes in adherent monolayers (Lewis & Austen, 1984). Although 
the 20-COOH metabolite is virtually inactive, 2 O-OH-LTB4  retains significant 
biologically activity, especially with respect to smooth muscle contraction (Ford- 
Hutchinson et al, 1983). Salmon, Simmons & Palmer (1982b) have shown that LTB4 , 
in the presence of human PMN’s, has a half-life of 25 minutes at 37°C. However, initial 
rapid binding of LTB4  to the cells, leading to loss of biological activity in the supernatant, 
occurs within 5-10 minutes.
3.4 (b) Leukotrienes, C4 ? D4  and E4
The processing of LTC4  to LTD4  and LTE4  by peptide cleavage represents 
the conversion from one active mediator to another and is not an inactivation process. 
However, human PMN’s stimulated with phorbol myristate acetate (PMA) metabolize 
LTC4 , D4 and E4 to a mixture of biologically less active and inactive compounds by an
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oxidative pathway involving hydrogen peroxide (H2 O 2 ) and myelo-peroxidase; 
hypochlorous acid (HOC1) appears to be the ultimate effector species (Lee et al, 1983b). 
Each of the three LT’s gives rise to a pair of 6 -trans LTB4  diastereoisomers and it’s 
corresponding sulphoxide derivative, also present as a pair of diastereoisomers. A third 
pair of minor metabolites remains unidentified (Lee et al, 1983b).
3 .5  Biological Actions of Leukotriene B4
3.5 (a) Effects on leukocytes
As described in chapter 1, the ability of PMN’s to detect, move towards and 
accumulate at a site of tissue injury is an important phenomenon in the inflammatory 
response. This is the process in which LTB4  seems to exert its most potent biological 
actions (Table 3.1) and upto 95% of the chemokinetic, chemotactic and aggregatory 
activity from ionophore-stimulated PMN’s can be ascribed to LTB4  (Ford-Hutchinson et 
al, 1980). Furthermore, the stereochemistry of the LTB4  molecule is of biological 
importance since the two 6 -trans-LTB4  diastereoisomers, produced non-enzymatically, 
have considerably reduced activity compared to LTB4  (Ford-Hutchinson et a l , 1981).
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LTB 4 L T C 4 , D4 , E 4
PM N: Chemokinesis
Chemotaxis
Adherence
Aggregation
Degranulation
Exudation of plasma
Exudation of plasma
Smooth muscle contraction
Smooth muscle contraction
(eg bronchoconstriction, 
vasoconstriction)
Table 3.1 Biological actions of the leukotrienes
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As a chemokinetic and chemotactic agent LTB4  has comparable activity (on 
a molar basis) to that observed for other known chemotactic factors such as C5a and 
FMLP (Bray, 1983). It is around 100-1000 times more active than any of the mono- 
HETE’s (Smith, Ford-Hutchinson & Bray, 1980) and in vitro appears to be chemotactic 
for both PMN’s and mononuclear cells from several species (Palmer et al, 1980). Like 
other chemotactic substances, LTB4  appears to have the ability to enhance the expression 
of complement receptors on human neutrophils (Nagy et al, 1982).
Adhesion of PMN’s to vascular endothelium is a pre-requisite for their 
translocation from the microcirculation into the extravascular space and their subsequent 
accumulation at the inflammatory site. Gimbrone, Brock & Schafer (1984) examined the 
effects of various LO products of AA on PMN adhesion to endothelial cells in culture and 
found LTB4  to be the most effective. The endothelial cells used included those cultured 
from both arteries and viens of several species. LTB4  is also a PMN-aggregating agent 
and induces aggregation to a greater degree and at lower concentration (1 0 "^M ), than 
any other LO product (Ringertz et al, 1982).
In addition to its chemotactic and aggregatory properties, LTB4  stimulates 
release of lysosomal enzymes from PMN’s (Feinmark et al, 1981). However it is 
relatively weak as a degranulating agent, being considerably less potent than FMLP in 
this respect.
There is some speculation that LTB4  could also act as an endogenous 
calcium ionophore in leukocytes, giving it a potentially important role in the control of 
calcium-dependent cell functions (Serhan et al, 1982). However, this hypothesis has not 
been conclusively proved.
The in vivo actions of LTB4  have been shown to reflect those in vitro. 
Injection of LTB4  into the peritoneal cavity of guinea-pigs stimulates an influx of PMN’s 
(and to a lesser extent eosinophils and macrophages) which continues upto 5 hours after 
treatment (Smith, Ford-Hutchinson & Bray, 1980). Extravascular accumulation of
79
leukocytes on application of LTB4  has also been studied using hamster cheek pouch 
preparations (Bray, Ford-Hutchinson & Smith, 1981). Within 2 minutes, a reversible 
reduction in the number of rolling PMN’s and a corresponding increase in the number of 
cells sticking to the vascular endothelium was observed which was followed by an 
increase in extravascular cell accumulation.
Leukocyte accumulation on stimulation with LTB4  has also been observed 
in the anterior chamber of rabbit eye (Bhattacherjee et al, 1981) and human skin (Lewis et 
al, 1981). The doses of LTB4  required for cell accumulation are relatively high (0.1-1.0 
fig) but are still within physiological ranges and the effects appear to last for several 
hours.
3.5 (b) Effects on the microcirculation
In parallel with its ability to stimulate cell accumulation, LTB4  also causes 
an increase in vascular permeability in rabbit, rat, guinea-pig and hamster (Bray, 1983). 
However, although LTB4  alone has only a weak effect on plasma exudation, the 
response is markedly enhanced by the presence of a vasodilator such as PGE2  
(Wedmore & Williams, 1981). Furthermore, LTB4 -induced plasma leakage appears to 
require adhesion of PMN’s to the vessel wall. This requirement has been demonstrated 
using animals depleted of PMN’s (Wedmore & Williams, 1981) and Bjork et al (1983) 
have shown that leakage of plasma after LTB4  application is always preceded by a 
marked adhesion of cells to the vessel walls. The mechanism by which adhering PMN’s 
increase vascular permeability is not known but CO products appear not to be required 
since indomethacin, an inhibitor of CO, has no effect (Bjork et al, 1983).
3.5 (c) Effects on smooth muscle
LTB4  contracts several smooth muscle tissues in vitro including guinea-pig 
duodenum, ileum, aorta and trachea and rat stomach and ileum (Sirois, Borgeat & 
Jeanson, 1981). However, in general it’s effects on smooth muscle are not nearly so 
potent as those of the other LT’s. In the case of guinea-pig lung parenchymal strips (an
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in vitro preparation of peripheral airways) it does seem to be equipotent with LTC4  and 
LTD4  in causing contraction (Piper & Samhoun, 1982). However, Piper & Samhoun 
have also shown that this activity is blocked by pretreatment of the tissue with 
indomethacin and that LTB4 -induced contraction is in fact, mediated by TXA2 .
3.6  Biological Actions of Leukotrienes C4, D4 and E4
3.6 (a) Effects on smooth muscle
The main biological actions of LTC4 , D4 and E4 are summerised in table 
3.1. One of the most potent effects of these cysteinyl-containing LT’s is their action on a 
variety of smooth muscle preparations which is typically slow in onset but long-lasting. 
The classical assay for SRS-A has been contraction of guinea-pig ileum where LTC4 , D4 
and E4 are thousands of times more active than histamine, the order of potency being 
LTD4  > C4 > E4 (Piper, 1983). Rat stomach strip and guinea-pig uterus are also 
contracted by these LT’s (Piper & Samhoun, 1982; Weichman & Tucker, 1982) but are 
not as sensitive as guinea-pig ileum.
It has been recognized for many years that SRS-A has bronchoconstrictor 
properties (Brocklehurst, 1960) and it’s LT constituents (particularly LTC4  and D4) are 
now known to be potent constrictors of isolated airway smooth muscle. However, 
considerable species variation exists and although these LT’s are, again, thousands of 
times more active than histamine on respiratory smooth muscle from human and guinea- 
pig lung (Dahlen et al, 1980; Lewis et al, 1980b), they are virtually inactive on tissues 
from other species, as in the case of rat trachea (Krell et al, 1981). LTC4  and D4 are 
often equipotent as constrictors of isolated airway smooth muscle while LTE4  is usually 
less potent (Piper, 1983).
In guinea-pig in vivo LTC4  and LTD4  have a direct bronchoconstrictor 
action when given by aerosol but when given intravenously cause a bronchoconstriction 
which is inhibited by indomethacin (Schiantarelli, Bongrani & Folc, 1981; Hamel et al,
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1982). Piper & Samhoun (1982) have shown that in guinea-pig isolated perfused lung 
LTC4  D4 and E4 cause release of TXA2 .
Human isolated bronchus and lung parenchyma are also contracted by the 
cytsteinyl-containing LT’s (Piper, 1985), although neither TXA2 nor PG’s appear to play 
a major role in these tissues since indomethacin does not alter the response to LT’s 
(Piper, 1985). In human volunteer studies, the nature of the LT-induced response in the 
respiratory system resembles that seen in asthma and suggests a role for these substances 
in allergic broncho-spastic disease (Piper, 1983).
3.6 (b) Effects on the microcirculation
In keeping with their actions on smooth muscle, LTC4  and D4 are also 
potent vasoconstrictors with actions in many different vascular beds from several species 
(Letts & Cirino, 1985). In particular, they appear to have potent effects in the coronary 
and cerebral circulations (Letts & Cirino, 1985).
Like LTB4  leukotrienes C4, D4 and to a lesser extent E4, promote plasma 
exudation from post-capillary venules, again at much lower concentrations than required 
for histamine (Piper, 1983). In guinea-pig skin, LT-induced plasma exudation is 
potentiated by vasodilator PG’s such as PGE2  or PGI2  which are thought to reverse the 
LT-induced vasoconstriction (Peck, Piper & Williams, 1981). In contrast to LTB4  
however, increased permeability is not dependent on the presence of PMN’s, but seems 
to occur via a direct action on the vascular endothelium (Bjork et ah 1983).
3.7  Leukotriene Receptors
There is a large body of both indirect and direct evidence for the presence of 
specific LT receptors in a variety of tissues (Bray, 1985). Radioligand binding studies 
have shown that, in contrast to those for the PG’s, LT receptors are a heterogeneous 
population with widely differing species and tissue specificities.
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The use of high specific activity 3H-LTB4  has permitted the demonstration 
of two classes of LTB4  receptors on human PMN’s that differ in their affinity for LTB4  
(Goldman & Goetzl, 1984). There is some evidence to suggest that these sites may 
transduce different biological responses, the high affinity site mediating aggregation and 
chemotaxis and the low affinity site mediating degranulation (Goldman & Goetzl, 1984). 
In addition, FMLP and C5a do not inhibit binding of 3H-LTB4  to PMN’s indicating that 
the chemotactic receptors for LTB4  are distinct from those of the peptide chemotactic 
factors (Goldman & Goetzl, 1984).
The cysteinyl-LT’s also appear to exhibit a marked heterogeneity in receptor 
specificity and distribution. LTC4 , D4 and E4 contract guinea-pig ileum with widely 
differing dose response relationships (Piper, 1983) while LTB4  is effectively inactive in 
this tissue. Highly specific, saturable binding sites for LTC4  have been identified on 
guinea-pig ileum and, since disrupted cells appear to have more binding sites than whole 
tissue, there is speculation that LTC4  receptors may be largely internalized, being 
recruited to the plasma membrane during cell activation (Bray, 1985). This would help to 
explain the slow contraction in response to LTC4 .
3 .8  Interaction of Leukotrienes with other Inflammatory Mediators
3.8(a) Other eicosanoids
The interaction between LT’s and CO products has effectively been 
discussed in section 3.6. The effects of the LT’s on the guinea-pig respiratory system 
have been seen to be largely due to the formation of TXA2  and possibly other PG’s. 
However, in human lung, studies strongly suggest that PG’s and TXA2  do not mediate 
the response to LT’s in this case. In addition, the synergism between the LT’s and the 
vasodilatory PG’s in causing increased vascular permeability may be of importance in the 
formation of oedema.
The addition of AA to a suspension of human leukocytes normally induces 
only very small amounts of 5-LO products (Clancy et al, 1983). However, Maclouf et al
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(1982) have demonstrated that co-incubation of platelets with leukocytes results in an 
activation of 5-LO with increased production of LTB4 . The compound responsible for 
the activation has been identified as 12-hydroperoxy-eicosatetraenoic acid (12-HPETE), a 
product of the platelet 12-lipoxygenase. Although inflammation can proceed in the 
absence of circulating platelets (Ubatuba, Harvey & Ferreiria, 1975), this observation 
suggests a possible role for platelets in the initiation or amplification of LT-modulated 
inflammation.
3.8(b) Cyclic AMP
Since LTB4  is able to induce degranulation of PMN’s it was thought likely 
that it was able to increase cAMP production. Claesson (1982) investigated the effects of 
various LT’s on cAMP formation in human PMN’s and showed that LTA4  and LTB4  
cause a small rise in cAMP levels. No effect was observed for LTC4 . Moreover, 
experimentally elevated cAMP levels were shown to lead to an inhibition of LTB4  
synthesis and enzyme release, a possible negative feedback mechanism.
In addition, inflammatory stimuli such as FMLP, C5a and ionophore 
A23187 have been shown to cause a small rise in cAMP levels (Claesson, 1982) also 
indicating a relationship between cAMP and PMN activation.
3.8 (c) Reactive metabolites of oxygen
Reactive metabolites of oxygen (“free radicals”) are among the many 
substances released from stimulated inflammatory cells along with the LT’s. Since LT’s 
are unsaturated compounds, in vivo reactions between them and free radicals produced 
simultaneously and in close proximity, are likely.
Henderson & Klebanoff (1983) have shown that the respiratory burst in 
stimulated PMN’s is not required for LT formation, but suggest that products of the burst 
may contribute by one or more mechanisms to the degradation of the LT formed. LTB4  
and LTC4  are both rapidly inactivated by the peroxidase-H2C>2 -halide system and by
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hydroxyl radicals, both products of the respiratory burst in PMN’s. Neutrophils from 
patients with chronic granulomatous disease which lack a respiratory burst, show 
increased production of LTB4  and LTC4  compared to normal cells when stimulated with 
A23187.
The relative free radical “scavenging” activity of a selection of LT’s in vitro 
has been examined (Chopra, Belch & Smith, 1988), the order of effectiveness being 
LTD4  > LTC4  > LTB4 . These LT’s were found to be reactive towards free radicals in 
general rather than to the superoxide ion specifically.
3.8 (d) Interleukin-1
Another means whereby LT’s can modulate inflammatory (and 
immunological) reactions is through their interaction with IL-1. Inhibition of IL-1 activity 
(standard thymocyte assay) by LO inhibitors such as eicosatetraynoic acid (ETYA) and 
BW755C has been demonstrated (Dinarello, Marnoy & Rosenwasser, 1983). In 
addition, Rola-Pleszczynski & Lemaire (1985) have shown a direct stimulation of IL-1 
production from human monocytes on addition of LTB4 . Stimulation of A A 
lipoxygenation by IL-1 has also been demonstrated (Farrar & Humes, 1985) suggesting 
that LT’s may play a role in the amplification if IL-1 production from human monocytes 
and macrophages.
3 .9  Role of LTB4 in Inflammatory Disease
In view of it’s biological properties it is thought that the main role of LTB4  
is to mediate at least in part, the recruitment of leukocytes during the inflammatory 
process. Simmons, Salmon & Moncada (1983) have established that LTB4  is present 
during acute experimental inflammation in the rat. Concentrations of LTB4  detected in 
the inflammatory exudate were sufficient to induce chemotaxis and degranulation of 
PMN’s and the peak LTB4  concentration correlated with the maximum rate of PMN 
influx into the exudate. However, other substances present in the exudate, such as C5a,
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will also induce cell influx and it is thought likely that LTB4  amplifies the chemotactic 
response in the early stages of inflammation (Simmons et al, 1983).
The contribution of LTB4  to chronic inflammatory disease is less clear. 
However, elevated LTB4  levels have been detected in a variety of human diseases. 
Klickstein, Shapleigh & Goetzl (1980) using HPLC, have detected increased levels of 
LTB4  in the synovial fluid of patients with RA and ankylosing spondylitis compared to 
non-inflammatory osteoarthritic controls. Davidson, Rae & Smith (1983) were also able 
to detect LTB4  in RA synovial fluid using a bioassay, albeit at much lower concentrations 
than those reported by Klickstein et al.
The role of LTB4  in gout has also been investigated (Rae, Davidson & 
Smith, 1982). Results showed that LTB4  is present in gouty effusions at concentrations 
which are greater than those found in RA synovial fluids. In addition, it was 
demonstrated that monosodium urate (MSU) crystals (the classical stimulus for the 
inflammation of gout) are able to stimulate production of LTB4  from peripheral PMN’s. 
Work done on MSU-induced synovitis in the dog however, has shown that there is 
probably no role for LTB4  in this animal model (Carlson et al, 1986).
It is thought that LTB4  may also have a role in the human inflammatory 
dermatoses, where PMN infiltration is often a characteristic feature. Brain et al (1982) 
have shown increased levels of LTB4  in affected psoriatic skin compared to un-involved 
areas and to normal control skin. In addition, Camp et al (1983a) have demonstrated that 
intra-dermal injection of LTB4  in human skin causes inflammatory changes accompanied 
by PMN infiltration.
Enhanced synthesis of LTB4  by colonic mucosa in patients with 
inflammatory bowel disease (IBD) has also been reported (Sharon & Stenson, 1984). 
Again, this disease is characterised by infiltration of the gut mucosa with PMN’s. At the 
same time, Sharon & Stenson showed that sulphasalazine (SASP), a drug often used in 
the treatment of IBD, substantially inhibited LTB4  production in colonic mucosa.
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3.10 Inhibition of the Leukotrienes and Potential for Anti-Inflammatory 
Therapy
The potent biological activity of LTB4  and the other LT’s has stimulated a 
search for inhibitors of LT synthesis (Fig. 2.3). In contrast to the CO which has fairly 
specific inhibitors, there are few compounds which specifically inhibit the 5-LO. 
However, given that inhibition of CO alone may cause substrate diversion and enhanced 
LT formation (see section 2.10), selective LO inhibition may result in increased PG 
production. If this is the case, then dual inhibitors are likely to have significant clinical 
advantage over single enzyme inhibitors.
In view of this new approach to anti-inflammatory therapy, much interest 
has been shown in the experimental dual inhibitor BW755C, a pyrazole derivative which 
inhibits peroxidation of AA in every tissue so far tested (Higgs & Vane, 1983). This 
compound has been found to be equipotent in reducing oedema, PG synthesis and 
leukocyte accumulation and is very similar in its anti-inflammatory effect to the 
corticosteroid dexamethasone (Higgs, Flower & Vane, 1979).
Another class of compounds which inhibits both CO and 5-LO pathways are 
the acetylenic analogues of A A (e.g. ETYA). These compounds compete with the natural 
substrate for enzyme but are unable to undergo peroxidation (Higgs & Vane, 1983).
Also of interest, is the fact that some natural plant products such as ginger, 
curcumin and onion, which have been known to possess anti-inflammatory properties for 
many years, have now been shown to be dual inhibitors of AA metabolism in neutrophils 
and platelets (Flynn, Rafferty & Boctor, 1986; Srivastava, 1986).
The investigation of the drug benoxaprofen as an anti-inflammatory agent 
illustrates the difficulties encoutered in the interpretation of inhibitor studies in vitro and 
in vivo. Benoxaprofen is an effective anti-inflammatory agent in man and causes a 
marked improvement in psoriasis, which is normally exacerbated by NSAID’s such as 
indomethacin (Kragballe & Herlin, 1983). As well as being a weak CO inhibitor,
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benoxaprofen had been reported to be an inhibitor of 5-LO in A23187-stimulated PMN’s 
(Myers & Siegel, 1983). The clinical effects of the drug were therefore attributed to 5-LO 
inhibition. However, benoxaprofen has since been reported as failing to inhibit a cell-free 
preparation of 5-LO from human PMN’s (Masters & McMillan, 1984) and Salmon, 
Tilling and Moncada (1984) have shown that it failed to reduce in vivo synthesis of 
LTB4  in an animal model of acute inflammation. These observations obviously cast 
doubt on the original hypothesis that the clinical effects of benoxaprofen are mediated by 
5-LO inhibition. The drug has now, in any case, been withdrawn from clinical use due to 
side effects.
Another approach to LT inhibition has been the development of antagonists 
which work at the receptor level and therefore have some specificity of action. One of the 
best characterised is the SRS antagonist, FPL55712 (Piper & Samhoun, 1987). A 
number of structural analogues which block the action of LTB4  have also been identified; 
these include the mono-HETE’s and the LTB4  methyl esters (Bray, 1983).
Ultimately, the therapeutic potential of inhibiting 5-LO as well as CO 
depends on the contribution of the LT’s to disease processes. In most cases, the extent of 
this contribution is still unknown. However, it seems likely that the development of 
inhibitors for 5-LO could lead to improved drugs for the treatment of chronic 
inflammatory conditions.
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CHAPTER 4
MATERIALS AND METHODS
4.1  Measurements of Eicosanoids
4.1 (a) Introduction
The in vitro effects of the eicosanoids are well documented, but in order to 
establish a role for them in vivo it is necessary to be able to measure them quantitatively in 
biological/pathological samples. Since the concentration of these compounds in such 
samples is usually low (pg-ng range), their measurement requires highly sensitive and 
specific assays. Techniques which have been used in the past include bioassay, GCMS, 
HPLC and radioimmunoassay (RIA), each of which has i t’s advantages and 
disadvantages.
4.1 (b) Bioassay
Bioassay is based on the observation of an in vitro effect such as smooth 
muscle contraction or cell aggregation. For example, tens of pg’s of LTB4  activity can be 
measured using aggregation of rat peritoneal neutrophils (Bray, 1983). One advantage of 
bioassay is that a biological activity can be measured before the principle causing the 
effect has actually been identified. However, specificity is often difficult to achieve 
without the use of certain inhibitors and antagonists. In addition, bioassay cannot be 
used to measure levels of metabolites such as 6 -keto-PGFia or TXB2  which are
relatively inactive.
4.1 (c) GCMS
. This is a relatively complicated, direct method of chemical analysis which is 
inaccessible to most laboratories, the main problem being the expense of the sophisticated 
equipment which is required. In addition, this method has a low sample capacity and 
requires a fairly large initial sample volume in comparison to other methods.
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4.1 (d) HPLC
High performance liquid chromatography (HPLC) with UV detection can also 
be used for the measurement of eicosanoids. Indeed, HPLC played an important role in 
the structural elucidation of the LT’s (Samuelsson, 1983). However, the main problem 
with this method is lack of sensitivity and, in addition, samples usually have to undergo 
extraction before they can be placed on the column.
4.1 (e) RIA
4.1 (e) (i) Introduction
The method chosen for measurement of eicosanoids in this work was RIA. 
Using this method the large numbers of samples encountered in clinical work can be 
assayed within a relatively short period of time and the sensitivity and specificity are 
better than with most other techniques. In addition, no sophisticated laboratory 
equipment is required other than a scintillation counter.
4.1(e) (ii) Principle of RIA
RIA is based upon the competition of antigen (the compound being analysed), 
and a fixed quantity of radioactively labelled antigen for a specific antibody site. A 
limiting and constant amount of antibody is incubated with a constant concentration of 
tracer, usually so that approximately 50% of the tracer is bound to antibody. On addition 
of the unlabelled antigen, competition occurs between it and the labelled antigen for the 
limited number of binding sites on the antibody i.e. the amount of labelled antigen bound 
by the antibody is inversely proportional to the amount of unlabelled antigen present. The 
amount of unlabelled compound present in a sample can be determined by comparison 
with standards containing known amounts of the compound via the construction of a 
standard curve. Each assay must also include tubes with no antibody present to 
determine non-specific binding (NSB) and tubes with no unlabelled compound to give 
maximum binding of tracer (zero standard or Bo).
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The amount of tracer bound as a percentage of B0  (%B/B0), is calculated according to the 
following equation:
%B/B0  = Standard or sample cpm - NSB cpm 
B0  cpm - NSB cpm
4.1(e) (iii) The antibody
Probably the most important component of any RIA is the antibody. The 
production of an antibody with the required specificity and affinity for the compound 
being measured is crucial to the success of the assay.
Eicosanoids are not themselves antigenic and must first be conjugated to an 
antigenic molecule such as bovine serum albumin (BSA), (Salmon, 1982a). This 
conjugate is then mixed with Freund’s adjuvant and injected into rabbits. After several 
booster injections to elicit a good response to the antigen, the animal is bled and the serum 
containing the antibody is separated and kept frozen or lyophilized. Cross-reactivity with 
all possible compounds of a similar structure must be checked before use and must be as 
low as possible (<0 .2 % is desirable); cross-reactivity for the metabolite to be measured 
must be 1 0 0 %.
4.1(e) (iv) The tracer
The isotopes most frequently used for RIA of eicosanoids are tritium (^H) and 
125lodine (125j). The higher the specific activity (S A) of the tracer, the smaller the mass 
which can be used in the assay, thus increasing sensitivity. Higher SA can be achieved 
with 125j tracers, which also have the advantage that they do not require scintillation fluid 
for counting. In this respect, therefore, they are probably cheaper and easier to use. 
However, ^H-tracers have a longer half-life and are safer to work with than gamma- 
emitters. Many high S A ^H-tracers are now commercially available.
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4.1 (e) (v) Separation method
In order to determine the amount of tracer which has been displaced from the 
antibody by unlabelled compound, a method for separating antibody-bound and free 
tracer is required. A common method of separation is adsorption of free tracer onto 
dextran coated charcoal (DCC) which is then centrifuged and the antibody-bound 
radioactivity counted in the supernatant. It is important that the separation is performed 
using ice-cold DCC suspended in buffer with the assay tubes in melting ice to avoid 
adsorption of the antibody-bound complex. In addition, the time taken to perform the 
addition, mixing and centrifugation of the tubes must be carefully standardized.
4.1 (e) (vi) Assay validation
There are several potential sources of error in RIA. Other factors besides 
presence of unlabelled antigen in the sample can affect the inhibition of binding of 
radioactive antigen to the antibody, including variations in pH, ionic strength, protein 
concentration or a significant level of cross-reacting compounds (Salmon, 1983). The 
specificity of an antibody is usually assessed by comparing the mass of the compound 
being measured with the masses of related compounds which cause 50% inhibition of 
binding of tracer to antibody, giving a measure of percentage cross-reactivity.
All of the assays in this work have been carried out using commercially 
available reagents (antibody/standard/tracer) either bought individually or in the form of 
RIA kits. The antibodies used therefore, are well characterized and their specificity has 
already been determined. Reproducibility was assessed by including a “standard” sample 
of known concentration in all assays performed (inter-assay variation) and by including 
several identical samples in the same assay (intra-assay variation). Inter- and intra- assay 
coefficients of variation are generally taken to be acceptable if less than 15%.
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4.2 Measurement of PGl2-MetaboIites in Plasma
4.2 (a) Method of sampling
Since PGI2  is unstable, it’s stable metabolites, a significant proportion of 
which is 6 -keto-PGFia (Myatt et al, 1981) must be used as indices of PGI2  production.
Measurement of PGl2 -metabolites (PGl2 -M’s) was carried out on plasma. 
Since leukocytes can produce PGI2  it is important that further in vitro generation after 
blood sampling is abolished. To this end, venous blood was collected into ice-cold 
plastic tubes containing 1:9 volumes of 3.8% w/v trisodium citrate with 3xlO'^M 
indomethacin and 10"^M adenosine. Tubes were kept on ice and centrifuged within 1 
hour at 4°C and 2500g. The plasma was then separated and stored at -70°C until 
assayed.
4.2 (b) Extraction of samples
It is common practice in RIA to extract plasma samples prior to assay in order 
to rid the sample of interfering substances and increase specificity. However, many 
extraction, purification and evaporation steps can add further impurities (Greaves & 
Preston, 1982) and where large numbers of samples are to be assayed, it may be 
impracticable to extract and purify every sample. Furthermore, only 40% of PGl2 -M’s in 
plasma are 6 -keto-PGFioc (Myatt et al, 1981) and extraction of samples for this 
metabolite alone could give an underestimation of circulating PGI2  levels. McLaren et al 
(1985) have shown that it is possible to obtain sensitive, specific and reproducible results 
for PGl2 -M’s by carrying out RIA directly on unextracted plasma. On this basis, all the 
plasma PGI2 -M determinations for the work presented here were carried out without 
prior extraction of the plasma.
4.2 (c) Assay procedure
The RIA used for the determination of PGl2 -M’s in plasma was based on that 
developed by McLaren et al (1985) who found that by reducing the amount of tracer and
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antibody (half the amounts recommended) and by increasing equilibration time, the 
sensitivity of the assay could be increased so that normal plasma was brought within the 
limits of detection of the assay.
Reagents were purchased in the form of a 6 -keto-PGFioc [^^1] assay kit 
from the Institute of Isotopes of the Hungarian Academy of Sciences, Budapest. Assays 
were performed in duplicate, directly on undiluted plasma. All other reagents were 
diluted in assay buffer which consisted of phosphate buffer 50mM, pH 6 .8  containing 
0.05% BSA.
Reagents were prepared as suggested by the makers of the kit, except that the 
tracer (6 -keto-PGFia [^^1 ]-iodotyrosine methyl ester, 1800 Ci/mmol, 5.4mCi) was
diluted in 20 ml of assay buffer rather than 10ml. Lyophilized anti-serum was 
reconstituted with 1 0  ml of distilled water to give a solution which in the assay, bound 
approximately 50% of the added tracer in the absence of sample. A series of standard 6 - 
keto-PGFioc solutions in the range 2.5-1250 pg/ml was made by serial dilution.
Polypropylene tubes (12mm x75 mm, Luckham) were labelled in duplicate for 
total counts (TC), buffer NSB, plasma NSB, zero standard (B0), standards and samples. 
The reagents were added to the appropriate tubes according to the protocol shown in 
Table 4.1, all tubes containing a final volume of 350 p.1. Each assay consisted of 100 
tubes, allowing construction of a standard curve and the assay of 37 unknowns in 
duplicate. A stock of normal pool plasma, collected in the same way as sample plasma 
and stored at -70°C in small aliquots was used as a control sample to assess assay 
reproducibility. After the addition of all the reagents, tubes were vortex mixed, covered 
and incubated for approximately 40 hr at 4°C.
On the third day, the tubes were placed in an ice-water bath and allowed to 
equilibrate for a few minutes. A suspension of 0.5% acid-washed charcoal (BDH) and 
0.1% dextran grade C (BDH) in assay buffer was continuously stirred in a beaker placed 
in an ice-water bath. All tubes received 300 pi of this DCC suspension except the TC
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tubes which received 300 |il of assay buffer. The tubes were vortex mixed after the 
addition of DCC to the last tube and at 10 + 1 minutes after DCC addition, the tubes were 
centrifuged at 2000 g and 4°C for 10 minutes (IEC Centra-7R, USA). Immediately after 
centrifugation, the tubes were placed back in the ice-water bath and the supernatants 
containing antibody-bound tracer were decanted into fresh tubes and counted for 1 minute 
each in a gamma-counter (Canberra Packard, 500 C, UK).
^ ^ ^ _ _ _ ^ T u b e
Reagent TC
Buffer
NSB
Plasma
NSB Bo Standards Samples
Standards - - - - 2 0 0 -
Sample - - - - - 2 0 0
125i_6_keto PGFioc 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0
Antiserum - - - 50 50 50
Buffer 250 250 50 2 0 0 - -
Pool plasma - - 2 0 0 - - -
MIX AND][NCUBATE
DCC - 300 300 300 300 300
Buffer 300 - - - - -
Table 4.1 Protocol for RIA of PGI2  - metabolites in plasma
(All volumes in microlitres)
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4.2 (d) Assay characteristics
Table 4.2 shows the observed cross-reactivities of the antibody used in the assay (as 
determined by the makers of the kit) with 6 -keto-PGFioc and some related compounds.
For each assay, a standard curve was constructed by plotting the amount of 
tracer bound as a percentage of B0  (% B/B0) versus pg/ml 6 -keto-PGFia on semi-log
graph paper. The standard curve obtained over ten assays is shown in Fig. 4.1; 50% 
displacement of bound 125j_6_jceto-PG Fia occurred around 13 pg of added 6 -keto-
PGFia-
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Total counts for the assay were 10,000-12,000 cpm, NSB was typically 3% for plasma 
and 1% for buffer. The lower limit of sensitivity of the assay (taken as 2 standard 
deviations from zero-dose binding) was 3.8 pg/ml. Inter- and intra-assay variation were 
4.9% and 4.0% respectively. All results were expressed as pg PGl2 -metabolites/ml.
Compound % Cross-Reactivity
6 -keto-PGF i a 1 0 0
PGF2 a 0 .8
PGE2 1.4
P G F ia 2 .0
PGEi 1 .2
Table 4.2 Cross-reactivity of “Hungarian” antiserum with 6-keto- 
PGF i a  and related compounds.
4.2 (e) Normal values for 6 -keto-PGF i oc in plasma
Widely differing values for plasma 6 -keto-PGF \ a  measured by RIA can be
found in the literature (Mitchell, 1978; Kinney & Domers, 1981; Patrono et al., 1982). 
In the early stages of RIA development for 6 -keto-PGFioc it was common to see values
in the range 70-120 pg/ml for normal plasma. These values are now thought to be 
unrealistically high, probably due to cross-reaction of the antibodies with other PG’s. In 
addition, some of the extraction methods used probably contributed to falsely high levels.
More recently, levels of 5-20 pg/ml have been detected by RIA (Patrono et al, 
1982; Gotoh et a l, 1983). Even lower values (< 2 pg/ml) have been determined by 
GCMS (Blair et a l,  1982), but GCMS measures only 6 -keto-PGFia  and not the
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remaining 60% of PGl2 -metabolites. These values, therefore, probably underestimate 
the true circulating levels of PGI2 .
Using the assay described above, the range for normal plasma in this work 
was 10-22 pg/ml, and the mean (SD) was 13.1 (4.0) pg/ml..
There are, however, limitations in the use of plasma assays of PGl2 -M’s. 
Perhaps the most significant problem is that, since levels in plasma are at or even below 
the limit of detection of RIA, it is usually impossible to use this method when decreased 
PGI2  production is suspected, for example, after NSAID’s or in certain conditions such 
as pregnancy induced hypertension (McLaren, 1986). For this reason, since this work 
was done, measurement of plasma PGI2 -M is now seldom used. Instead, measurement 
in serum is employed, since higher levels are generated due to leukocyte production in 
vitro.
4.3 Measurement of TXB2  in Serum
4.3 (a) Method of sampling
Due to the very short half-life of TXA2 , TXB2  , the stable breakdown 
product, is used as an index of TXA2  production.
The first RIA’s for TXB2  used plasma (Granstrom & Kindahl, 1978). 
However, this method received much criticism due to the potential for artefactually high 
levels of TXB2  . Since TXA2  is generated by platelets, any trauma associated with 
venepuncture will activate platelets to give increased levels. Likewise, further generation 
of TXA2  may take place during the processing of the sample. Attempts were made to 
surmount these problems by standardizing venepuncture technique and adding a CO 
inhibitor (indomethacin) to the anti-coagulant. However, the method was still 
unsatisfactory.
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An alternative method, introduced by Patrono et al., (1980) uses serum. The 
TXB2  measured in the serum reflects the generation of TXA2  by platelets in response to 
an endogenous stimulus ie thrombin generated during blood clotting.
All TXB2  measurements in this work were performed on serum. 
Venepuncture was carried out using a 19 guage butterfly and the blood transferred into 
glass tubes. The amount of TXB2  generated during blood clotting has been shown to be 
temperature dependent (Block et al., 1987). For this reason the samples were incubated 
in a 37°C water bath for at least 1 hour, although one study (section 5.2) pre-dated the 
introduction of this methodology and serum samples in this case were left to clot at room 
temperature. Subsequently, the tubes were centrifuged at 2500g for 15 minutes and the 
separated serum stored at -70°C until use.
4.3 (b) Assay Procedure
The RIA used for the determination of TXB2  was based on that developed by 
Granstrom, Kindahl & Samuelsson (1976), and used ^H-TXB2  as a tracer. The 
antibody and standard were gifted by Mr. Simon Thomas, Medical Science Liaison 
Officer, Upjohn Ltd., Crawley and the tracer was purchased from Amersham 
International. All reagents were diluted in assay buffer which consisted of 0.1M 
phosphate buffer, pH 7.0 containing 0.1% BSA and 0.5% bovine y-globulin.
Assays were performed in duplicate in LP3 tubes (Luckham), all serum 
samples being diluted 1:300 in assay buffer just prior to assay. A series of standard 
solutions of TXB2  were made in the range 3.8-1000 pg/ml and the anti-serum was 
diluted (final 1:10,000) so that approximately 50% of added tracer bound in the absence 
of competing antigen. Tubes were labelled for TC, buffer NSB, serum NSB, B0, 
standards and samples and reagents were added as shown in Table 4.3, all tubes 
containing a final volume of 400 |il. A sample of standard pool plasma, undiluted, was 
included in each assay to assess inter-assay variations.
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After addition of all the reagents, tubes were vortex mixed, covered and 
incubated overnight (16-18h) at 4°C. The following morning separation of bound and 
free counts was achieved by adding 300 (il of 0.1% DCC to all tubes (except TC), mixing 
and centrifuging in the same way as described for the PGI2 -M assay. After 
centrifugation, the supernatants containing the antibody-bound tracer were decanted into 
10ml of scintillation fluid (Packard Insta-gel) and counted for 2 minutes in a beta-counter 
(Canberra Packard 460, UK).
------ ^ ^ T u b e
R e a g e i r t^ - ^ - ^ ^ TC
Buffer
NSB
Serum
NSB B0 Standards Samples
Standards - - - - 2 0 0 -
Sample - - - - - 2 0 0
3H-TXB2 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0
Antiserum - - - 1 0 0 1 0 0 1 0 0
Buffer 300 300 1 0 0 2 0 0 - -
Pool Serum - - 2 0 0 - - -
MIX AND INCUBATE
DCC - 300 300 300 300 300
Buffer 300 - - - - -
Table 4.3 Protocol for RIA of TXB2 in serum
(All volumes in microlitres)
4.3 (c) Assay characteristics
The standard curve obtained over six assays is shown in Fig. 4.2 . Total 
counts for the assay were normally 1200-1500 cpm and 50% displacement of bound ^H- 
TXB2  occurred at approximately 13pg of added TXB2  . The lower limit of sensitivity of 
the assay was 6  pg/ml, NSB was typically 4% for serum and 3% for buffer. Inter- and 
intra-assay variation were 11.2% and 5.2% respectively. All results were expressed as 
ng TXB2  /ml, the mean (SD) value for normal serum (using clotting at room 
temperature) being 13.2 ( 8 .6  ng/ml).
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4 .4 Measurement of LTB4 Production from PMN’s
4.4 (a) Preparation of PMN suspensions
The method used to separate the PMN cells from whole blood was based on 
that described by Boyum (1968). Venous blood (10 ml) was taken into heparin (10 
units/ml blood) in plastic tubes. The blood was then mixed with 5ml of 6 % w/v dextran 
70 (Macrodex) and the red blood cells (RBC’s) allowed to sediment under gravity for 60- 
90 minutes. After this time, the top layer (leukocyte-rich plasma) was removed and 
carefully layered onto 5 ml of Lymphoprep (9.6% w/v sodium metrizoate, 5.6% w/v 
ficoll; Nyegaard & Co., Oslo) which was then centrifuged at 200 g for 10 minutes to 
sediment the PMN’s. The mononuclear cells, which remain in a band at the interface 
between plasma and lymphoprep, were discarded. Any remaining RBC’s in the PMN 
pellet were removed by gentle hypotonic lysis with 0.87% ammonium chloride (10-15 
minutes).
After further centrifugation (160g for 5 minutes), the PMN’s were washed 
once in HEPES-buffered Hank’s balanced salt solution (HEPES/HBSS), pH 7.4 (Flow 
Laboratories, Irvine, UK) and finally resuspended in 1ml of this buffer. The cells were 
then counted using a haemacytometer, PMN cells normally constituting >97% of the total 
leukocyte count. Cell viability, assessed by Trypan Blue exclusion was normally >95%.
4.4 (b) Incubation of PMN suspensions with calcium ionophore A23187
The concentration of the PMN suspensions was adjusted so that 5 xlO^ cells 
were suspended in 0.9ml of HEPES/HBSS in a micro-centrifuge tube (Eppendorf). The 
suspensions were then warmed to 37°C in a water bath (2 minutes) after which 0.1ml of 
calcium ionophore (Cal) A23187 (Sigma Chemicals, Poole, Dorset, UK) was added as a 
10 jig/ml solution in dimethylsulphoxide (DMSO)/buffer to give a final concentration of 1 
p,g/ml (2 |iM). The final concentration of DMSO in the incubation mixtures was 0.1%. 
The cell suspensions were then agitated in the shaking water bath for exactly 5 minutes, 
the incubation being terminated by immediate centrifugation at 12000g for 30 seconds in a
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microcentrifuge (Eppendorf). The cell-free supernatants were removed and stored at - 
70°C until use.
The dose of Cal used in stimulation and the incubation time, had been 
previously determined and were in agreement with those reported by others (Salmon, 
Simmons & Palmer, 1982a). Addition of A23187 (0.25-10.0 |J.g/ml) to PMN 
suspensions gave a dose-related increase in LTB4  production which was maximal at 1 
|ig/ml (Fig. 4.3). In control incubations, where only buffer was added, no LTB4  could 
be detected within the limits of the assay. Using 1 p.g/ml A23187 in a time-course 
experiment, LTB4  production was shown to increase from 0-5 minutes and thereafter 
decline, presumably due to re-uptake by the cells as a pre-requisite for cu-oxidation (Fig. 
4.4).
In addition, since in many inflammatory states, pyrexia can occur (Duff, 
1985), it was felt necessary to determine whether a typical febrile temperature of 39°C 
could affect LTB4  production in PMN’s. However, when LTB4  formation by Ca I 
A23187 - stimulated cells was measured at 37°C and 39°C, there was found to be no 
significant difference (Fig. 4.5). It is unlikely therefore, that falsely elevated levels of 
LTB4  would be encountered in patients sampled while pyrexic.
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4.4 (c) Assay procedure
The RIA used for the determination of LTB4  was based on that developed by 
Dr. John Salmon of Wellcome Laboratories (Salmon, Simmons & Palmer, 1982a). 
Antiserum to LTB4  and LTB4  standard were both purchased from Wellcome 
Diagnostics, Dartford, England. Tritiated LTB4  ([5,6,8,9,11,12,14,15-^H] - LTB4 ) 
was purchased from Amersham International, Amersham, UK (specific activity 210 
Ci/mmol). Antiserum and standard were kept frozen at -20°C in aliquots sufficient for 
1x 1 0 0  tube assay.
The detailed protocol for the LTB4  assay is shown in Table 4.4. The assay 
was performed directly on cell supernatants, usually diluted 1 :1 0 0  in assay buffer which 
was 50 mM Tris-HCl, pH 8 .6  containing 0.1% gelatin. All assays were carried out in 
10mm x 75mm glass tubes (Samco, UK) and reagents were freshly diluted in buffer 
immediately prior to the performance of the assay. Antiserum was diluted 1:1000 (final 
1:4000), so that approximately 50% of added tracer was bound in the absence of 
unlabelled LTB4  . A series of standard solutions (78-5000 pg/ml) was made by serial 
dilution. Stock tracer was diluted 1:100.
Test-tubes were labelled in duplicate for TC, NSB, B0 , standards and 
samples. Reagents were added to the appropriate tubes as shown in Table 4.4. All tubes 
contained a final volume of 400 (il. One assay normally consisted of 100 tubes, allowing 
construction of a standard curve and the assay of 40 unknowns in duplicate.
A control supernatant, used to assess assay reproducibility was included as a 
sample in each assay. These were generated by incubating several PMN suspensions 
from the same donor with Cal A23187 in the usual way. The resulting supernatants were 
then pooled, mixed, aliquoted into small amounts and stored at -70°C.
After the addition of all the reagents, tubes were vortex mixed and incubated 
overnight at 4°C. On the second day, the bound and free counts were separated as 
previously described in 4.2 (c), using a suspension of 2% charcoal, 0.4% dextran in
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assay buffer. After centrifugation, supernatants were decanted into 10ml of ‘Insta-gel’ 
and counted for 4 minutes each in a (3-counter.
Tube
Reagent TC NSB B0 Standards Samples
Buffer 1 0 0 2 0 0 1 0 0 - -
Standards - - - 1 0 0 -
Samples - - - - 1 0 0
3H-LTB4 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0
Antiserum 1 0 0 - 1 0 0 1 0 0 1 0 0
Buffer 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0
MIX AND INCUBATE 1
DCC - 2 0 0 2 0 0 2 0 0 2 0 0
Table 4.4 Protocol for RIA of LTB4  in PMN supernatants
(All volumes in microlitres)
4.4 (d) Assay characteristics
For each assay a standard curve was obtained by plotting % B/B0  versus pg 
LTB4  /ml on semi-log graph paper. The standard curve obtained over ten assays is 
shown in Fig. 4.6. Total counts were approximately 4000 cpm and 50% displacement of 
bound 3H-LTB4 occurred at 70 pg of added LTB4  . Non-specific binding was typically 
<4%; NSB in the presence of sample was similar. Assay sensitivity was 75 pg/ml; inter- 
and intra-assay variation were 8 .6 % and 6 .6 % respectively. Results were expressed as 
ng LTB4  /1 0 6  cells, the normal range being 6-37 ng/10^ cells. The mean (SD) was 21.9 
(7.1) ng/106 cells . The intra-personal variation as measured in one individual (the author) 
over a two year period (n=12), was 15.7%.
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4.4 (e) Justification for direct assay of supernatants
The measurement of LTB4  by direct RIA of cell-free supernatants has been 
validated by Salmon et al (1982a). The assay was found to be relatively specific in that 
PG’s, TX’s and AA did not cross-react (< 0.03%); cross-reactions with LTC4  and LTD4  
were also insignificant (0.03%). Minor cross-reactions were observed with the 
diastereoisomers of 6 -trans LTB4  (3.3%) and 12-HETE (2.0%). The w-oxidation 
products of LTB4  did not cross-react (Salmon, Simmons & Palmer, 1982b). Table 4.5 
shows a list of all the observed cross-reactivities. In addition, when purified extracts 
from PMN-incubations with A23187 were run on RP-HPLC, only one major peak of 
immunoreactive material (co-eluting with authentic LTB4 ) was detected. After allowing 
for procedural losses, the concentration of LTB4  determined by RIA after extraction and 
purification was comparable to that obtained from direct RIA (Salmon, 1985).
I l l
Compound % Cross-reactivity
LTB4 1 0 0
LTC4 0.03
LTD4 0.03
Diastereoisomers of 5,12- 
di-OH-6,8,10-trans-14- 
cis-eicosatetraenoic acid
3.3
Diastereoisomers of 5,6- 
di-HETE
1 .6
5(S), 12(S)-diHETE 0.14
5-HETE 0.03
12-HETE 2 . 0
11-HETE 0.04
15-HETE <0.03
PGE2  and other PG’s <0.03
Arachidonic acid <0.03
Table 4.5 Cross-reactivity of LTB4 antiserum with LTB4 and related 
compounds
4.5 Measurement of PGl2 -Metabolite Production in PMN’s
4.5 (a) Assay procedure
In one study, the supernatants generated by the A23187-stimulation of PMN’s 
were also assayed for PGl2 -M’s using a [1^1] assay system purchased from Amersham. 
All reagents were diluted in assay buffer (phosphate buffer 0.05M, pH 6 .8  containing 
0.05% BSA) as instructed by the kit method. A series of working standards was 
prepared by serial dilution in the range 31-4000 pg/ml. The tracer, a
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methyl ester (2pCi) was diluted in 10ml assay buffer. Lyophilized antiserum was 
reconstituted by adding 10ml of distilled water.
Polypropylene tubes (12mm x 75mm, Luckham) were labelled in duplicate for 
TC, NSB, B0, standards and samples. Reagents were added to the tubes as shown in 
Table 4.6. A sample of pooled supernatant which was stored in small aliquots at -70°C 
was included in each assay to assess reproducibility. All tubes contained a total volume 
of 500 pi.
After addition of reagents the tubes were vortex mixed and incubated 
overnight at 4°C. The following morning, all tubes (except TC), received 500 pi of 
‘Amerlex-M’ second antibody which was provided with the kit. This, being an anti-body 
to the 6 -keto-PGFioc antiserum, bound antibody-bound tracer. The tubes were then
vortexed and left to incubate at room temperature for 10 minutes. After centrifugation 
(2 0 0 0 g for 10  minutes), the supernatants were decanted to leave the antibody -bound 
fractions which were drained and counted in a gamma-counter for 1 minute each.
Tube
Reagent TC NSB B0 Standards Samples
Buffer - 400 300 2 0 0 2 0 0
Standards - - - 1 0 0 -
Samples - - - - 1 0 0
125l-6-keto PG Fia 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0
Antiserum - - 1 0 0 1 0 0 1 0 0
MIX AND INCUBATE
Amerlex-M - 500 500 500 500
second antibody
Table 4.6 Protocol for RIA of PGl2 -metabolites in PMN supernatants 
(Amersham 125j assay)
(All volumes in microlitres)
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4.5 (b) Assay characteristics
The standard curve obtained over six assays is shown in Fig. 4.7. Total 
counts were approximately 30,000 cpm and the added antiserum bound roughly 40% of 
the added tracer; 50% inhibition of binding occurred at 20 pg of added standard. The 
lower limit of detection of the assay was <31 pg/ml. Inter- and intra- assay coefficients 
of variation were 9.8% and 4.1% respectively. The specificity of the antiserum is 
outlined in Table 4.7.
Compound % Cross-reactivity
6 -keto-PGFioc 1 0 0
PGF2 oc 0 .8
PGE2 0.5
PGFicx 1 .0
PGEi 0.5
TXB2 <0.3
Table 4.7 Cross-reactivity of antiserum in Amersham kit with 6 -keto- 
P G F la and related compounds.
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4.6 Other Methods
The RIA’s described in the preceding sections of the chapter constitute the 
core of the methodology used in this thesis. Additional materials and methods which 
have been used are described elsewhere within the relevant sections. In particular, 
methods relating to the measurement of platelet sensitivity to PGI2  and the use of 
umbilical artery rings to investigate the ability of plasma to support PGl2 -like activity are 
outlined in sections 5.1 and 5.2 respectively.
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CHAPTER 5
INFLAMMATORY VASCULAR DISEASE
5.1 R a y n a u d ’ s  P h e n o m e n o n
5.1 (a) General introduction
Raynaud’s phenomenon (RP) first described over 125 years ago by Maurice 
Raynaud (1862), is constriction of the small blood vessels in one or several fingers or 
toes upon exposure to cold or sometimes to emotion. The classical manifestations are 
pallor of the affected digits, followed by cyanosis and rubor, although this triphasic 
colour change is not now thought to be essential for diagnosis. It exists in various 
degrees of severity in 5-10% of the population and, if severe, can cause pain, digital 
ulceration and even gangrene. Women are affected nine times more commonly than men 
(Belch & Sturrock, 1983).
There is a wide spectrum of disorders with which RP may be associated 
(Table 5.1). In recent years, the development of more sensitive laboratory tests has 
revealed that greater than 50% of patients with RP have an associated systemic disease. 
Over the years the nomenclature used to describe the various sub-classes of the disease 
has been inconsistent and confusing. In this work, the terminology used sub-divides RP 
into Raynaud’s disease (RD), i.e. RP with no associated systemic disease and Raynaud's 
syndrome (RS), i.e. RP with associated disorder. These are also known as “primary” 
and “secondary” Raynaud’s respectively. Long-term studies have shown that RD may be 
the precursor of systemic illness by many years.
Hand and digital blood flow is diminished during an attack of Raynaud’s, 
although the mechanism whereby this is produced is unclear. Table 5.2 shows a list of 
factors which have been suggested as being important in the pathogenesis of RP. 
Naturally, many of the older studies were concerned with the vessel wall and the
117
A . Immunological and connective tissue disorder
Progressive systemic sclerosis 
Systemic lupus erythematosus 
Rheumatoid arthritis 
Mixed connective tissue disease 
Dermatomyositis and polymyositis 
Hepatitis B antigenaemia
B . Occupational
Vibration white finger 
Vinyl chloride workers 
Cold injury (frozen food packers) 
Ammunition (nitrate) workers
C . Obstructive arterial disease
Atherosclerosis 
Thoracic outlet syndromes 
Emboli
D. Drug induced
Beta blockers 
Anti-migraine drugs 
Cytotoxics 
Bromocriptine 
Sulphasalazine
E . Miscellaneous
Cold agglutinins 
Cryoglobulinaemia 
Thyroid disease 
Neoplasm
Chronic renal failure 
Idiopathic Raynaud’s disease
Table 5.1 Disorders with which Raynaud’s Phenomenon is associated
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development of spasm; increased sympathetic tone, local arterial sensitivity to cold and 
deposition of immune complexes in the vessel wall have all been considered (Belch & 
Sturrock, 1983). However, more recently, attention has focussed on the contribution to 
decreased blood flow made by biochemical and cellular abnormalities in the blood e.g. 
leukocyte adherence, plasma viscosity, red cell deformability and platelet aggregation 
(Belch et al, 1987a).
Plasm a Vessel Wall Blood Cells
Hormones
Viscosity
(fibrinogen,
proteins)
Sympathetic innervation 
Immune complexes 
Fibrinolysis
Factor VIH von W.factor 
Prostacyclin
Leukocyte
Erythrocyte
Platelet
Table 5.2 Suggested factors im portant in the pathogenesis of Raynaud’s 
Phenomenon
Treatment of more severe Raynaud’s whether by drugs or sympathectomy, 
has often been unsatisfactory in the past. However, recent work has shown that PGEi 
(Martin et al, 1980) and PGI2  (Belch et al, 1981; Dowd et al, 1982) may be useful in the 
management of this disorder. When given intravenously, these prostaglandins have been 
shown to increase blood flow to the hands and to elevate hand temperature for up to six 
weeks after infusion.
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5.1 (b) Plasma levels of PGl2-metabolites in Raynaud’s phenomenon
5.1 (b) (i) Patients and methods
Since PGI2  is of benefit in the treatment of Raynaud’s, the aim of this study 
was to measure endogenous stable metabolites of PGI2  in 110 patients with RP of 
varying aetiology i.e. 40 patients with primary Raynaud’s disease (RD), 28 patients with 
suspected secondary disease (SS) and 42 with secondary Raynaud’s syndrome (RS); SS 
patients have some, but not all of the criteria required for diagnosis of a connective tissue 
disorder. Results were compared with 50 age, smoking and sex-matched controls.
Plasma samples were prepared and PGl2 -metabolites measured by RIA as 
previously described.
5.1 (b) (ii) Results
It can be seen from Table 5.3 that PGI2 -M levels were found to be elevated in 
patients with SS and RS compared to normal controls. In patients with RD alone and no 
other symptoms, levels were normal. Although the most severe group (RS) demonstrated 
the highest PGl2-M’s, no correlation could be found between PGl2-M’s and frequency or 
duration of spasm attacks as recorded in patient diaries over the two week period 
immediately after blood sampling.
NORMALS RD SS RS
13 + 4 10 ± 2 36 ±7 * 55 ± 6 *
* p < 0.01 (Mann-Whitney)
Table 5.3 Plasma PGI2 -metabolite levels (pg/ml) in patients with
Raynaud’s phenomenon and normal controls (mean ± SD)
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5.1 (b) (iii) Discussion
Given that intravenous infusion of PGI2  is of benefit in the treatment of 
Raynaud’s RS patients might have been expected to produce inadequate amounts of 
PGI2 . However, this study has shown increased levels in patients with SS and RS 
compared to normal controls. This finding is supported by other work. McLaren (1986) 
has reported increased levels of PGl2 -metabolites in diabetics with vascular disease and 
in patients with cardiovascular disease. In addition, PGE-metabolites have been shown 
to be elevated in RP (Horrobin, Jenkins & Manku, 1983).
There are a number of possible explanations for the increased levels of PGI2  
found in secondary Raynaud’s.Firstly, this could be a compensatory mechanism. It is 
known that the endothelium produces PGI2 in response to noxious chemical or 
mechanical stimuli (Ritter et al, 1983), this, repeated vasospastic attacks could lead to a 
chronic increase in PGI2 . If excess PGI2 , production is a compensatory mechanism, 
then infusions of PGI2 given therapeutically would augment this.
A second possibility is that PGI2 may be produced along with other PG’s as 
part of the general picture of inflammation. Chronic re-exposure to increased levels may 
desensitize cells to the action of PGI2 but the even higher levels achieved via infusion 
may be enough to allow the cells to respond normally.
The third possibility is that a cellular resistance to PGI2  exists in RS. 
Prostacyclin increases intracellular cAMP which is then thought to cause a negative 
feedback inhibition of PG production (Horrobin, 1980). However, should this increase 
in cAMP not occur because of a cellular resistance, then PGI2  production would continue 
unchecked. Although “resistance” could be due to an inherent receptor defect or 
decreased number of receptors, it could be as a result of receptor blockage by immune 
complexes (Moretta, Mingari & Romanzi, 1978). A pharmacological dose of PGI2  could 
overcome this resistance and has been shown to normalize cAMP levels in lymphocytes 
from patients with systemic sclerosis (Kirby et al, 1980).
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5.1 (c) Platelet sensitivity to a prostacyclin analogue in systemic 
sclerosis in vitro
5.1 (c) (i) Introduction
Progressive systemic sclerosis (PSS), is a connective tissue disease 
characterized by fibrotic changes involving predominantly skin and blood vessels. Over 
80% of patients with PSS exhibit RP. The pathogenesis is still incompletely understood, 
but it has been suggested that the changes in vascular endothelium seen in the disease may 
be associated with an inflammatory immune response (Kahaley & Leroy, 1979). The 
vascular damage thus produced may contribute to the development of RP.
The previous study showed elevated levels of plasma PGl2 -metabolites in 
RS. One theory to explain this was that there might be abnormal sensitivity to PGI2  in 
RS cells. The aim of this study was to evaluate the PGI2  sensitivity of systemic sclerosis 
platelets compared to that of age- and sex-matched controls. As PGI2  is unstable, 
thereby presenting methodological difficulties such as dose standardisation a stable 
carbacyclin analogue of PGI2 , ZK 36.374 (Schering Chemicals, Ltd) was used (Fig. 
5.1). This analogue, also known as iloprost, has been shown to act via the same platelet 
receptors as PGI2  both in vitro and in vivo (Sturzebecher & Losert, 1987). It is more 
potent than PGI2  as an antiplatelet agent, but induces less vasodilatation (Schror et al, 
1981).
In addition, the PGI2 -sensitivity of platelets from patients receiving either 
CL115,347, a transdermally absorbed PGE analogue (Cyanamid International) or oral 
nifedipine, a calcium antagonist (Bayer) was determined. Both drugs are effective in the 
treatment of RP.
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5.1 (c) (ii) Patients
Twenty-four patients (mean age 45 ±11 years) with classical PSS, as defined 
by the American Rheumatism Association (A.R.A.) criteria, were enrolled in the study. 
Of these, 17 patients were on no drug therapy known to interfere with PG metabolism; 4 
patients from this group subsequently received transdermal CL115,347 and were 
therefore sampled twice. Of the 7 patients remaining, one was sampled while receiving 
the transdermal PG (lmg/24h) and 6  were taking oral nifedipine (10 mg t.i.d.). Again, 
patients sat in a warm room for at least 30 minutes before blood sampling.
Eighteen matched controls (age 44 ± 9 years) were also sampled.
5.1 (c) (iii) Methods
Blood (9 ml) was drawn from the antecubital fossa and anticoagulated with 1 
ml of 3.2% trisodium citrate. The blood was carefully mixed and centrifuged (150 g) for 
7 minutes at room temperature to obtain platelet-rich plasma (PRP). Platelet-poor plasma 
(PPP) was then prepared by centrifugation of the remaining blood at 2000 g for 15 
minutes. The platelet count in the PRP was standardized to approximately 250 x 10% by 
diluting with autologous plasma.
Platelet aggregation (PA), was studied in 200 |il of PRP according to the 
method of Born (1962), using a two channel Matin’s aggregometer connected to a chart- 
recorder. The aggregometer works on the principle of change in tight absorbance in the 
PRP. Addition of an aggregating agent causes the platelets to clump thereby decreasing 
the turbidity of the sample and allowing more tight to pass through. The transmitted tight 
is converted to an electrical signal which results in an aggregation curve (Fig. 5.2) being 
generated on the chart recorder. The aggregation rate is calculated by measuring the 
gradient at the steepest part of the curve (arbitrary units).
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Each of the PRP samples being studied was incubated (with continuous 
stirring) in turn with 1 0 0  p.1 isotonic saline, 1 0 0  p.1 of iloprost (2  ng/ml) and 1 0 0  pi 
of iloprost (3 ng/ml) for 3 minutes at 37°C. The dilutions of iloprost were made in 
saline. Following the 3 minute incubation, each sample received 3 p.1 of 2^nM 
adenosine-5-diphosphate (ADP) (Sigma), as an aggregating agent. Each incubation was 
carried out in duplicate. The doses of iloprost were compatible with those intended for 
therapeutic use of the drug (Belch et al, 1984).
The difference in rate of aggregation (gradient) obtained between iloprost- 
treated and saline-treated samples was expressed as a percentage inhibition of the saline 
control.
5.1 (c) (iv) Results
The results obtained from this study are shown in Table 5.4 and graphically, 
in Figures. 5.3 and 5.4.
% Inhibition of platelet aggregation
2  ng/ml iloprost 3 ng/ml iloprost
NORMALS 59 ± 17 85 ±11
PSS 18 ± 13 * 49 ± 19 *
PSS + Rx 6 8  ±18 85 ±15
* significantly different from normal controls ( p < 0.001, Mann-Whitney) 
Rx = treatment (CL 115,344 or nifedipine)
Table 5.4 Platelet sensitivity to iloprost in patients with progressive 
systemic sclerosis (PSS) and normal controls (mean ± SD)
Pre-incubation of normal PRP with 100 p.1 of 2 ng/ml iloprost caused 59 ± 
17% of aggregation to ADP to be inhibited. However, when the same amount of iloprost
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was added to the platelets from PSS patients on no treatment, only 18 ± 13% of PA was 
inhibited. The same pattern was repeated at the higher dose of iloprost (3 ng/ml), 85 ± 
11% inhibition of PA for normal controls and 49 ± 19% for patients (Fig. 5.3). These 
results were statistically significant (p < 0.001, Mann-Whitney).
In contrast, the platelet sensitivity to iloprost in PSS patients on either 
nifedipine or CL115.347 was in the normal range (6 8  ±18%  and 85 ± 15%) (Fig. 5.4). 
In an effort to show that this difference was not due to a difference between the two 
groups of patients, but due to the effect of treatment, four of the patients originally on no 
treatment were given a 2 -week course of CL115,347 and then re-tested. It can be seen 
from Fig. 5.5 that the initial abnormal sensitivity to iloprost was normalised by this 
treatment
The baseline (saline only) rate of aggregation in this study demonstrated no 
significant difference between PSS patients and normal controls (12.9 ± 4.2 and 12.8 ± 
3.6, respectively).
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Fig. 5.3. Percentage inhibition of platelet aggregation curves by 2 and 3 ng/ml 
iloprost (ZK 36.374) in normal controls and PSS patients.
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.1 (c) (v) Discussion
This study demonstrated that the platelets of patients with progressive 
systemic sclerosis are somewhat resistant to the anti-aggregatory effects of the synthetic 
PGI2  analogue iloprost. The platelets of patients with other vascular disorders have been 
shown to display a similar decrease in responsiveness to PGI2  (Mehta & Mehta, 1980; 
Briel, Kieback & Lippert, 1984) and it is thought that this contributes to the clinical 
manifestations of ischaemia. Moreover, since PGI2  sensitivity decreases even further at 
lower temperatures (Mikhailidis, Hutton & Dardona, 1981), aggregation of 
“desensitized” platelets in the microcirculation with the concomitant release of 
vasoconstrictor substances, could play an important role in the development of Raynaud’s 
phenomenon.
It appears that PG resistance may be a general phenomenon is PSS since both 
the lymphocyte (Kirby et al, 1980) and the macrophage (Whicher et al, 1984) in this 
disorder appear to display resistance to PG’s. Since PGI2  levels have been shown to be 
elevated in PSS patients, it may be that a “tachyphylaxis” or “down-regulation” is 
occurring. A possible analogous situation has been observed in pregnancy, where PGI2  
resistance develops physiologically as the plasma levels of PGI2  increase (Briel et al, 
1984) and also during long-term intra-arterial infusions of PGI2  (Sinzinger et al, 1981). 
Although in this study, the transdermally absorbed PGE appeared to normalize the 
response of the platelets to iloprost, it may be that pharmacological doses of PG’s only 
allow resistant cells to respond normally for a limited period of time, before tachyphylaxis 
re-occurs.
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The calcium antagonist nifedipine was also shown to normalize the platelet 
sensitivity to iloprost. Nifedipine is known to decrease platelet activation and the 
subsequent release of TXA2  either directly by it’s action on platelets or indirectly by it’s 
action on smooth muscle, or both (Malamet et al, 1985). Since TXA2  is antagonistic to 
the action of PGI2 , any decrease in this mediator may enhance the action of available 
PGI2 .
The intracellular response to PGI2  is mainly, if not exclusively, mediated by 
stimulation of the receptor-coupled adenylate cyclase system which causes an increase in 
cAMP and subsequently, a rise in intracellular calcium. The mechanism whereby 
decreased sensitivity occurs has been studied in a neuronal hybrid cell line where 
prolonged culture in the presence of iloprost results in a substantial loss of sensitivity to 
PGI2  and PGEi (Leight & MacDermot, 1985). It was discovered that desensitization in 
this case was accompanied by a loss of high affinity receptors. It seems likely, therefore, 
that the phenomenon in general may be associated with “exhaustion” of PG receptors.
In conclusion, therefore, a resistance of the PSS platelet to the anti­
aggregatory effects of PGI2  has been demonstrated and could be an important factor in 
the development of digital ischaemia. This observation supports the hypothesis of a 
generalized cellular resistance in PSS, which, if it is extrapolated to other cell types, could 
explain some of the additional manifestations of this disease. For instance, in PSS there 
is augmented growth of collagen-producing fibroblasts (Botstein, Sherer & Leroy, 1982) 
which are normally inhibited by PGI2 . If these fibroblasts are resistant to the negative 
control of PG, this might explain the increased collagen production seen in this condition.
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5.1 (d) Leukotriene B4 production from PMN’s in Raynaud’s 
phenomenon
5.1 (d) (i) Introduction
Although platelets, RBC’s and plasma constituents have long been recognized 
as being involved in the maintenance of blood flow and in the development of 
thrombosis, relatively little attention has been given to the possible contribution of 
leukocytes. Recent studies however, have noted that subjects at risk from developing 
ischaemic events have increased leukocyte numbers (Kostie, Turkevich & Sharp, 1984; 
Lowe et al, 1985). In addition, histopathological studies of ischaemic tissue have shown 
adhesion and aggregation of leukocytes, mainly PMN’s, to the endothelium and 
migration of cells into the necrotic area (Simpson & Lucchesi, 1987). These PMN 
aggregates may physically obstruct blood flow and cause further tissue damage by the 
release of free radicals and other active substances.
Leukotriene B4  has been shown to play an important role in the regulation of 
PMN behaviour. Hence, PMN’s and their potential to produce LTB4  could be important 
in the development of vascular occlusion and RP. The aim of this study was to 
investigate LTB4  generation of PMN cells in patients with secondary RP compared to that 
in normal controls. However, in this instance, two distinct groups of secondary 
Raynaud’s patients were examined; those with RP associated with systemic sclerosis and 
another group suffering from RP of occupational origin, also known as Vibration- 
Induced White Finger Syndrome (VWF). This condition affects a large proportion of the 
workforce exposed to vibrating tools (pneumatic drills, chain-saws, polishing tools), and 
can be of such severity that since 1985 it has been a prescribed disease eligible for 
compensation (Taylor, 1985). As yet, the pathophysiology is not fully known, but the 
manifestations closely resemble the spontaneous vasoconstrictive phenomena induced by 
exposure to cold in RP.
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5.1 (d) (ii) Patients and methods
Twenty-six patients with grade 3 VWF as classified by the Taylor-Pelmear 
scale (Table 5.5) were enrolled in the study. All were, or had been, employed as 
boilermakers exposed to vibrating machines such as chippers, grinders and buffs. Fifty 
five patients with secondary RP associated with systemic sclerosis were also studied. As 
VWF is predominantly a disease of men and systemic sclerosis a disease of women, these 
two groups could not be matched for sex. Results were compared to those of 59 age- and 
smoking-matched normal controls who had not been exposed to vibration. The 
comparability of the three groups is outlined in Table 5.6.
None of the subjects had taken any medication known to interfere with the test 
and smokers were asked to refrain from smoking from 12  midnight prior to the day of 
sampling.
Blood was collected and PMN’s prepared and stimulated with Cal A23187 as 
previously described. The resultant supernatants were assayed for LTB4  using RIA, also 
as previously described (section 4.4).
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TAYLOR-PELMEAR SCALE
STAGE CONDITION OF DIGITS WORK AND SOCIAL 
INTERFERENCE
0 No blanching of digits No complaints
OT Intermittent tingling No interference with activities
ON Intermittent numbness No interference with activities
1 Blanching of one or more 
fingertips with or without 
tingling and numbness
No interference with activities
2 Blanching of one or more 
fingers with numbness. 
Usually confined to Winter
Slight interference with home and social 
activities. No interference at work.
3 Extensive blanching. Frequent 
episodes Summer as well as 
Winter.
Definite interference at work, at home 
and with social activities. Restriction of 
hobbies.
4 Extensive blanching. Most 
fingers; frequent episodes 
Summer and Winter
Occupation changed to avoid further 
vibration exposure because of severity 
of signs and symptoms.
Table 5.5 Classification of the stages of the vibration syndrome (Taylor- 
Pelmear)
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VWF PSS Controls
Numbers 26 55 59
Age (median (range)) 49 (27-65) 43 (28-68) 35 (22-60)
Sex M:F 26:0 8:47 33:26
Smokers 17 29 25
Duration of symptoms 5 9 _
(years, median (range))
(3-20) (2-15) -
Duration of vibration 29 _
exposure (years,
median (range)) (5-49) - -
Table 5.6 Comparability of VWF, PSS and control groups
(VWF = vibration white finger 
PSS = progressive systemic sclerosis)
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5.1 (d) (iii) Results
Results (median (interquartile range)), are shown in Table 5.7 and graphically
in Fig. 5.6.
PSS VWF Normal Controls
24.5 * 
(21.0 - 29.5)
26.2 * 
(2 2 .0  - 28.8)
2 0 .0  
(15.0 - 25.8)
* p < 0.001 Mann-Whitney
Table 5.7 LTB 4 levels (ng/106 cells) in stimulated PMN’s from PSS, 
VWF and normal controls (median (IQR))
Leukotriene B4  production from stimulated PMN’s was increased in patients 
with VWF and PSS (both p <0.001, Mann-Whitney) compared to normal controls. 
Comparison of the LTB4  produced by PMN’s from age-matched male and female normal 
subjects showed that there was no inherent difference in levels between the two sexes 
(Fig. 5.7).
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5.1 (d) (iv) Discussion
This study has demonstrated for the first time, an increased production of 
LTB4  from PMN’s of individuals with Raynaud’s phenomenon secondary to systemic 
sclerosis and VWF. This observation appears to be consistent with the hypothesis that a 
generalised loss of sensitivity to PGI2  occurs in PSS cells, since decreased sensitivity of 
PMN’s could lead to loss of the suppressive effect of PGI2  on LTB4  synthesis 
(Claesson, Lundberg & Malmsten, 1981), resulting in increased levels.
Leukotriene B4  has previously been shown to be a potent PMN chemotactic 
and aggregating agent, as well as a mediator of increased adhesion of PMN’s to the 
endothelial lining of blood vessels. PMN’s from PSS patients were, in fact, observed to 
be abnormally adherent during preparation. All of these effects could contribute to the 
development of vascular occlusion. In addition, PMN’s activated in this way have been 
implicated in vessel wall damage via the release of other substances including lysosomal 
enzymes and reactive metabolites of oxygen.
It is unlikely in either systemic sclerosis or VWF, that increased potential for 
LTB4  production is a primary event in the pathophysiology of these conditions. The 
initial effect of vibration on the digital vasculature is to stimulate proliferation of the 
medial coat and subsequently, the intima of the arterial wall (Belch et al, 1989). Although 
this may not be severe enough to cause arterial occlusion, the abnormal vessel wall may 
activate PMN’s as they flow past. This would then contribute to decreased blood flow as 
described and may enable a vicious cycle of ischaemia, reperfusion, vessel damage, PMN 
activation then further ischaemia, to be set up.
The finding that LTB4  is increased in VWF supports other evidence 
suggesting that this disease is a true secondary Raynaud’s syndrome. Other 
abnormalities, such as decreased RBC deformability, increased whole blood viscosity 
and higher plasma factor VIII von Willebrand factor have been found in VWF as well as 
RS (Belch et al, 1989).
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In summary, the increase in LTB4  production seen in PMN’s from systemic 
sclerosis and VWF patients could be relevant to the development of RP. The increase in 
LTB4 is unlikely to be a primary event in either disease, but does suggest a common 
mechanism in part of their pathophysiology.
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5.1 (e) Effect of transdermal iloprost on production of leukotriene B4 
from PMN’s in normal volunteers
5.1 (e) (i) Introduction
The intravenous infusion of prostacyclin has proven beneficial in the treatment 
of patients with Raynaud’s syndrome (Belch et al, 1981). However, intravenous 
administration entails some degree of inconvenience to the patient as it requires hospital 
admission. Although the synthetic analogue of PGI2  , iloprost, is chemically more stable 
than PGI2  , studies of orally administered iloprost have shown that the drug is rapidly 
metabolized when given in this way (Krause, Skuballa & Schulze, 1983). Any increase 
in dosage may merely increase side-effects.
The clinical aim of this study was to investigate the possibility of using 
transdermally applied iloprost, since this could be more easily and continuously applied. 
It was necessary in the first instance, to try the method on normal volunteers and this 
provided an opportunity to study the possible effect of iloprost on LTB4  production by 
PMN cells ex vivo. This was of particular interest in view of results from the previous 
study which showed that LTB4  production from PMN’s was increased in RS.
5.1(e) (ii) Study design and methods
Eight normal volunteers were enrolled. A grid (10 x 10 cm) was drawn on 
the skin of the back and different doses of iloprost, diluted in 70% ethanol, were applied 
using a fine paint brush. The area was left to dry and then occluded. Two volunteers 
received 0.37 jig of iloprost, two 0.57 fig, two 0.75 jig and two 1.50 jig. Subjects were 
sampled prior to the start of the study, and again at 1, 3, 6 , 24, 48 and 72 hours later. 
The dose-pair receiving the highest dose of iloprost (1.50 p,g) were also sampled at 12 
hours. Two “control” volunteers, receiving no iloprost were to be sampled at intervals 
throughout the day to check for the effect of diurnal variation on blood tests. However, 
due to difficulties encountered in the bleeding of one of these subjects, only one “control”
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was sampled. Blood was collected, PMN’s isolated and after Ca ionophore stimulation, 
the resultant supernatants assayed for LTB4  using RIA as previously described.
5.1 (e) (iii) Results
The LTB4  levels determined by RIA in PMN’s sampled throughout the period 
of transdermal application of iloprost are shown in Fig. 5.8. The results obtained are 
difficult to summarize for although there appears to be good correspondence in change in 
LTB4  levels between dose-pairs, it is difficult to assess a clear dose effect on LTB4  by 
iloprost. At all doses, a “spike” of increased LTB4  production was seen at 0-3 hours, 
although this varied in magnitude. In all but one case, LTB4  levels then appeared to fall 
below baseline level at some stage in the next 72 hours; this fall was earliest and most 
pronounced in the pair which received the highest dose of iloprost.
Levels of LTB4  in the cells of the control subject remained essentially 
unchanged  th ro u g h o u t p e rio d  o f m easu rem en t (F ig . 5 .8).
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144
 I_______________________ I____________________ I___________________ I____________________ I--------------------------------- 1
pre 3 6 24 48 72
Hours
Fig. 5.9. Effect of transdermal iloprost on whole blood platelet aggregation in 
normal volunteers.
(Reproduced with permission from Belch et al, 1987b)
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5.1 (e) (iv) Discussion
Drugs administered transdermally can be given long-term and patient 
acceptance is good. The aim of this study was to determine the efficacy of iloprost 
administered in this way. Parallel measurements of whole blood platelet aggregation 
made in the same study (Belch et al, 1987b), showed that the transdermally applied 
iloprost had a definite systemic effect since a decrease in platelet aggregation was 
observed at all doses and was more prolonged at the higher doses(Fig. 5.9)
Some subjects experienced a transient (but clinically insignificant) fall in blood 
pressure during the treatment, but other side-effects which potentially include nausea, 
flushing and headache, were minimal.
The reason for the initial increased production of LTB4  observed in the first 3 
hours is uncertain. However, as previously described (section 2.9), PG’s have a dual 
effect on inflammation followed by a later suppressant effect due to elevated cAMP 
levels. It may be that the immediate effect of iloprost in this instance (either direcdy or 
indirectly) was PMN activation resulting in an increased potential for LTB4  production 
followed by a decrease potential as cAMP levels were increased. Schillinger (1984), in 
early pharmacological studies of iloprost, noted that serotonin release from adherent 
platelets in vitro initially increased and then decreased after treatment with iloprost or 
prostacyclin. No explanation could be given for this increase at that time.
Whatever the mechanism, if this transient increased potential for LTB4  
production is a real phenomenon in vivo, then it may be an undesirable effect in 
Raynaud’s patients. However, results also indicate that in the longer term (in the next 
few days) and at the higher doses of iloprost, PMN’s may actually exhibit a decreased 
potential to synthesize LTB4 . This would seem to support other work, carried out in 
vitro. Claesson, Lundberg & Malmsten (1981), have demonstrated a clear inhibition of 
LTB4  release from activated PMN’s at pharmacological doses of PGI2 - In addition, 
Belch et al (1987c) have shown that iloprost inhibits PMN adhesion and aggregation in 
vitro, both functions mediated by LTB4 .
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In summary, although the results from this study suggest that iloprost may 
have a suppressive effect on LTB4  production in PMN’s ex vivo, it’s beneficial anti­
platelet and vasodilatory effects are likely to be the most important in giving improved 
blood flow in RS patients.
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5.1 (f) Effect of iloprost on LTB4 production from PMN’s in vitro
5.1 (f) (i) Methods
In view of the results from the previous study, it was decided to look at the in 
vitro effect of iloprost on LTB4  production from normal PMN’s. Polymorpho-nuclear 
leukocytes were isolated in the usual way and 5 x 1 0^ cells were resuspended in 0.8 ml 
of HEPES/HBSS in polypropylene micro-centrifuge tubes (Eppendorf). To these 
suspensions were added either 0.1 ml of phosphate buffered saline (PBS) or 0.1ml 
iloprost/PBS dilutions to give final concentrations of 0.2, 2.0 and 200 pM iloprost. 
Three tubes were set up for each concentration of iloprost. The cells were then pre­
incubated at 37°C for 20 minutes by gentle rolling of the tubes on an automatic roller. 
The tubes were subsequently removed from the rollers and, after addition of 0.1 ml Cal 
A23187 (10 pg/ml), were further incubated for 5, 10 or 20 minutes with vigorous 
shaking in a 37°C water bath. The reaction was terminated by centrifugation and the 
supernatants removed for measurement of LTB4  by RIA as previously described.
It must be emphasized that even the minimum concentration of iloprost used in 
these in vitro experiments (0.2 pM) was approximately one hundred times the plasma 
concentration of iloprost likely to be achieved in the transdermal study. The highest 
concentration used in the in vitro study (200 pM) was approximately equal to the 
concentration which is achieved during I.V. infusion of iloprost in RS patients and which 
had already been shown to be clinically effective (Belch et al, 1981).
5.1 (f) (ii) Results
The results are shown in Fig. 5.10. Each point is the mean (SEM) of five 
experiments. Iloprost-treated PMN’s gave the same pattern of LTB4  production as 
control cells i.e. LTB4  synthesis peaked after 5 minutes of incubation with Cal A23187 
and thereafter declined. No significant difference in LTB4  production was found 
between control cells and those treated with iloprost.
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5.1 (f) (iii) Discussion
The effect of iloprost on LTB4  production from PMN’s in this in vitro 
system, if any, was undramatic. In contrast, Claesson et al (1981) found that PGI2  at 
pharmacological concentration (2-3 |i.M) gave a 55% inhibition of LTB4  release from 
human PMN’s activated with serum-treated zymosan. In addition, Ham et al (1983) 
reported a 50% inhibition of LTB4  production from PMN’s incubated with 100 |iM 
PGEi and PGE2  using another leukocyte activator, FMLP. It is possible therefore, that 
inhibition by iloprost is only observed in vitro when stimuli more subde than Cal A23187 
are used.
The possibility that iloprost could have a different effect from authentic PGI2  
seems unlikely, since both bind to the same receptor sites and iloprost appears to 
suppress LTB4 -mediated PMN functions (Belch et al, 1987c).
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5.1 (g) Effect of transdermal iloprost on production of LTB4 from  
PMN’s in Raynaud’s patients
5.1 (g) (i) Introduction
The clinical aim of this study was to assess the efficacy of transdermally 
administered iloprost in the treatment of Raynaud’s phenomenon. In view of the results 
from the normal volunteer study (section 5.1 (e)) it was also of interest to see if LTB4  
production from isolated PMN’s was altered over a treatment period of 20 weeks. In 
addition, it was proposed to correlate baseline LTB4  values with the frequency and 
duration of spasm attacks in the 2  weeks immediately after baseline sampling.
5.1 (g) (ii) Patients and methods
Fourteen patients with RP of varying aetiology were enrolled in the study 
which was of the “single-blind” type i.e. only the clinician knew who was receiving 
which treatment. Over a period of 16 weeks patients received sequentially (4 weeks 
each), placebo, “low dose” iloprost (1.5 pg once daily), “middle dose” iloprost (2.0 jig 
once daily) and “high dose” iloprost (2.0 pg twice daily). Patients were sampled once 
during each of the placebo, low dose and middle dose periods and twice (weeks 2 and 4) 
during the high dose period. The number, duration and severity of spasm attacks was 
recorded by the patients in special diaries. Not all patients completed the study.
Polymorphonuclear leukocytes were isolated from blood, stimulated with Cal 
A23187 and the supernatants assayed for LTB4  in the usual way.
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5.1 (g) (ill) Results
The effect of the three different doses of transdermal iloprost on LTB4  
production from PMN’s in Raynaud’s patients is shown in Table 5.8. Values 
(mean(SD)) are expressed as a percentage of those obtained during the placebo phase. 
There was a significant decrease in LTB4  production with low dose and middle dose 
iloprost (both p <0.03) but not with the high dose.
LTB4 (% of placebo)
Placebo Low Dose Middle Dose High Dose
week 2 week 4
Mean 1 0 0 98.8* 89.8* 1 0 2 .0 94.5
(SD) (25.0) (14.8) (26.8) (28.0)
n =  11 n = 5 n = 5 n = 9 n = 8
* p < 0.03, (Mann-Whitney)
Table 5.8 Effect of low dose (1.5 |ig once daily), middle dose (2.0 jig 
once daily) and high dose (2 .0  p,g twice daily) transdermal 
iloprost on LTB4 production from Cal A23187-stimulated 
PMN’s in Raynaud's patients
However, a significant decrease in both the frequency (p <0.02) and duration 
(p <0.01) of Raynaud’s attacks was observed on “high dose” iloprost (Mann-Whitney), 
but not at the low and middle doses.
No significant correlation could be found between LTB4  and the duration or 
frequency of spasm attacks as recorded in patient diaries in the 2  weeks immediately after 
baseline blood sampling.
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5.1 (g) (iv) Discussion
Previous studies have shown that I.V. infusion of PGl2 /iloprost is beneficial 
in the treatment of Raynaud’s Phenomenon (Belch et al, 1981; Dowd et al, 1982). 
Results from this study have shown that transdermally applied iloprost is also able to 
produce a clinical improvement in RP patients with respect to the duration and frequency 
of spasm attacks. No objective parameters of disease activity (such as change in digital 
blood flow) were examined in this study.
It has already been demonstrated (section 5.1 (d)), that the potential for LTB4 
production in PMN’s from RP patients is increased in comparison to normal controls. 
Since the PGl2 -sensitivity of other cells including platelets (section 5.1 (c)) and 
lymphocytes (Kirby et al, 1980) is decreased in RP, it may be that PMN’s also exhibit 
this resistance resulting in a loss of the suppressive effect of PGI2  on LTB4 synthesis. 
In the case of the platelet, pharmacological doses of PGl2 /iloprost appear to overcome 
this resistance, resulting in reduced platelet aggregability. Results from this limited study 
suggest that the RP PMN may also respond to iloprost, resulting in decreased production 
of LTB4. However, the fact that the clinical improvement in the RP patients did not 
coincide with the reduction of LTB4 levels, reinforces the idea that the beneficial effects 
of iloprost in the treatment of RP are mediated mainly by it’s platelet anti-aggregatory and 
vasodilatory effects rather than its effects on leukocytes, but does not preclude the 
possibility that the inhibition of LTB4 made some contribution..
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5.1 (h) Effect of ketanserin on LTB4 production in PMN’s in Raynaud’s 
Phenomenon
5.1 (h) (i) Introduction
Many different therapeutic approaches to the treatment of RP, based on 
different theories regarding it’s pathogenesis, have been tried. Serotonin (5-hydroxy 
tryptamine) is a platelet aggregant and a potent vasoconstrictor which also amplifies the 
constriction induced by noradrenaline and cooling (Van Nueten et al, 1988; Vanhoutte & 
Janssens, 1978). In pathological conditions where platelet activation occurs, large 
amounts of TXA2  and serotonin may be released and a mutual amplification of then- 
contractile effects on smooth muscle probably occurs (Van Nueten et al, 1988). It has 
been suggested therefore, that the local release of serotonin may be involved in the cold- 
induced vasospasm of RP.
Previous studies have shown that the serotonin-antagonist ketanserin (Janssen 
Pharmaceuticals) given intravenously, increased finger blood flow and temperature in 
patients with RP (Stranden, Roald & Krohg, 1982; Coffman & Cohen, 1988). 
Pharmacologically, Ketanserin is a selective antagonist of serotonin at S2 receptors in 
blood vessels and platelets where it antagonizes serotonin-induced vasoconstriction and 
aggregation respectively (Van Neuten et al, 1981). However, orally administered 
ketanserin has not been consistently shown to be of benefit in RP in studies of small 
groups of patients (Roald & Seem, 1984; Bounameaux et al, 1984). For this reason, in 
1986/87, a large multi-centre study (222 patients) of ketanserin in the treatment of RP 
was undertaken. As a result, a group of RP patients at Glasgow Royal Infirmary were 
enrolled in the study. This provided an opportunity to study the effect of ketanserin on 
LTB4  production from PMN’s in RP patients.
5.1(h) (ii) Patients and methods
Sixteen patients were enrolled in the study after informed consent had been 
obtained. However, 4 patients did not fulfill the inclusion criteria of the study and were
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not sampled beyond the run-in period when all patients discontinued vasoactive 
medications and received placebo for a period of 1 month. Thereafter, the 12 remaining 
patients were randomly assigned in a double-blind manner, to receive ketanserin (2 0  mg 
three times a day for 2 weeks, then 40 mg three times a day for 14 weeks) or identical 
placebo tablets. All patients were sampled at the end of the run-in period (time 0) after 
which it was intended that the patients be sampled at 2 weeks and then every 4 weeks. 
However, since the study took place during the winter months and included the 
Christmas holiday period (December-March), patient attendance was poor. In addition, 
on occasion PMN preparations from these patients had to be discarded due to their 
tendency to clump during isolation.
Both primary and secondary Raynaud’s patients were included in the study. 
These were of the ratio 1:5 in the active treatment group and 2:4 in the placebo group. 
Patients kept daily diaries of frequency, duration and severity of attacks during the run-in 
and treatment periods.
Isolation of the PMN’s and their subsequent stimulation with Cal A23187 
was carried out as previously described. The resultant cell supernatants were assayed for 
LTB4  using RIA also as previously described.
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5.1 (h) (iii) Results
The change in LTB4  production from A23187-stimulated PMN’s over the 
period of ketanserin treatment is shown in Fig. 5.11. Values are expressed as a 
percentage of those obtained at the end of the run-in period (time 0). LTB4  levels in the 
placebo group had a tendency to rise over the 16 week period while those in the 
ketanserin group tended to be more stable or fall. Inter-group analysis (Mann-Whitney) 
showed a significant difference in LTB4  between the two groups at 8-10 weeks (p 
<0.002) although this difference was not apparent at 14-16 weeks (Table 5.9).
Leukotriene B 4 (% of run-in)
4-6 weeks 8 -1 0  weeks 14-16 weeks
Ketanserin 93.6 85.6* 1 1 1 .8
Group
(21.5) (2 0 .6 ) (37.6)
Placebo 113.7 131.6 123.0
Group (31.4) (19.5) (30.2)
Table 5.9 Effect of oral ketanserin on LTB4 production from Cal A23187 
- stimulated PMN’s of Raynaud’s patients (Mean (SD)).
* significantly different from placebo group at 8-10 weeks (p <0.002, Mann- 
Whitney).
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5.1 (h) (iv) Clinical evaluation of ketanserin-collated results from multi­
centre study
Clinical results from the multi-centre study were collated and published by 
Coffman et al (1989). Subjective assessment of treatment (patient diaries) showed that 
the frequency of vasospastic attacks decreased with both ketanserin and placebo, but a 
significantly greater reduction of 34% occurred with ketanserin compared to 18% with 
placebo (p = 0.011). There was no significant difference in duration or severity of 
attacks in either group.
Objective assessment was carried out by measuring digital blood flow using 
strain gauge plethysmography. However, no significant changes in finger blood flow 
were found in either group.
Global evaluation showed overall benefit with ketanserin compared to placebo 
whether assessed by the investigator (p = 0.03) or the patient (p <0.01). Patients with 
primary or secondary RP responded similarly to treatment.
5.1 (h) (v) Discussion
In vitro pharmacological studies have demonstrated S2-receptors in arteries 
and veins of the human hand which can be stimulated by serotonin and antagonized by 
ketanserin (Ameklo-Nobin & Owman, 1985). However, studies with ketanserin in RP 
have produced varying results, probably due to variation in aetiology and severity within 
small groups of patients. In a multi-centre study, using a large sample of RP patients, 
ketanserin has been demonstrated to be of benefit in RP (Coffman et al, 1989).
Treatment of a small group of RP patients at Glasgow Royal Infirmary as part 
of this larger study provided an opportunity for the effects of ketanserin on LTB4  
production by PMN’s ex vivo to be investigated It was notable that in the placebo group, 
the potential for LTB4  production tended to increase over the study period and a 
significant difference was observed, compared to the ketanserin group, at 8 - 1 0  weeks. 
This is consistent with the fact that these patients had been withdrawn from their usual
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therapy and were sampled during the winter months when vasospastic attacks are 
typically most frequent and severe. In contrast, in the group receiving ketanserin, LTB4  
levels appeared to be more stable, which may reflect a decreased incidence of vasospastic 
episodes in these patients. Thus, ketanserin, by it’s antagonistic action towards serotonin 
may affect the cycle of vasospasm, ischaemia, reperfusion, vessel damage and PMN 
activation which is postulated to occur in RP (Belch et al, 1989).
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5.1 (i) Effect of stanozalol on LTB4 , production from normal PMN’s in 
vitro
5.1 (i) (i) Introduction
Many patients with Raynaud’s phenomenon, particularly those with 
secondary disease, have reduced blood fibrinolytic activity leading to raised plasma 
fibrinogen concentrations and possibly deposition of fibrin in the vascular endothelium 
(Jarrett, Morland & Browse, 1978). This is thought to contribute to impaired blood flow 
in RP.
In normal subjects, fibrin is removed by enzymatic degradation mediated by 
plasmin. Plasmin is produced by cleavage of it’s inactive precursor plasminogen and the 
rate of this reaction is determined by the relative proportion of activators and inhibitors of 
fibrinolysis present. Belch et al (1987a) have shown a decrease in plasminogen activator 
activity and an increase in plasma fibrinogen in patients with RS.
Stanozalol (Sterling Research) is an anabolic steroid which enhances natural 
fibrinolysis in both normal volunteers (Preston, 1981) and RS patients (Jarrett et al, 
1978). Treatment of RS patients with stanozalol results in increased hand blood flow and 
a reduction in other symptoms. However, these changes were found to persist for at least 
three months after the cessation of treatment, despite the fact that plasma fibrinogen and 
blood fibrinolytic activity had returned to pre-treatment values.
This has led to the conclusion that stanozalol does not operate solely through a 
reduction in plasma fibrinogen and the concomitant decrease in blood viscosity, thus, it’s 
mode of action still remains to be conclusively determined. The aim of the study was to 
determine what effect, if any, stanozalol had on LTB4  production from normal PMN’s in 
vitro.
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5.1 (i) (ii) Methods
Polymorphonuclear leukocytes were isolated from the blood of normal 
subjects as described previously. The cells (5 x 10^) were resuspended in 880 p.1 of 
HEPES/HBSS (pH 7.4) and 20 |il of stanozalol in ethanol/buffer or 20 |il of 
ethanol/buffer alone were added to the suspensions. The final concentration of ethanol in 
the incubation buffer was 0.7%. The final concentrations of stanozalol in the incubations 
were 0.16, 1.6 and 16 Jig/ml. The value of 1.6 |ig/ml corresponds approximately to the 
in vivo therapeutic dose (5-10 mg/day). The cells were then incubated for 20 minutes at 
37°C by rotating the tubes gently on rollers. On two occasions, Cal A23187 (final 
concentration 1 Jig/ml) was added immediately after this incubation and the cells 
incubated for a further 5 minutes or 15 minutes in a vigorously shaking water bath at 
37°C. On two other occasions, the same procedure was followed except that, after the 
incubation with stanozalol, the cells were pelleted and washed once with 1 ml of 
HEPES/HBSS before proceeding with the ionophore stimulation.
After stimulation with A23187, the cells were immediately sedimented by 
spinning in a micro-centrifuge for 30 seconds at 12,000 g. The resulting supernatants 
were assayed for LTB4  by RIA as previously described.
5.1 (i) (iii) Results
Figure 5.12 shows the effect that pre-treatment with stanozalol had on LTB4 
production from normal PMN’s stimulated with Cal A23187. In all four experiments, 
stanozalol at 1.6 and 16 (ig/ml caused an inhibition of LTB4  production such that levels 
fell below the detection limit of the assay (<0.6 ng/10^ cells). In two of the experiments, 
stanozalol at a final concentration of 0.16 |ig/ml was included, this was found to cause an 
approximately 50% inhibition of LTB4  production. Inhibition was observed at all three 
concentrations of stanozalol whether or not the cells were washed after stanozalol 
treatment.
161
In all cases where the PMN’s were treated with stanozalol at 16 Jig/ml, the 
cells visibly clumped. This brought into question the viability of the cells after stanozalol 
treatment. The viability of PMN’s treated with 1.6 P-g/ml stanozalol was therefore 
checked using Trypan Blue exclusion and was found to be 98%.
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5.1 (i) (iv) Discussion
This study has demonstrated that the anabolic steroid stanozalol causes a clear 
inhibition of LTB4  production from ionophore-stimulated PMN’s in vitro. It does not 
necessarily follow that this effect can be extrapolated to the in vivo situation, but the 
concentrations of stanozalol causing inhibition are certainly compatible with the 
pharmacological dose.
The fact that inhibition occurs after washing of the cells indicates that 
stanozalol is not merely preventing the action of the calcium ionophore, but is acting on 
the LTB4  pathway itself. The possibility that stanozalol is also an inhibitor of PGI2 
synthesis in PMN’s was investigated at a later date, but unfortunately, the control value 
(before stanozalol treatment) for the chosen donor was below the detection limit of the 
assay and time did not permit the experiment to be repeated. However, there is other 
indirect evidence which suggests that stanozalol does not inhibit PG production since it 
was found, by RA patients who had mistakenly stopped their NSAID’s while on 
stanozalol, that the drug had no analgesic effect (Belch et al, 1986a). It seems possible 
therefore that stanozalol may be a specific 5-LO inhibitor although much more detailed 
studies would be required to demonstrate this conclusively.
Whatever the mechanism whereby stanozalol causes inhibition of LTB4  
production it may be that this is an additional mode of action contributing to it’s 
effectiveness in RP. Similarly, the effectiveness of stanozalol in treating other 
inflammatory diseases such as RA (Belch et al, 1986) may be due to it’s LTB4 -inhibiting 
action as well as it’s fibrinolytic effect.
Although stanozalol could be of use in other conditions where LTB4  is 
implicated in the pathophysiology, it’s side effects, which include disordered liver 
function and virilization in some women, would obviously restrict it’s use. Presently, it 
is only used as a last resort treatment in RS, usually in men and post-menopausal women.
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5 .2  P r o s t a n o id  A b n o r m a l it ie s  in  H e n o c h -S c h o n l e in
P u r p u r a
5.2 (a) In troduction
Henoch-Schonlein purpura (HSP) is the most commonly encountered type of 
vasculitis in childhood. The skin lesions (purpura) are the most obvious sign, but 
visceral involvement makes the disease potentially more serious. In two thirds of patients 
arthritis and gastrointestinal involvement occur and chronic renal impairment may develop 
(Meadow, 1979). Although HSP may follow exposure to drugs or allergens and in some 
cases is preceded by an upper respiratory tract infection (Ackroyd, 1953), the exact 
aetiology and pathogenesis remain obscure. The primary manifestations however, are 
known to be due to inflammation of the small blood vessels (Meadow, 1979).
As previously mentioned, there are many reports in the literature regarding the 
role of PGI2  and TXA2  in the pathogenesis of various vasculopathies. Remuzzi et al first 
showed decreased PGI2  production in the haemolytic uraemic syndrome (1978a) and the 
related disorder of thrombotic thrombocytopenic purpura (1978b). In addition, plasma 
from these patients had a low capacity to support PGI2  production in vitro from rat aortic 
rings. In contrast, normal human plasma is a powerful stimulant for PGI2  production 
and several other researchers have reported the existence in plasma of factor(s), as yet 
uncharacterized, which appear to regulate the production of PGI2  from vascular 
endothelium (McIntyre et al, 1978; Deffeyn et al, 1980).
The aim of this study was to examine various aspects of vascular PGI2  
metabolism and it’s control in the acute phase of HSP which had hitherto been 
uninvestigated. The work was carried out in conjunction with Dr. S. Turi and the Royal 
Hospital for Sick Children, Glasgow.
5.2 (b) P atien ts
Seventeen patients with HSP aged between 2 and 13 years (mean (SD), 5.7 
(2.5) years) and 17 controls matched for age and sex were studied. The control children
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were free of renal, cardiovascular, pulmonary and inflammatory disease and had been 
admitted for minor surgical operations. All patients had the classic purpuric rash and in 
13 cases the skin lesions were associated with joint manifestations. In 8 cases 
gastrointestinal symptoms were observed and 8 patients had abnormal urinalysis; 3 
patients had mild illness with no abnormal urinalysis or abdominal or joint 
manifestations.
5.2 (c) M ethods
5.2 (c) (i) Sample preparation
After informed consent had been obtained from both patient and parent, 15 ml 
of venous blood was taken from controls and from patients during the acute phase of the 
disease, 1-5 days after the occurrence of the rash.
Blood for the estimation of the ability of plasma to support PGl2 -like activity 
(PSA) was anticoagulated with 3.2% trisodium citrate in a ratio of 9:1. Plasma was 
prepared within 2 0  minutes of collection by centrifugation for 1 0  minutes at 2 0 0 0  g and 
4°C. Plasma and serum samples for estimation of PGl2 -M’s and TXB2  respectively 
were prepared as previously described. All plasma and serum samples were stored at - 
70°C until use.
Platelet-rich plasma (PRP) for aggregation studies was prepared from normal 
adults by centrifugation of citrated blood at 150 g for 7 minutes at room temperature. The 
final platelet count was adjusted to 250-300 x 10^/1  by dilution with autologous platelet- 
poor plasma.
No patient or control was taking any drug known to alter PG metabolism for 
at least 2  weeks before the study.
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5.2 (c) (ii) Estimation of ability of plasma to support vascular PGl2 -like 
activity (PSA)
The ability of test plasma (patient and control) to support PGl2 -like activity 
was assessed by measurement of the platelet anti-aggregatory activity of the plasma after 
incubation with arterial rings. Remuzzi et al (1978 a & b) and others, have used rat or 
rabbit aortic rings for this type of work. The same principle was used in this case except 
that human umbilical artery was employed, the use of human tissue always being 
preferred where possible.
The umbilical arteries, which were dissected from freshly delivered umbilical 
cords, were freed from all surrounding tissue, cut into rings 1 mm in length and kept in 
Ringer’s buffer, pH 7.4 at 4°C for not more than 60 minutes. In order to establish that 
they were functioning normally with respect to PGI2  production, the rings (5 rings/tube) 
were incubated in 1 ml of glycine buffer pH 8 .6  for 5 minutes at 37°C. The PGl2 -like 
(antiaggregatory) activity of the supernatant was tested as follows. An aliquot (100 (il) of 
supernatant was removed and added to 200 |il of PRP in the dual channel aggregometer. 
The mixture was incubated at 37°C with stirring for 1 minute, then collagen 
(Hormonochemie) (final concentration 2 pg/ml) was added as aggregating agent. The 
rate of aggregation was recorded and calculated as previously described, all aggregation 
measurements being carried out in duplicate. The supernatant buffer from a sample of 
freshly prepared rings would normally completely inhibit platelet aggregation.
In order that PSA could be measured the rings had first to be “exhausted” of 
PGI2  production. This was achieved by washing the rings several times with Ringer’s 
buffer at 37°C until little or no platelet anti-aggregatory activity could be detected. The 
exhausted rings were then incubated with 1 ml of test plasma at 37°C for 20 minutes and 
PGl2 -like activity assessed as before. The ability of each test plasma to support PGI2 - 
like activity was expressed by calculation of the percentage difference in inhibition of 
platelet aggregation obtained using the same exhausted rings, before and after addition of
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the test plasma. Test plasma which had not been incubated with arterial rings was also 
added to PRP as a control
5.2 (c) (iii) Detection of inhibition of PGl2 -like activity (PSAI)
To detect inhibitory activity in the test plasma a modified method of Levin et al 
(1983) was used. Fresh, unexhausted umbilical artery rings (one ring per incubation) 
were incubated in phosphate buffered saline (PBS), pH 7.4 at 37° for 5 minutes. The 
PGl2 -like activity of the supernatant was compared with that produced by the same ring 
after 5 minutes incubation with test plasma.
5.2 (c) (iv) Preservation of PGl2 -like effect of iloprost
The preservation of the PGl2 -like effect of the stable PGI2  analogue iloprost 
by test plasma was assessed as follows: iloprost at a final concentration of 2  ng/ml was 
incubated in 300 |il of test plasma for 5 minutes at 37°C. A 100 pi aliquot of this mixture 
was then added to 200 pi of PRP and after 1 minute of incubation with stirring, collagen 
was added and platelet aggregation was measured as before. The concentration of 
iloprost used gave a total inhibition of platelet aggregation when incubated with normal 
plasma.
5.2 (c) (v) Radioimmunoassay of plasma PGl2 -metabolites and serum
TXB2
Plasma PGl2 -metabolite and serum TXB2  levels were measured by RIA as 
previously described in chapter 4. In this instance serum clotting was carried out at room 
temperature since this was the standard method in use at the time. It should also be noted 
that at the time of this study, the normal range for plasma PGl2 -M’s was inexplicably 
higher than had previously been observed using the same assay kit (the same 
phenomenon was noted by other users of the kit at this time) and was probably due to a 
change in cross-reactivity of the antibody. However, this does not necessarily invalidate 
the results since patient and control samples were compared in the same assay.
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5.2 (d) Results
5.2 (d) (i) Estimation of PSA
The ability of plasma to support PGl2 -like activity was reduced in 13 of the 
17 patients and in 5 cases, PSA was undetectable (Fig. 5.13). The difference between 
the results (median (IQR)) of the patient group (16 (0-41)%) and the control group 
(55 (50-61.5)%)) was significant (p <0.001, Mann-Whitney). In addition, the results of 
those patients with abnormal urinalysis and gastrointestinal involvement (6.5 (0-22)%) 
were significantly different from the results of those patients with neither of these 
manifestations (36 (10-54)%), p <0.01 (Mann-Whitney).
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5.2(d) (ii) Detection of PS Al
Plasma from 6  patients in which PSA was low or absent was further 
investigated to see whether or not a definite inhibitory activity could be demonstrated. 
Less PGl2 -like activity was produced by the unexhausted arterial rings when incubated 
with plasma from the 6  patients than with either PBS or control plasma (Table 5.10).
Case No *PSA (%) tpSAI Preservation of 
iloprost effect
PATIENTS
1 0 + Normal
2 o + Decreased
3 o + Decreased
4 o + Decreased
5 0 + Normal
6 23 + Normal
CONTROLS
1 62 - Normal
2 57 - Normal
3 65 - Normal
Table 5.10 Plasma factors influencing prostacyclin (PGl2)-like activity 
in Henoch-Schonlein purpura.
* Estimation of ability of plasma to support vascular PGl2 -like activity, 
t  Inhibition of vascular PGl2 -like activity (+ = present, - = absent)
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5.2 (d) (iii) Preservation of PGl2-like effect of iloprost
The platelet anti-aggregatory effect of iloprost was noticeably depressed after 
incubation with plasma from 3 of the 6  patients in which PSAI was present (Table 5.10).
5.2 (d) (iv) Plasma PGl2 -metabolites and serum TXB2
The plasma PGl2 -metabolite concentrations (median (IQR)) of the patients 
with HSP were significantly lower (14.8 (9.4-25.0) pg/ml) than those of the normal 
controls (37.5 (28.5-39.0) pg/ml), p <0.001 (Mann-Whitney) (Fig. 5.14). A positive 
correlation was found between PSA and PGI2 -metabolite values, r = 0.52, p <0.05 
(Spearman rank correlation).
There was no significant difference in serum TXB2  concentration between 
patients (10.0 (2.0-23.8) ng/ml) and controls (9.5 (2.8-17.6) ng/ml) (Fig. 5.15). No 
significant correlation was found between the TXB2  results and plasma PGl2 -metabolite 
results (Spearman rank correlation).
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5.2 (e) D iscussion
Henoch-Schonlein purpura is a type of small vessel vasculitis. Abnormalities 
of vascular prostaglandin metabolism have been documented in other vasculopathies, 
particularly the haemolytic uraemic syndrome, but up until the time of this study HSP had 
not been investigated.
It has been shown that plasma from patients with HSP in the acute phase of 
the illness has a diminished or absent ability to support PGI2  generation in vitro from 
human umbilical arterial rings. Absent or depressed PSA may theoretically be due to a 
number of factors either singly or in combination; first, a decreased ability of the plasma 
to stimulate PGI2  production (Remuzzi et al, 1978a); secondly, the presence of inhibitory 
activity in the plasma either to the production (Levin et al, 1983) or the effect of PGI2  
(Machin et al, 1982); and thirdly, increased degradation of synthesized PGI2  (Chen et al,
1981). All six patients in this study who had very low or absent PSA, showed the 
presence of PSAI. This inhibitory activity may be against PGI2  synthesis or biological 
effect or, could conceivably be due to increased PGI2  degradation. In an attempt to 
differentiate between these possibilities, the ability of test plasma to preserve the effect of 
iloprost was examined and was found to be decreased in three of the six patients studied. 
The concentration of iloprost used, which was significantly higher than the physiological 
concentration of PGI2 , was chosen because a definite anti-platelet effect was desired. It 
is possible, therefore, that the other patient plasma samples may not have preserved the 
effect of iloprost at lower (more physiological) concentrations. The effect of test plasma 
on the degradation of PGI2  was not examined in this study.
On the basis of these data it would seem that in patients with low or absent 
PSA, inhibitory activity may exist to either PGI2 production or PGI2  effect or both.
It has also been shown that the HSP patients in this study had decreased 
plasma PGl2 -M’s compared to normal controls. It is of interest, however, that two 
patients showed a relatively high concentration of PGl2 -M’s in combination with a low
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or absent PSA and plasma inhibitory activity to the effect of iloprost. This would tend to 
suggest the presence of a circulating inhibitor to PGI2  effect in these cases.
No significant difference in serum TXB2  concentrations between the patient 
group and the control group was found. Furthermore, there was a poor correlation 
between serum TXB2  and plasma PGI2 -M concentrations. These results suggest that 
platelet activation does not occur in HSP. In view of the small number of patients in the 
study it was thought inappropriate to attempt to correlate the demonstrated abnormalities 
with the clinical manifestations. However, it was observed that patients whose clinical 
picture included abnormal urinalysis and gastrointestinal involvement, had a mean PSA 
that was significantly depressed compared to that of patients in whom these clinical 
manifestations were absent.
The above findings suggest that an abnormality of PGI2  metabolism does 
occur in HSP, but that it is rather complex and heterogenous in nature. This study was a 
preliminary investigation and further studies will be required to define the biochemical 
nature of the inhibitor(s) and to establish whether low or absent PSA always reflects the 
presence of inhibitory activity. It seems likely, however, that these abnormalities having 
been shown in yet another vasculitic syndrome, are most probably a secondary 
manifestation of endothelial damage. However, the disturbance in PGI2  metabolism may 
well be of importance in extending the primary microvascular insult
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CHAPTER 6
LEUKOTRIENE 8 4  IN INFLAMMATORY JOINT AND SKIN DISEASE
6.1 Leukotriene 8 4  Production by Peripheral Blood PMN’s in
Rheumatoid Arthritis
6.1 (a) Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease which affects 
mainly the peripheral synovial (articulating) joints, but is is often associated with extra- 
articular features, and practically every tissue in the body can be involved including eyes, 
heart, kidneys and nervous system (Hill, 1982). It is a relatively common disease, 
affecting approximately 1% of the population world-wide and is 2-3 times more common 
in females. Peak incidence is from age 35-55 years in women and 40-60 years in man, 
although it may start at any age and a juvenile form is recognized (Still’s Disease) (Ansell,
1982).
The clinical features of joint inflammation in RA are basically the classical 
signs of inflammation namely pain, redness, heat, swelling and loss of function. The 
established disease typically causes a symmetrical peripheral polyarthritis with early 
involvement of the small joints of the hands and wrists. Any synovial joint may become 
affected in severe disease, but in early disease, hips and the distal interphalangeal (DIP) 
joints of the fingers are usually spared (Thompson, 1982).
Results from biochemical and haematological screening of RA patients are 
frequently abnormal, but most are simply indicative of a chronic inflammatory condition 
and have no specific diagnostic value. However, they often give useful information 
about the severity of the disease and the beneficial or toxic effects of drug therapy.
A range of auto-antibodies can be found in the blood and joints of RA 
patients and almost all patients produce “rheumatoid factor’s” (RF’s) which are
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immunoglobulins, mainly of the M class directed against immunoglobulin G (IgG) 
(Thompson, 1982). However these are not confined to RA, being found in a wide 
variety of diseases and even in a small proportion of the “normal” population. 
Conversely, RF cannot be detected in all RA sera and so a distinction is made between 
“sero-positive” and “sero-negative” patients. It is generally accepted that sero-positive 
patients (around 60%) progress to more severe erosive disease and develop more 
systemic features in the long term. Assay of RF thus remains useful in making a 
diagnosis of RA and in following the course of the disease.
Rheumatoid factor-containing immune complexes (IC’s) are also found in 
RA, both circulating and deposited in the joints (Winchester, Kunkel & Angello ,1971). 
These are believed to be responsible for the chronic activation of complement in the 
disease and, as with RF, high litres of IC’s are associated with more severe and in 
particular, more systemic disease. Extra-articular lesions may, in fact, represent systemic 
IC deposition.Erythrocyte sedimentation rate (ESR) is the most commonly measured 
parameter related to inflammation per se and is almost always elevated in RA, tending to 
parallel the activity of the disease. Similarly, levels of acute phase reactants, particularly 
C-reactive protein (CRP) have been used to assess disease activity and drug efficacy 
(Kendall, 1982)
In terms of pathogenesis, the focus of RA in the joint is the synovial lining. The 
anatomy of the typical synovial joint is shown in Fig. 6.1. Cartilage covers the bone 
surface to provide a cushioning effect and a smooth surface for each of movement. 
Enclosing the joint is a capsule of fibrous tissue which has a certain degree of elasticity to 
allow joint movement; this is thickened in areas of stress to form ligaments which 
increase joint stability. The inner surface of the joint capsule is formed by synovial 
tissue, made up of an inner lining of specialized cells over loose, vascular, connective 
tissue. The lining cells secrete synovial fluid, a viscous solution (due to it’s hyaluronic 
acid content) which lubricates the articular surfaces.
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A central event in the pathogenesis of RA appears to be the formation of 
IC’s within the joint, which activates complement and attracts PMN’s. PMN’s are 
abundant in RA synovial fluid (Palmer, 1968) and complement levels are often decreased 
with a corresponding increase in chemotactic factors, particularly C5a, reflecting 
activation of the complement cascade (Ward & Zvaifler, 1971). Phagocytosis of IC’s by 
PMN’s results in the release of mediators which sustain the inflammation and as a result, 
the synovium is stimulated to proliferate as granulation tissue or ‘pannus’ which 
eventually spreads over adjacent cartilage (Mohr, Westerhelliveg & Wessinghage, 1981). 
Thus, by-products of the phagocytic process such as lysosomal proteases and reactive 
oxygen species, are brought into intimate contact with articular cartilage which is 
gradually destroyed (Weismann, 1982). Depending on the duration and severity of the 
disease, areas of cartilage may be completely lost and the underlying bone eroded by a 
similar process. Once this stage has been reached, there is significant disability and 
irreversible joint damage has occurred.
Despite many years of intensive research the cause of RA remains 
unknown. It seems likely, however, that several factors may operate together, an 
environmental agent provoking onset in genetically predisposed individuals. Evidence 
for genetic predisposition comes from family and twin studies and also from HLA-typing 
which shows that 60-70% of patients with sero-positive RA carry the antigen HLA-DR4 
(Welsh & Black, 1983).
Infection as the cause of RA has attracted great attention and much research 
has been devoted to isolation of a virus or some other single, causative pathogen. It is 
clear that various bacterial agents can cause acute and chronic rheumatic disease in man; 
rheumatic fever, Reiter’s syndrome and reactive arthritis being examples (Currey, 1978). 
At present, however, no single infectious agent is universally accepted as the cause of 
RA.
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Evidence for an auto-immune disturbance in RA rests largely upon the 
presence of RF and other auto-antibodies. This would seem to suggest an impairment of 
discrimination between “self’ and “non-self’ and it may be that viral interaction with 
plasma membrane constituents is involved.
6.1(b) Aim of study
On the basis of it’s actions in vitro (Ford-Hutchinson et al, 1980) and in 
view of the fact that it can be detected at inflammatory loci (Simmons et al, 1983) it is 
clear that LTB4  has a role in the inflammatory process. However, there was little 
evidence to support the hypothesis that excess LTB4  production contributes to the 
development of pathological inflammation such as that seen in RA. Klickstein et al 
(1980), using HPLC, detected increased LO products in the synovial fluid of patients 
with RA compared to osteoarthritic controls, findings which were supported by Davidson 
et al (1983). However the increased amounts of LTB4  detected in these studies may 
merely have reflected an increased population of activated PMN’s within the synovial 
fluid.
The aim of this study was to determine whether peripheral PMN’s from RA 
patients when maximally stimulated, produced more LTB4  per se than those from normal 
controls. The results obtained were correlated with three conventional markers for RA 
disease activity: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels 
and the Ritchie articular index (Al) (Ritchie et al, 1968). Furthermore, since in vitro 
studies have shown that NSAID’s can potentiate the production of LTB4  from PMN’s 
(Higgs et al, 1981), the possibility that this phenomenon occurred in vivo, in patients 
taking NSAID’s, was investigated.
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6.1 (c) Patients and methods
One hundred and five patients, with classical or definite RA according to 
ARA criteria (Ropes et al, 1959) were enrolled in the study after informed consent had 
been obtained. Of these, 84 patients were taking various NSAID’s, all at or near the 
maximum dose. Twenty one patients were not on NS AID therapy at least 2 weeks prior 
to sampling (median 6  weeks, range 2-24 weeks). No patient was taking any disease 
modifying drug.
All patients attended the out-patient department where 90 out of 105 had a 
Ritchie Al calculated. Twenty millilitres of blood were drawn from the antecubital fossa 
of these 90 patients; 5 ml, anti-coagulated with EDTA were taken for measurement of 
ESR (Westergren method), 5 ml of clotted blood were taken for analysis of serum CRP 
and 10 ml was taken into heparin for measurement of LTB4  production from PMN’s.
Fifty nine age- and sex-matched normal volunteers also had blood sampled 
for estimation of LTB4 from PMN’s and measurement of CRP levels.
Polymorphonuclear leukocytes were separated and stimulated with calcium 
ionophore A23187 as previously described. Leukotriene B4  levels in the cell 
supernatants were measured by RIA, also as previously described. Measurement of ESR 
and CRP were carried out by the routine laboratory and Al was assessed by the clinician.
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6.1 (d) Results
Table 6.1 shows the comparability between the RA patients and controls in 
the study. There was no significant difference in age between the two groups (Mann- 
Whitney). The clinical and laboratory results (medians and ranges) from RA patients are 
also shown in this table.
RA CONTROLS
Age (years) 48 (26-68) 35 (22-60)
Articular index 3 ( 0 -2 0 ) -
ESR (mm/h) 31 ( 3-99) -
CRP (mg/1) 17 (10-88) All <10
Table 6.1 Comparability of RA patients and normal controls (median 
(range)).
Figure 6.2 shows the amount of LTB4  (ng/lO^ cells) produced by patient 
and control PMN’s. Cells from RA patients produced significantly higher levels of LTB4 
than those of normal controls, 27.5 (22.9-33.0) and 20.0 (14.8-25.0) ng/10^ cells 
respectively (median (IQR)), p <0.001 (Mann-Whitney).
Figure 6.3 shows the RA patient group divided according to drug therapy. 
There was no significant difference in LTB4  levels between those on or off NSAID’s, 
28.0 (22.2-34.5) ng/10^ cells and 26.0 (21.0-28.5) ng/10^ cells, respectively (median
(IQR)).
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Fig. 6 .2 . LTB4 production from stimulated PMN’s  of RA patients and normal 
controls.
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Fig. 6.3. LTB4 production from stimulated PMNs of RA patients on and off NSAID’s.
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Fig. 6.5. Correlation of LTB4  with CRP in RA patients.
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Using linear regression, the Pearson’s correlation coefficient (r) for LTB4  
and Al was 0.08 (p = 0.49). However, weak but significant correlations for LTB4  and 
ESR (r = 0.25, p <0.02) and LTB4  and CRP (r = 0.3, p <0.03) were observed (Fig. 6.4 
and 6.5).
When these relationships were analysed using Spearman Rank Correlation, 
no significant correlations were observed.
6.1 (e) Discussion
Increased levels of LTB4  have been demonstrated in synovial fluid from 
rheumatoid joints (Klickstein et al, 1980; Davidson et al, 1983). However, these 
observations do not differentiate between increased production by the RA PMN per se 
and increased production secondary to PMN infiltration. Results from this study showed 
that LTB4  from stimulated peripheral PMN’s is increased in RA suggesting a real 
difference between RA cells and those of normal controls. Calcium ionophore A23187 
was chosen as activator in order to bypass specific receptors (Weissmann, 1982) and 
produce a maximal stimulation of LTB4  synthesis in response to calcium influx, using 
endogenous AA. It was assumed, therefore, that this method reflected the total enzymatic 
capacity of PMN’s from RA patients and controls to synthesize LTB4 .
The reason for the increased capacity for LTB4  synthesis in RA PMN’s is 
not yet clear. It has been suggested that the use of NSAID’s might be a contributing 
factor since the potentiation of LTB4  production by NSAID’s has been demonstrated in 
PMN’s in vitro (Higgs et al, 1981). Suggested explanations for this effect have included 
diversion of A A substrate towards the 5-LO pathway (Higgs et al, 1981) and removal of 
the negative regulatory effect of PG’s on LTB4  synthesis (Horrobin, 1980). However, 
results obtained in this study showed no difference in production of LTB4  between those 
who were taking NSAID’s and those who were not. This would seem to suggest that the 
potentiation of LTB4  production by NSAID’s whatever it’s mechanism in vitro, does not 
play a part in increasing LTB4  production from PMN’s in RA. It may be possible that
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substrate diversion from CO to 5-LO pathway after NSAID treatment could be significant 
in other cells such as macrophages where the capacities for PG and LT production are 
approximately equal (Chensue & Kunkel, 1983).
Analogous observations to those made in RA have been found in 
inflammatory bowel disease (IBD), where increased activity of LTB4  in the gut mucosa 
reflects infiltration by PMN’s (Sharon & Stenson, 1984). Subsequent examination of 
peripheral blood PMN’s from IBD patients showed that increased amounts of LTB4  were 
released upon stimulation (Nielsen, Ahnfelt-Rpnne & Elmgreen, 1987). In addition, 
enhanced capacity for release of LTB4  from PMN’s in RA has also been demonstrated by 
other workers using a slightly different approach (Elmgreen, Nielsen & Ahnfelt-Rpnne, 
1987). Again, the stimulus used was Cal A23187, but LTB4  and other metabolites of 
AA were estimated using radioactive labelling of endogenous AA and thin layer 
chromatography (TLC). These experiments showed that although RA PMN’s had an 
increased capacity for metabolizing endogenous AA into LTB4 , the release of AA and the 
formation of 5-HETE and CO products were all within normal limits. Since 20- OH and 
2 O-COOH-LTB4  levels were also increased, suggesting that LTB4  was not increased due 
to reduced metabolism via w-oxidation, it was concluded that increased LTB4  levels 
might be explained in terms of increased activity of epoxide hydrolase. The same 
conclusion was reached in the case of IBD (Nielsen et al, 1987).
Although the mechanism for increased synthesis of LTB4  by RA PMN’s is 
not completely understood, such an increase is likely to intensify the pro-inflammatory 
effects of LTB4  within the RA synovium. By virtue of it’s actions on chemotaxis (Ford- 
Hutchinson et al, 1980), adherence (Gimbrone et al, 1984) and aggregation (Ford- 
Hutchinson et al, 1980) of PMN’s, LTB4  will theoretically induce further recruitment and 
accumulation of PMN’s, thereby amplify and perpetuating the inflammatory response. 
Additionally, generation of oxygen free radicals (Weissmann, 1982) and release of 
lysosomal enzymes (Fienmark et al, 1981) both involved in local destruction of tissue 
would result from it’s cell-activating properties. It is also recognized that LTB4  can act in
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concert with the vasodilatory PG’s, PGE2  and PGI2 , to produce increased vascular 
permeability and exudation of plasma (Wedmore & Williams, 1981).
It is generally accepted that LTB4  production is an undesirable consequence 
rather than a cause of pathological inflammation (Simmons et al, 1983; Clancy & Hugli, 
1985). Either way, it is clear that inhibition of LTB4  production may allow improvement 
in the clinical symptoms of RA. Results from this study showed only a weak correlation 
of LTB4  with two conventional markers of disease activity. It is unlikely, therefore, if 
these markers are of real importance in the progression of RA, that lowering LTB4  levels 
would have a disease-modifying effect. However, it may well decrease inflammatory 
symptoms in RA via inhibition of the cell-mediated mechanism of inflammation in which 
it appears to play a significant role. It has been suggested that the use of dual 5-LO/CO 
inhibitors in inflammatory disease might be the way forward, since these may emulate the 
action of the corticosteroids, but without production of steroid-like side effects (Higgs et 
ah 1979).
In conclusion, therefore this study has demonstrated that the capacity for 
production of LTB4  is increased in PMN’s from patients with RA; this does not appear to 
be dependent on NSAID therapy. There are weak but significant correlations with 
conventional measures of disease activity. Although there is no evidence to suggest that 
inhibition of LTB4  would have a disease-modifying effect, it may however result in 
symptomatic improvement.
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6.2 Leukotriene B4  Production by Peripheral Blood PMN’s in Psoriatic 
Arthritis
6.2 (a) Introduction
Psoriasis is estimated to occur in 1-2% of the population and 5-7% of 
people with psoriasis also have an associated polyarthritis ranging from predominantly 
DIP joint involvement to clinical syndromes similar to RA and ankylosing spondylitis 
(Wright, 1982). For many years psoriatic arthritis (PA), was considered to be essentially 
the coincidence of two relatively common diseases, but is now recognized as a distinct 
condition. In contrast to RA, PA is always sero-negative (for IgM rheumatoid factor) and 
there is no difference in prevalence between the sexes (Scarpa et al, 1984).
Although the aetiology is not completely known, heredity appears to play a 
major part and over 30% of patients with psoriasis have a family history of the disease. 
In PA, the HLA antigens associated with psoriasis (HLA-B13 and B17) and the HLA- 
B27 antigen, usually associated with ankylosing spondylitis, are commonly found 
(Wright, 1982). The pattern of disease onset is not consistent; in most cases the psoriasis 
appears to antedate the arthritis, while in others the arthritis precedes the psoriasis, and in 
some cases synchronous onset is observed (Scarpa et al, 1984).
The arthritis in PA has many similarities to RA in that it is a synovitis which 
may involve almost any joint in the body, but unlike RA it is more often assymetrical with 
single joints involved here and there. However, it is not usually a severe disease 
producing less pain and disability than the rheumatoid form and extra-articular 
manifestations are rare (Wright, 1982). Patients with PA require virtually the same 
therapy for their joint disease as those with RA, although corticosteroids are less 
effective.
In it’s classical form, psoriasis presents as raised, erythematous, scaly 
lesions (plaques) and most commonly involves areas around the knees and elbows and
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the scalp. Itching of the lesions is common. Histologically, these manifestations are 
reflected by increased basal cell proliferation, rapid epidermal turnover and infiltration of 
PMN’s (Burton, 1985).
6.2 (b) Aim of study
Leukotriene B4  and other LO products have been detected in increased 
amounts of psoriatic skin (Brain et al, 1984; Camp et al, 1983b; Grabbe et al, 1984) 
where they are believed to have a role in the pathogenesis of the psoriatic lesion. The 
cellular source of the LTB4  is uncertain, but contributions are likely to come both from 
infiltrating PMN’s and from epidermal cells which have been shown to synthesize LTB4  
in vitro (Fincham, Camp & Leigh, 1985).
When LTB4  is injected into normal human skin, an infiltration of PMN’s 
occurs (Soter et al, 1983) and clinically, this results in the formation of intra-epidermal 
microabscesses, which are a histological hallmark of psoriasis (Camp et al, 1984). The 
fact that topical application of indomethacin exacerbates the psoriatic lesion (Ellis et al,
1983) provides additional support for the role of LTB4  in the pathogenesis of psoriasis 
since the mechanism is assumed to be diversion of AA substrate to the 5-LO pathway. 
Furthermore, there is an increased proliferation of keratinocytes in psoriasis and LTB4  
has been shown to stimulate DNA synthesis in cultured human keratinocytes (Kragballe, 
Desjarlais & Voorhees, 1985).
It can be seen, therefore, that LTB4  has a potential role in both the skin and 
joint manifestations of PA. Given that PMN’s from RA patients have already been 
shown to have an increased capacity to synthesize LTB4 , the aim of this study was to 
establish whether such an intrinsic abnormality in AA metabolism exists in the PMN’s of 
patients with PA. In addition, conventional measures of joint activity (CRP, ESR, Al, 
duration of morning stiffness) were recorded and the degree of skin involvement was 
assessed using visual analogue scales (percentage body area affected, scaling, erythema, 
itch). The relationship between these parameters and LTB4  levels was examined.
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6.2 (c) Patients and methods
In total, 118 patients which chronic stable plaque psoriasis and 
inflammatory arthritis were sampled for measurement of LTB4  from stimulated PMN’s. 
All were sero-negative for rheumatoid factor and were on a stable dose of paracetamol or 
the same NS AED for at least one month before sampling. Patients undergoing treatment 
with systemic steroids, were excluded. All patients had skin and joint activity assessed 
and recorded as previously outlined. In addition, 59 age- and sex-matched normal 
controls had blood sampled for estimation of LTB4  from isolated PMN’s.
Polymorphonuclear leukocytes were separated, stimulated with Cal A23187 
and the cell supernatants assayed for LTB4  using RIA as previously described.
6.2 (d) Results
Comparability of PA patients and normal controls is shown in Table 6.2. 
Some patient clinical and laboratory measurements are also shown.
PATIENTS CONTROLS
AGE (years) 40 (18-76) 35 (22-60)
M : F 45:73 33:26
Al 9 (3-22) -
ESR (mm/h) 16(2-110) -
CRP (mg/1) 15 (10-88) < 1 0
Table 6.2 C om parab ility  of PA patien t and norm al contro l groups 
(median (range)).
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The median (IQR) levels of LTB4  from PMN’s after 5 minutes stimulation 
with Cal A23187 in PA and control cells were 22.2 (19.6-28.0) and 20.0 (14.8-25.0) 
ng/lO^ cells respectively (Fig. 6 .6 .). The difference was statistically significant (p 
<0.001, Mann-Whitney).No significant correlations were found between LTB4  and 
indices of joint or skin disease activity.
6.2 (e) Discussion
There is considerable evidence that LTB4  is involved in both the skin and 
joint manifestations of psoriatic arthritis. The role of LTB4  in the pathogenesis of 
inflammatory joint disease has already been discussed in section 6.1. In addition, several 
factors support the hypothesis that LTB4  is a participant in the pathophysiology of 
psoriasis. Increased levels of LTB4  have been detected in psoriatic plaques and when 
LTB4  is applied to normal human epidermis, microabscess formation is induced. It has 
also been demonstrated that while topical indomethacin exacerbates the psoriatic lesion, 
treatment with corticosteroids or putative 5-LO inhibitors such as benoxaprofen 
(Kragballe & Herlin, 1983) gives improvement.
Results from this study have indicated that significantly greater amounts of 
LTB4  are synthesized by maximally stimulated PMN’s from PA patients than by those of 
normal controls. Although very little work appears to have been reported in the literature 
on AA metabolism in psoriatic arthropathy, considerable attention has been paid to the 
phenomenon of disordered A A metabolism in psoriasis. Maurice, Camp & Allen (1987) 
have studied the metabolism of AA by peripheral blood PMN’s in patients with chronic 
plaque psoriasis using HPLC. In contrast to the results of the present study, they found 
no significant difference in the amounts of LTB4  formed by PMN’s stimulated with Cal 
A23187 in psoriatic and control groups. Since increased LTB4  production is observed in 
both RA and PA, but not in psoriasis alone, this would seem to suggest that LTB4  is 
associated with inflammatory joint disease rather than inflammatory skin disease. 
However, Maurice et al (1987) did detect increased levels of the co-oxidation products of
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LTB4  in psoriatics and, since there was no significant difference in the kinetic constants 
for psoriatic 2 0 -hydroxylase, they concluded that this increase may be secondary to 
increased synthesis of LTB4 . It may be the case therefore that increased LTB4  levels are 
only detected when they reach such a level that the 2 0 -hydroxylase can no longer cope 
with the increased substrate load.
It has also been observed that levels of free AA are chronically elevated in 
psoriatic epidermis (Voorhees, 1983). In addition, evidence exists to suggest that CO 
activity in psoriatic skin is much less than that of 5-LO and 12-LO, a fact which is 
attributed to the presence of an endogenous CO inhibitor in psoriatic plaque which gives a 
chronic “indomethacin-like” effect in vivo (Penney s et al, 1975). This would result in 
diversion of the large amounts of free A A available to the 5-LO and 12-LO pathways. It 
is possible, therefore, that the intrinsic ability of PA PMN’s to synthesize increased 
amounts of LTB4  may be further increased after they have infiltrated the epidermis.
No significant correlations were found between LTB4  levels and markers 
for joint or skin activity. This is in contrast to RA where LTB4  did correlate with 
markers for joint activity, albeit weakly.
In conclusion, peripheral PMN’s from patients with psoriatic arthropathy 
appear to have an increased capacity to synthesize LTB4  and this may be augmented in 
vivo by the presence of an endogenous CO inhibitor. It would appear, therefore, that 
there is the potential for treatment of psoriasis and psoriatic arthropathy via inhibition of 
the 5-LO, more so since NSAID’s have a clear deleterious effect on skin symptoms (Ellis 
etal, 1983).
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CHAPTER 7
DIETARY MANIPULATION OF ESSENTIAL FATTY ACIDS
IN INFLAMMATORY JOINT AND SKIN DISEASE
7.1 Introduction
Two groups of fatty acids which are essential for normal bodily function, 
cannot be synthesized de novo in mammalian systems and therefore must be obtained 
from diet. The co- 6  series is derived from linoleic acid (18 :2  co-6 ) and the co-3 series is 
derived from a-linolenic acid (18 : 3 co-3) (Willis, 1981). (In this notation the first 
number indicates the number of carbon atoms in the molecule, the second indicates the 
number of double bonds and the last refers to the position of the first double bond starting 
from the methyl end of the fatty acid chain.) The derivation of the eicosanoids from their 
precursor EFA’s is illustrated in Fig. 7.1; linoleic and a-linolenic acid can be regarded as 
the ultimate dietary precursors of the eicosanoids. However, the standard Western diet is 
rich in A A (20 : 4 co-6 ) and leads predominantly to the formation of the 2-series 
prostanoids and the 4-series LT’s which, in general, have pro-inflammatory effects. It is 
now becoming apparent that the eicosanoid profile of cells and tissues may be changed by 
providing alternative substrate (via diet) for metabolism by the CO and 5-LO enzymes.
Evening primrose oil (EPO) is a naturally occurring seed oil which contains 
relatively large amounts of y-linolenic acid (GLA). This can be converted to dihomo-y- 
linolenic acid (DGLA; 20 : 3 co-6 ), a precursor of the monoenoic PG’s such as PGEi 
(Fig. 7.1) which is thought to possess anti-inflammatory properties (Zurier & Balias, 
1973; Bonta & Pamham, 1978b; Martin & Stackpool, 1981). DGLA cannot be 
converted to LT’s as it lacks desaturation at the A5 position (Willis, 1981), but it can be 
converted to a 15-hydroxy derivative which potently inhibits the transformation of A A to 
LT’s (Scholkens et al., 1982, Miller et al., 1988) Dietary DGLA may therefore act as a 
competitive inhibitor for the formation of the 2-series prostanoids and the 4-series LT’s to 
give rise to products with less inflammatory activity.
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Several animal studies have suggested that DGLA has an overall anti­
inflammatory effect. Local injection of DGLA has been shown to inhibit granuloma 
growth in an animal model of inflammation (Elliot et al., 1986) and a diet rich in DGLA 
appears to decrease the chemotactic response of rat PMN’s (Kunkel et al., 1982). 
Furthermore, it has been demonstrated that EPO suppresses MSU-induced inflammation 
in rats (Tate et al., 1988) and increases lifespan in MLRi mice who develop a 
spontaneous autoimmune disease which manifests itself as vasculitis and arthritis 
(Godfrey etal., 1986).
Several in vivo and in vitro human studies have also suggested a beneficial 
effect with EPO/DGLA. Baker , Krakauer & Zurier (1986) have demonstrated that 
synovial cell proliferation, a hallmark of RA, is decreased in vitro after addition of 
DGLA. Wright & Burton (1982) have shown a significant clinical improvement in 
patients with eczema after EPO treatment. Two clinical studies with EPO in RA proved 
disappointing (Brown et al., 1980; Hansen et al., 1983), however, the doses of EPO 
were low (50 mg/day and 360 mg/day respectively) and the study periods short (12 
weeks in both instances).
Another derived EFA, eicosapentaenoic acid (EPA; 20 : 5 co-3) which is 
abundant in fish oils, can also be metabolized to eicosanoids (Fig 7.1). In humans, 
dietary EPA can be transformed to PGI3 (Fischer & Weber, 1984) which has anti­
aggregatory and vasodilatory properties similar to those of PGI2 (Needleman et al., 
1979). In addition, small quantities of TXA3 are formed by human platelets after dietary 
EPA, in conjunction with decreased TXA2 production (Fischer & Weber, 1983). Since 
TXA3 is a far less potent platelet aggregator than TXA2 (Needleman et al., 1979), the net 
effect of the EPA metabolites is anti-platelet and vasodilatory. Formation of the 3-series 
prostanoids therefore, would appear to be a means of favourably altering the PGI/TXA 
balance and indeed, EPA is associated with reduced incidence of cardiovascular disease 
(Dyerberg et al., 1978). It has been suggested that the low incidence of coronary heart
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disease in Greenland Eskimos may result, in part, from their high intake of marine foods 
rich in EPA (Dyerberg & Bang, 1979).
Metabolism of EPA via the 5-LO pathway leads to production of the 5-series 
LT’s. In experiments with human PMN’s, EPA enrichment by dietary means, followed 
by stimulation with Cal A23187 results in the formation of LTB5 with a concomitant 
decrease in LTB4 generation (Strasser, Fischer & Weber, 1985; Lee et al.., 1985). 
Leukotriene B5 appears to be considerably less potent than LTB4 (10-30 times) in causing 
aggregation, chemotaxis and degranulation of PMN’s and in the potentiation of plasma 
exudation (Terano, Salmon & Moncada, 1984; Prescott, 1984).
Dietary supplementation with EPA has been shown to reduce inflammation 
in some, but not all, animals models. Treatment with EPA markedly reduces the severity 
of glomerulonephritis and it’s associated mortality in NZB/NZW mice (the animal model 
for systemic lupus erythematosus; SLE) (Robinson et al., 1985) and the manifestations of 
salmonella-associated arthritis induced by collagen in mice is also decreased after an EPA- 
rich diet (Leslie et a l , 1985), although adjuvant arthritis in rats is augmented by EPA 
(Prickett, Trentham & Robinson, 1984).
Several human studies with dietary EPA have also been carried out. Studies 
of normal volunteers whose diet was supplemented with EPA show a shift from LTB4 to 
LTB5 production in stimulated PMN’s (Lee et a l, 1985; Prescott, Zimmerman & 
Morrison, 1985). Functional changes in leukocytes, including decreased chemotaxis and 
adherence, have also been observed after 6  weeks of EPA ingestion (Lee et al., 1985), 
but not after 3 weeks (Prescott et al., 1985).
Several clinical studies with EPA (with respect to inflammatory disease) 
have been carried out with varying results. In a placebo-controlled study, treatment of 
SLE patients with EPA for 12 months resulted in no significant changes in disease 
activity, although there did appear to be a “rebound” of symptoms after withdrawal of 
EPA, suggesting an effect in some individuals (Moore et al., 1986). Results from studies
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with RA patients have been more promising. In two studies, Kremer et al. (1985 and 
1987) reported a clinical improvement in RA patients whose diet was supplemented with 
EPA. In the later study an observed decrease in joint tenderness correlated with 
decreased LTB4 production from stimulated PMN’s. More recently, Sperling et al. 
(1987) and Cleland et al. (1988) have reported improvement in disease activity and 
reduced LTB4 production from PMN’s in RA patients taking EPA. In two studies of 
psoriasis, EPA treatment resulted in a mild to moderate improvement in symptoms (Ziboh 
etal., 1986; Bittener etal., 1988).
Like EPA, docosahexaenoic acid (DCHA; 22 : 6  co-3) is a highly 
unsaturated long chain fatty acid found in fish oils and marine mammals, which can be 
incorporated into inflammatory cell membranes and which competetively inhibits the 
utilization of AA by CO (von Schacky et al., 1985). Unlike EPA, DCHA is a poor 
substrate for the 5-LO; addition of DCHA to ionophore-stimulated neutrophils in vitro 
yields only a mono-hydroxy derivative and has little, if any, effect on LT synthesis (Lee 
etal., 1984).
7 .2  Dietary Manipulation of EFA’s in Rheumatoid Arthritis
7.2 (a) Aim of study
“First-line” treatment for RA is by the use of non-steroidal anti­
inflammatory drugs. These act by inhibiting the CO enzyme thereby decreasing the 
production of pro-inflammatory prostanoids from A A. Treatment with NSAID’s may 
therefore ameliorate the PG-mediated aspects of inflammation, but allow those dependent 
on 5-LO products to proceed unchecked. Furthermore, NSAID’s may produce side- 
effects such as gastric irritation as a result of indiscriminate inhibition of PG’s.
In theory, therefore, it should be possible to substitute DGLA or EPA in 
place of NS AID treatment since this would produce a decrease in the pro-inflammatory 
PG’s and LT’s while other, less inflammatory eicosanoids (such as PGEi and LTB5)
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would be increased. In addition, there should be no gastrointestinal side-effects with 
such therapy.
The aim of this study was to determine whether an EPO or EPO/fish oil 
combination (Efamol Marine) could be substituted in place of NSAID therapy without 
deterioration in the clinical symptoms of RA. In addition, the effects of these dietary
supplements on LTB4 production from stimulated PMN’s was investigated. The study
was double blind and placebo controlled.
7.2 (b) Patients
Forty-nine patients with classical or definite RA as defined by ARA criteria 
were enrolled in the study after informed consent had been obtained. All patients required 
first-line (NSAID) therapy for control of their symptoms but none were considered severe 
enough to warrant second-line therapy. Sixteen patients received EPO treatment taken as 
12 capsules/day, providing a daily dose of 540 mg GLA; 15 patients received EPO/fish 
oil (12 capsules/day) providing a total daily dose of 450 mg GLA and 240 mg EPA. 
Eighteen patients received 12 capsules/day of placebo (indigestible liquid paraffin). In 
addition, all capsules contained vitamin E as an anti-oxidant (dose 120 mg/day).
All three types of capsule were supplied by Efamol Ltd. and were visually 
identical. They were issued to patients in a randomised, double-blind fashion.
7.2 (c) Study design
The duration of the study was 15 months. For the first 3 months, patients 
were instructed to take the 12  capsules of oil per day, plus their full dose of NSAID’s. 
From 3-6 months in particular, but also up to 12 months, patients were instructed to 
decrease or stop their NSAID’s if possible. From 12-15 months they were told to 
maintain, if possible, their current dose of NSAID’s. Patients were only to decrease or 
stop NSAID’s if this could be done without exacerbation of RA symptoms. At 12 
months all patients received placebo capsules (12/day). As this was part of the study
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design, investigators were aware of the treatment in all patients from 12-15 months; the 
patients, however, remained blinded. The aim of this placebo phase was to monitor 
relapse. The patients attended the clinic at monthly intervals for the first 6  months and 
thereafter at 3-monthly intervals.
7.2 (d) Clinical assessment of disease activity
Full metrological assessment was carried out by the clinician prior to the 
start of the study and at 3,6,12 and 15 months. The duration of morning stiffness in 
minutes, the grip strength of left and right hands (mmHg, mean of 3 readings) and the 
Ritchie articular index were noted. In addition, patients completed a 10 cm visual 
analogue pain scale, and the occurrence of side effects was recorded. Patients were also 
asked whether they obtained benefit or otherwise from the treatment.
7.2 (e) Biochemical assessment of disease activity
Blood was sampled prior to the start of the study and again at 3,6,12 and 15 
months for measurement of ESR, CRP, haemoglobin (Hb) and RF. All of these 
estimations were carried out by routine laboratory services. In addition, samples from 
0,6 and 12 months were separated and stored at -70°C for later analysis of plasma and 
erythrocyte membrane EFA levels to assess patient compliance. These analysis were 
carried out by Efamol Ltd.
7.2 (f) Measurement of LTB4 from stimulated PMN ’ s
Blood samples for PMN isolation and estimation of LTB4 were taken every 
month from 0-6 months and thereafter every 3 months. Due to the fact that the 
standardised method for Cal A23187-stimulation of PMN’s was established shortly after 
commencement of the study, only 13 patients from the EPO/fish oil group, 12 patients 
from the EPO group and 12 patients from the placebo group were sampled at month 0 for 
this estimation.
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Separation of PMN’s from whole blood and their subsequent stimulation 
with Cal A23187 was carried out as described in section 4.4. Leukotriene B4 in the 
resultant supernatants was measured by RIA also as described in section 4.4.
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7.2 (g) Statistical analyses
Comparability between the treatment groups was analysed using the Mann- 
Whitney U test. Sequential analysis were carried out using the 2-tailed paired Wilcoxon 
test, except for sequential LTB4 determinations which were analysed using the Mann- 
Whitney U test, since paired data were not always available.
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Placebo EPO EPO/fish oil
Age (Years) 48 46 53
(30-74) (35-68) (28-73)
Duration (years) 5 5 5
(1-2 0 ) d-18) d-25)
Sex M:F 1:17 1:15 4:11
Morning stiffness (min) 31 47 31
(0-240) (0 - 1 2 0 ) (0-240)
Grip strength (mmHg, 106 116 105
right hand) (53-260) (58-207) (50-300)
Articulat index 6 5 7
(0-24) (0-14) (0 -1 2 )
Visual analogue scale (cm) 2.3 3.6 3.0
(0 -8 .0 ) (0-9.5) (0-7.3)
ESR (mm/h) 30 2 2 26
(3-75) (4-81) (4-55)
CRP (mg/1) 19 19 13
(8-76) (10-43) (10-38)
Hb (g/1) 1 1 .8 1 2 .6 13.8
(10-15.5) (8.8-14.9) (11.7-16.8)
RF (titre) 1:16 1:128 1:128
(0-1024) (0-1024) (0-1024)
Table 7.1 Comparability of the three treatment groups of RA patients at 
start of study (median (range)).
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7.2 (h) Results
7.2 (h) (i) Clinical aspects
Table 7.1 shows the comparability of the 3 treatment groups for clinical and 
laboratory measurements at the start of the study. No significant differences in the patient 
populations were apparent. Table 7.2 shows the number of patients withdrawn from the 
study by 12 months. One patient out of 16 in the EPO group and 2 out of 15 in the 
EPO/fish oil group were withdrawn due to increasing symptoms of RA, compared to 10 
out of 18 placebo patients (both p <0.001, Mann-Whitney). These results are shown in 
Fig. 7.2 expressed as a percentage of the total numbers in each group. Subsequent 
results have also been expressed as a percentage of baseline so that the different group 
totals can be more easily compared.
Placebo EPO EPO/fish oil
Increasing RA symptoms 10 1 2
Gastro-intestinal upset 0 2 0
TOTAL 10 3 2
Table 7.2 RA patients withdrawn from the Efamol study by 12 months.
Figure 7.3 shows a compilation of results illustrating the dose of NSAID’s 
in all 3 groups prior to the start of treatment and at 3,6 and 12 months. As 1 EPO and 3 
placebo patients were not taking NSAID’s at the start of the study they were not included 
in these analyses. Eleven out of 15 EPO patients and 12 out of 15 EPO/fish oil patients 
reduced or stopped their NSAID’s by 12 months, compared to 5 out of 15 of the placebo 
patients (p <0.003, p <0.002, p <0.05 respectively, paired Wilcoxon).
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Figure 7.4 shows a compilation of results (means) for the clinical 
measurements in the 3 groups; no significant change in any of the four parameters 
measured (morning stiffness, grip strength, visual analogue and articular index) was 
observed over the study period.
Figure 7.5 shows the results (means) of the 3 groups for “laboratory” 
indices of disease activity (Hb, RF, ESR and CRP). Again, no significant change in 
these parameters was noted over the study period although, as with the clinical 
observations, the EPO group appeared to fare better.
Figure 7.6 shows the subjective response for the 3 patient groups over the 
study period. As one would expect (Beecher, 1955), the control group did show a 
marked placebo response of about 40% at 6  months. Surprisingly, this persisted 
throughout the study, although it fell to about 30% by 12 months. Despite there being no 
significant change in objective measured of disease activity, 94% of the EPO and 93% of 
the EPO/fish oil group felt a subjective improvement in their condition at 12 months. 
Most patients on active treatment recorded an increase in their general sense of well­
being.
Following the 3 months placebo phase, all of the EPO patients and 80% of 
the EPO/fish oil patients had either returned to “baseline” or become worse. This 
compared to a relapse rate of only 14% in the placebo group.
Four patients in the study experienced side-effects. Two in the EPO group 
(one with nausea and one with gastrointestinal upset) required to be withdrawn from the 
study at 2 months and 1 month respectively (Table 7.2). Two patients in the EPO/fish oil 
group also experienced side-effects (nausea and headache) although neither was required 
to be withdrawn from the study.
Estimation of fatty acid levels in plasma and erythrocyte membranes by 
HPLC (Efamol laboratories) confirmed compliance in all subjects apart from one
210
EPO/fish oil patient. This patient was one of the two from this group who were 
withdrawn due to increasing RA symptoms.
7.2 (h) (ii) Effect on LTB4 production
In the EPO group, LTB4 production from A23187-stimulated PMN’s 
appeared to fall from 1 month onwards and a significant decrease was noted at 3  months 
(p <0.02, Mann-Whitney) and 5 months (p <0.05, Mann-Whitney) (Fig. 7.7). The 
maximum decrease in LTB4 observed over this period was 37%. During the placebo 
phase, LTB4 levels appeared to rise again and by 21 months had returned to pre-study 
levels.
In the EPO/fish oil group, no significant change in LTB4 was noted 
throughout the study, although levels did appear to fall during the treatment period and 
rise again during the placebo phase (Fig. 7.8).
In the placebo group, a significant increase in LTB4 (p <0.04, Mann- 
Whitney) was noted at 4 months (Fig. 7.9). No LTB4 determinations were made 
between 9-12 months in this group basically due to a paucity of placebo patients 
continuing beyond 9 months. Figure 7.9 also shows the 5,6 and 9 month data analysed 
to include “last data” of the patients withdrawn after 4 months. The reason for this is 
discussed in section 7.2 (i) (ii).
Figure 7.10 shows the LTB4 results for all three groups on one graph for 
direct comparison.
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7.2 (i) Discussion
7.2 (i) (i) Clinical aspects
The theory and evidence which suggests that dietary supplementation with 
EPO/fish oil may produce anti-inflammatory effects similar to CO inhibition by NSAID’s 
have been outlined in section 7.1. Indeed, additional effects might be anticipated because 
of the inhibition of LT production not seen with the NSAID’s. Furthermore fewer gastric 
side effects would be expected as PG’s of a less inflammatory nature would still be 
available for gastric cytoprotection.
The results of this study have shown that it was possible for some patients 
with RA to decrease or stop NSAID treatment when EPO or EPO/fish oil was given. 
This was achieved with no deterioration in clinical or laboratory measures of RA disease 
activity. A decrease in NSAID dose was also observed in the placebo group, though this 
was much less marked. In combination with the 30% placebo subjective response, this 
stresses the importance of placebo controlled studies in RA.
Despite there being no objective improvement in symptoms on the active 
oils, there was a very definite subjective improvement, most patients reporting an 
improvement in their general sense of well-being. The mechanism for this is unclear, 
however, EPO has been used with some success in the treatment of pre-menstrual tension 
and is known to alter PG production in the brain (O’Brien, 1983; Brush, 1983). In 
addition, PGEi has been reported as having an anti-depressant effect (Parmigiani, 1982) 
and an increase in PGEi during EPO treatment may have been responsible for the 
subjective improvement witnessed in the study. It is also possible that reducing NSAID 
therapy may remove some of it’s negative effects on the patients’ well-being.
The relapse in patients during the placebo phase of the study was also 
examined, since only 14% of the placebo group relapsed it seems likely that spontaneous 
remission had occurred in the other placebo patients. In contrast, all the patients in the 
EPO group either felt worse or returned to pre-study level of subjective symptoms and
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80% of the EPO/fish oil group relapsed on placebo. The fact that 20% of patients in the 
EPO/fish oil group maintained their improvement suggests that the fish oil may have had 
a longer lasting effect. There is some evidence to suggest that EPA is metabolized more 
slowly than DGLA (Tate et al., 1988) and may therefore persist in cell membranes for 
longer. Unfortunately EFA analysis of the 15 month samples was not part of the protocol 
so this was never checked. However, it is also possible that DGLA incorporation into 
cell membranes could have been enhanced by the presence of EPA in this group since in 
animal studies, the tissue DGLArAA ratio is increased substantially in animals fed a 
combination of GLA and EPA (Nassar et al., 1986). This effect may be attributed to 
inhibition by EPA of the conversion of DGLA to AA (Tate et a l, 1988) thus increasing 
the amount of DGLA incorporated into cell membranes.
In two previous studies which looked at the effect of EPO on RA (Brown et 
al., 1980; Hansen et al., 1983) no clinical improvement was observed. However, both 
these studies used a lower dose regime of EPO and a study period of only 3 months; 
results from our study suggest that improvement is most marked from 6  months onwards 
both with respect to NSAID withdrawal and subjective improvement. In addition, the 
patients in these two other studies stopped NSAID’s abruptly prior to the start of the 
studies which may have caused an initial flare in symptoms. The combination of NSAID 
withdrawal and short treatment period may therefore explain the negative findings. It is 
also possible that these two studies looked at different patient populations. All of the 
patients in our study had mild RA as shown by the clinical and laboratory parameters in 
Table 7.1. In contrast, the other two studies looked at patients with more severe disease, 
in particular, the group studied by Hanson et al. had markedly higher ranges of ESR and 
much lower ranges of Hb. Furthermore, these patients had been on second-line drugs 
such as prednisolone prior to the study and may already have had decreased LT levels, 
leaving little scope for further benefit via inhibition of LTB4 by EPO.
Studies investigating the effect of EPA in RA have been more numerous. In 
the first of the studies by Kremer et al. (1985) an improvement in AI was noted at 12
217
weeks in the fish oil group, but not in the placebo group. In the later study (Kremer et 
al., 1987), four other indices of disease activity were significantly improved after 14 
weeks treatment. Cleland et al. (1988) reported similar results with a significant 
improvement in AI and grip strength after 12 weeks of EPA treatment. Sperling et al. 
(1987), in an open study, observed an improvement in several indices of disease activity, 
but only the more subjective measures (AI and patient assessment of overall disease 
activity) reached statistical significance. These studies however, cannot be directly 
compared with the present study where fish oil was used only in combination with EPO; 
the only valid assessment of the effect of EPA which can be made in this case is in 
comparison with the EPO group. Although results suggest that there was a slightly 
earlier response with the combined therapy (NSAID dosage and subjective response) and 
that the effect was preserved for longer after cessation of treatment, there was no 
significant difference in the clinical or laboratory response between the EPO and EPO/fish 
oil groups. It is possible that the addition of fish oil had no effect and the slightly lower 
dose of EPO used in this group was sufficient to allow NSAID withdrawal. 
Alternatively, it is possible that the fish oil contributed to the effect of the lower dose EPO 
making the two groups undistinguishable. Certainly, there is evidence in the literature to 
suggest a synergism between EPA and DGLA (Juan & Sametz, 1985; Nasar et al., 1986; 
Tate et al., 1988), however the design of the present study was not adequate to test for 
this hypothesis.
In all the other studies cited above, dietary supplementation was carried out 
against a background of stable NSAID (and sometimes corticosteroid) therapy, and 
investigators were looking for further improvement in symptoms on the dietary 
supplements. However, the emphasis of the study reported here was slightly different in 
that it’s aim was to gradually replace NSAID therapy with EPO and EPO/fish oil 
supplements with no deterioration in RA symptoms, and this was achieved. In this 
respect, therefore, the EPO and EPO/fish in the present study can be considered to be 
stabilizing RA symptoms during NSAID withdrawal rather than giving a positive 
improvement.
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7.2 (i) (ii) Effect on LTB4 production
The fact that DGLA is not metabolized to LT’s and that it forms a 15-OH 
derivative which inhibits the transformation of A A to LT’s, (Willis, 1981) implicates it as 
a potential modulator of LTB4 synthesis in PMN’s. In this study, stimulated PMN’s 
from the patient group treated with EPO (540 mg GLA/day), did show decreased 
generation of LTB4 as measured by RIA (Fig. 7.7). This decrease was apparent by 1 
month into the study and reached statistical significance by 3 months. The reason why 
this significant decrease (37%) was not sustained is not clear, however, it should be 
noted that NSAID withdrawal was initiated after 3 months and may have had some effect, 
albeit opposite to the predicted effect. During the placebo period and beyond (12-24 
months), LTB4 levels rose steadily to return to pre-treatment values.
Surprisingly, patients on the EPO/fish oil supplement showed less of an 
effect on LTB4 production than those taking EPO alone (Fig. 7.8). Although median 
levels did fall during the treatment phase and rise again during the placebo phase, 
statistical significance was not achieved. However, it is well established in the literature 
than EPA is a good substrate for the 5-LO and that the efficiency of conversion of EPA to 
LTB5 is similar to that of AA to LTB4 (Lee et al., 1985). Results from other studies 
(both clinical and normal volunteer) have demonstrated a clear inhibitory effect of EPA on 
LTB4 synthesis in PMN’s, the amount of LTB4 being reduced by upto 48% at 6  weeks 
(Lee et al., 1985; Sperling et al., 1987; Cleland et al., 1988). In some studies, the level 
of LTB4 inhibition achieved has been shown to be disproportionate to the percentage 
incorporation of EPA into PMN membranes, an observation which has been attributed to 
inhibition of epoxide hydrolase by LTA5 (Sperling et al., 1987). In another more short­
term study of 3 weeks (Prescott et al., 1985), LTB4 was shown to decrease 
proportionately to the synthesis of LTB5 and it is possible that a more substantial 
enrichment of membranes with EPA is required before enough LTA5 becomes available 
to significantly inhibit the epoxide hydrolase. It may be, therefore, that the dose of EPA 
employed in our study (240 mg/day) was not sufficient to have a clear inhibitory effect on
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LTB4 synthesis; in other studies where decreased LTB4 has been demonstrated, 
somewhat higher doses of EPA were used (Cleland et al., 3.2 g/day; Lee et a l,  3.2 
g/day; Sperling et al., 3.6 g/day).
Additionally, the daily dose of GLA in the combined therapy group (450 
mg) was lower than that in the EPO-only group. Other work has suggested that a 
synergistic effect between DGLA and EPA may occur, which was the basis of giving a 
reduced daily dose of EPO in combination with fish oil. For instance, EPA is thought to 
inhibit the conversion of DGLA to AA, thereby increasing DGLA incorporation into cell 
membranes (Nassar et a l  (1986) and in a study of MDSU-induced inflammation in rats 
(Tate et al:„ 1988), a GLA enriched diet has been observed to suppress the cellular 
aspects of the inflammatory response whereas an EPA-enriched diet suppressed the fluid 
phase; a combined diet was required to reduce both phases and produced the most 
effective result. Within the limitations of our study however, synergy between DGLA 
and EPA was not witnessed, either in terms of LTB4 inhibition or change in disease 
activity. The suggestion from the clinical observations that the EPO/fish oil produced an 
earlier and a longer-lasting response than the EPO supplement was not supported by their 
comparative effects on LTB4 production.
Also to be taken into consideration is the fact that LTB5 may be expected to 
exhibit a cross-reaction of around 17% with LTB4 antiserum in the RIA (Terano et a l, 
1984). However, the amounts of LTB5 formed during EPA supplementation are 
relatively low (Cleland et a l, 1988) and even combined LTB4 + LTB5 levels have been 
shown to be decreased compared to LTB4 levels prior to supplementation (Lee et al., 
1985; Cleland et a l, 1988).
The significant increase in LTB4 at 4 months in the placebo group probably 
reflects the worsening of these patients following the initiation of NSAID withdrawal 
(Fig. 7.9). The apparent decrease at 5 months and beyond therefore, is most likely a 
spurious result due to removal of these patients from the analysis. For this reason, the
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5,6 and 9 month results are also shown including the “last data” for patients who were 
withdrawn after 4 months.
7.2 (i) (iii) Conclusion
In conclusion, this study has demonstrated that it was possible to reduce or 
stop NSAID therapy in some RA patients, probably those with milder disease, by 
introducing dietary supplements of EPO or EPO/fish oil. This was achieved with no 
deterioration in any of the indices conventionally used to assess disease activity and in 
addition a subjective improvement in RA symptoms was observed.
A significant decrease in LTB4 production from stimulated PMN’s was 
detected after 3 months on the EPO diet, but a combination of EPO and fish oil produced 
a less clear inhibition of LTB4 . This may have been due to the fact that the dose of EPA 
was too low to produce a decrease in LTB4 and that the lower dose of EPO in the 
combined therapy was also insufficient to produce a decrease. However this could not be 
conclusively determined with the particular study design employed in this case.
Since LTB4 levels decreased during the period of active treatment (when 
improvement was observed in both groups) and increased during the placebo phase 
(when most patients returned to pre-treatment level of symptoms), inhibition of LTB4 
could be one factor contributing to symptomatic improvement in patients on these dietary 
supplements (EFA’s have other functions independent of their role as eicosanoid 
precursors; these are discussed in chapter 9). However, it seems unlikely that treatment 
with these oils would alter the course of prognosis of the disease and might be best used 
in clinical situations where NSAID therapy should be avoided, for example, in patients 
with peptic ulceration or renal impairment. It would also seem desirable that where 
dietary supplements are used, NSAID’s are withdrawn gradually rather than stopped 
abruptly.
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7 .3  Dietary Manipulation of EFA’s in Psoriatic Arthritis
7.3 (a) Aim of study
Management of the arthritis in patients with psoriatic athropathy is often 
difficult, with some NSAID’s exacerbating the psoriasis and an uncertain clinical 
response to second line drugs. An ideal therapy would be one which would benefit both 
the arthritis and psoriasis with a low incidence of side-effects. The observation that 
Eskimos have a lower incidence of psoriasis than Danes (Kromann & Green, 1980) led to 
speculation that dietary fish oil may be a contributory factor and two studies have 
subsequently suggested that fish oil is of benefit in psoriasis (Ziboh et al., 1986; Bittener 
et al., 1988). Dietary fish oil is also thought to give improvement in RA (Kremer et al., 
1985; Cleland et al., 1988). The same rationale for the use of DGLA in the treatment of 
RA (section 7.1) applies in the case of PA. The aim of this study was to determine 
whether an EPO/fish oil combination (Efamol Marine) could be substituted in place of 
NSAID therapy without deterioration in the clinical symptoms of PA. In addition, levels 
of PGl2-M’s and LTB4 from stimulated PMN’s and serum TXB2 were measured 
throughout the study.
7.3 (b) Patients
Thirty-eight patients with chronic stable plaque psoriasis and inflammatory 
arthritis were enrolled in the study. All patients had peripheral joint involvement plus or 
minus sacro-iliitis and all were seronegative for RF. Patients were on a stable dose of 
NSAID for at least one month prior to entering the study. Those undergoing treatment 
with systemic steroids were excluded.
Nineteen patients were randomly selected to receive 12 Efamol Marine 
capsules per day providing a total daily dose of 480 mg GLA, 240 mg EPA, 132 mg 
DCHA and 120 mg vitamin E. The remaining 19 patients received 12 visually identical 
capsules continuing liquid paraffin.
2 2 2
7.3 (c) Study design
The duration of the study was 12 months. Patients were instructed to take 
their oil capsules in addition to their usual dose of NSAID’s for the first 3 months. 
Thereafter, they were instructed to try to reduce their NSAID intake provided this 
produced no flare in their symptoms. From 9-12 months, all patients received placebo. 
The study was double-blind although investigators were aware that all patients were 
taking placebo in the final 3 months.
7.3 (d) Clinical assessment of disease activity
Full metrological assessment was carried out by the same investigator at the 
start of the study and at months 1,3,6 ,9 and 12 to assess change in indices of 
inflammatory joint disease namely grip strength, number of active joints, Ritchie AI, 
duration of morning stiffness and NSAID intake. Change in psoriasis was assessed 
using 10  cm visual analogue scales on which the clinician recorded severity of disease, 
percentage body area affected, scaling and erythema. The patient was asked to record, 
also on a visual analogue scale, whether any change in skin itch had occurred.
7.3 (e) Biochemical assessment
At each visit blood samples were taken for determination of Hb, ESR and 
CRP by the routine laboratories. Samples were also taken at 0,3,6 ,9 and 12 months for 
estimation of fatty acids in plasma and erythrocyte membranes to assess compliance 
(Efamol Laboratories).
7.3 (f) Measurement of eicosanoids
The effect of the dietary supplementation on AA metabolism was 
investigated by measuring LTB4 and PGl2 -metabolites in supernatants from 
Cal A23187-stimulated PMN’s and TXB2 levels in serum in both the active and placebo 
groups. All metabolites were measured using RIA as described in sections 4.3, 4.4 and 
4.5.
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7.3 (g) Statistical analyses
Comparability between the two treatment groups was analysed using the 
Mann-Whitney U test. Sequential analyses on individuals were performed using the two- 
tailed paired Wilcoxon test except in the case of eicosanoid measurements where the 
Mann-Whitney U test was used.
7.3 (h) Results
7.3 (h) (i) Clinical aspects
Patients in the two groups at the beginning of the study were comparable for 
all laboratory and clinical parameters except skin itch which was significantly worse in the 
active group (p <0.035, Mann-Whitney) Table 7.3). Of the 39 patients enrolled in the 
study, 34 completed to month 9 and 32 completed to month 12. Of the 6  withdrawals, all 
were on active treatment - 1 patient had an exacerbation of migraine, 2  patients 
experienced gastro-intestinal upset, 2  patients were withdrawn because of inefficacy and 
1 patient defaulted after month 6 . No information regarding patient compliance (as 
determined by EFA analysis at Efamol Labs.) was available at the time of this report.
At month 3, the placebo group showed a significant improvement in 
articular index when compared to the active group, although this difference was not 
apparent at 6,9 or 12 months (Table 7.4). No other parameters of joint activity showed a 
significant change over the study period. With regard to skin symptoms, although itching 
was initially worse in the active group, this difference was not apparent at 3 months, 
suggesting a clinical improvement (Table 7.4). During the placebo phase, a worsening of 
skin itch in the active group was observed, but this did not reach statistical significance. 
All other parameters of skin severity showed no significant change over the treatment 
period.
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In the case of ‘laboratory’ indices of disease activity, no significant 
differences were noted in ESR, CRP or Hb over the study period in either group (Table 
7.5).
Table 7.6 shows the numbers of patients in the two groups who had 
reduced or stopped their NSAID therapy by the end of the study. Since 2 patients in the 
active group and 3 patients in the placebo group were not on NSAID’s at the start of the 
study this meant that 6/17 (35%) of patients in the active group and 7/16 (44%) of 
patients in the placebo group had reduced or discontinued NSAID’s by the end of the 
study.
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PLACEBO ACTIVE
Age (yrs) 40 (25-58) 40 (18-76)
Male:FemaIe 7:12 7:12
Duration Arthritis (yrs) 11 (2-26) 9 (1-30)
Duration Psoriasis (yrs) 16 (2-30) 16 (2-30)
Articular Index 9 (3-16) 8 (4-22)
Morning Stiffness (mins) 60 (0-240) 60 (0-720)
Skin Severity 2 0  (0-80) 15 (0-70)
Percentage Body Area 20 (0-77) 19 (0-81)
Itch 7.5 (0-53) 18 (0 -8 6 )*
ESR (mm/h) 16 (2-103) 15(2-110)
CRP (N.R. <10 mgA) 12  (1 0-8 8 ) 18 (10-83)
Hb (g/1) 12.7 (8.5-16.2) 12.9 (10-16.7)
* p <0.035 (Mann-Whitney U test)
Table 7.3 Comparability of active and placebo treatment groups of PA 
patients at start of study (Median (range)).
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M onth 0 3 6 9 1 2
Skin Itch
Active 18 (0 -8 6 ) 9 (0-55) 2 2  (0 -6 6 ) 11 (0-70) 14 (0-70)
Placebo *7.5 (0-53) 4.5 (0-75) 8 (0-77) 5 (0-55) 3 (0-67)
A rticular Index
Active 8 (4-22) 11.5 (0-25) 9.5 (1-28) 10 (1-27) 10 (1-32)
Placebo 9 (3-16) *5.5 (0-18) 7 (2-33) 9 (3.20) 10 (2-35)
Table 7.4 Changes in skin itch and articular index in active and placebo 
groups of psoriatic arth ritis  patients (Median (range)).
* both p< 0.035 (Mann-Whitney)
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ACTIVE PLACEBO
Total patients 19 19
Reduced NSAID’s 3 3
Stopped NSAID’s 3 4
Not on NSAID’s 2 3
Reduced or stopped by 12 
months
6/17 7/16
(35%) (44%)
Table 7.6 Number of psoriatic arthritis patients in active and placebo 
groups who reduced or stopped NSAID therapy over the 12 
month study period.
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7.3 (h) (ii) Eicosanoid production
The median (IQR) values for LTB4 , PGl2-M’s and TXB2 determined in 
both the placebo and active groups throughout the study period are shown in Figures 
7.11, 7.12 and 7.14 respectively.
Leukotriene B4 production from A23187-stimulated PMN’s in the active 
group tended to fall from 1 month onwards and a significant decrease (2 2 %) was 
obtained at 9 months (p <0.035, Mann-Whitney). Levels appeared to rise again during 
the 3 month placebo phase, but this did not reach statistical significance. No significant 
change in LTB4 levels was detected in the placebo group throughout the 12 months (Fig. 
7.11).
No significant difference in PGI2-M production from stimulated PMN’s 
was found in either the placebo or active groups when intra-group comparisons were 
made (Fig. 7.12). However, in comparison to the placebo group values in the active 
group appeared to fall and a significant difference between the two groups was observed 
at 6  months (p <0.035, Mann-Whitney) (Fig. 7.13). (There had been no significant 
difference in PGl2-M’s between the two groups at month 0). In addition, the “rebound” 
effect on PGl2-M’s observed in the active group during the placebo phase suggested that 
the Efamol Marine was having a suppressant effect.
Serum TXB2 levels (reflecting the generation of TXA2 by platelets during 
blood clotting at 37°C in vitro) rose in the placebo group throughout the study period. In 
contrast, TXB2 levels in the active group remained relatively constant until 9 months 
when patients switched to placebo and an increase was observed (non-significant). Inter­
group analysis showed a significant increase in TXB2 production in the placebo group at 
6  months (p <0.006) and 9 months (p <0.045, both Mann-Whitney) (Fig. 7.14). There 
had been no significant difference in TXB2 levels between the two groups at month 0.
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7.3 (i) Discussion
7.3 (i) (i) Clinical aspects
Since dietary supplementation with EPO and/or fish oil appears to have a 
beneficial effect on both inflammatory arthritis and psoriasis, when studied 
independently, it would seem to suggest itself as an ideal treatment for individuals with 
psoriatic arthropathy. However, the results from this study were somewhat 
disappointing in that PA patients receiving Efamol Marine were not able to significantly 
decrease or stop their NSAID therapy. This in contrast to the RA study in which similar 
doses of Efamol Marine allowed NSAID’s to be withdrawn.
These studies did, however, employ somewhat lower daily doses of EPA 
(240 mg) in comparison to other studies where clinical improvement in arthritis or 
psoriasis was observed. Kremer et al. (1987) and Cleland et al. (1988) used 2.7g 
EPA/day and 3.2g EPA/day respectively, in the treatment of RA. In a study by Bittener 
et al. (1988), 1.8g EP A/day produced a mild to moderate improvement in psoriatic 
lesions. In another psoriatic study, Ziboh et al. (1986) demonstrated a statistically 
significant reduction in scaling, erythema and lesional thickness after giving large 
quantities of liquid fish oil equivalent to 13.5g EPA (9g DCHA) daily. An interesting 
observation in Ziboh’s study was that although an overall statistically significant 
improvement was seen with the 13 patients studied, these could in fact, be divided into 8 
'clinical responders'and 5 'non-responders'. Moreover, a correlation between EPA: 
DCHA ratio achieved (in epidermis and neutrophils) and clinical response was observed 
which suggested that the non-responders had incorporated relatively larger quantities of 
DCHA into their cell membranes.
It may be the case therefore, that higher doses of EPA are required to give 
clinical improvement in PA. The designers of the present study may have speculated that 
the effect of the relatively low dose of EPA employed would be supplemented by the 
presence of the EPO; this did not seem to be the case.
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There was a suggestion from the results that skin itch had improved in the 
active group during treatment and worsened during the placebo phase. Curiously, Wright 
& Buron (1982), in a study of eczema, also found that itch was the first symptom to 
respond to low doses of EPO, whereas at higher doses, an improvement in scaling and 
overall severity was observed. This would also seem to suggest that larger doses of 
EPO/fish oil may have been more effective.
The reason for the significant decrease in the number of active joints 
detected in the placebo group at 3 months is not known, but may reflect a degree of 
spontaneous remission which sometimes occurs in patients with psoriatic arthritis 
(Voorhees, 1983).
7.3 (i) (ii) Effect on LTB4 production
In agreement with the results obtained in the RA study, the effect of the 
EPO/fish oil supplementation on LTB4 production from PMN’s was not as great as might 
have been anticipated. However, the median LTB4 level did fall during the treatment 
period and rise during the placebo phase in the active group. The fact that the decrease in 
LTB4 only reached statistical significance by 9 months may support the idea that the dose 
of EPO/fish oil was not quite high enough to give a clear, early effect on LTB4 synthesis 
and therefore on clinical symptoms.
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7.3 (i) (iii) Effect on PGI2-M production
The effect of an EPA-rich diet on PGI2 production in humans is not entirely 
clear, but most investigators have reported unchanged or even increased amounts of PGI2 
after EPA ingestion, both in terms of urinary metabolites of PGI2 (Fischer & Weber, 
1984; von Schacky et al., 1985) and production from PMN’s ex vivo (Weber et al, 1985). 
The ex vivo results appear to be in contrast to those from studies with human endothelial 
cells in culture, where reduced PGI2 synthesis was observed after pre-incubation of the 
cells with EPA (Spector et al., 1983). Decreased levels of PGl2-M’s after EPA 
supplementation have also been detected in rat aorta (Homstra et al., 1981) but animal 
studies are not analogous to human studies in this respect, since rats do not form PGI3 
after dietary EPA.
PGl3-M’s may be expected to cross-react with antiserum for PGl2-M’s in 
RIA and although the extent of the cross-reaction in the RIA used in this work is not 
known, results obtained can be assummed to be a measure of combined PGI2 /PGI3- 
M’s. PGIi is not formed in vivo (Willis, 1981), but the effect of an EPO-rich diet also 
seems to be increased PGI2 generation (Belch etal., 1986b).
The contribution make by DCHA to the observed effects on prostanoid 
metabolism after fish oil supplementation is difficult to assess. However, it has been 
reported as having a strong, selective inhibitory effect on the CO pathway (Corey, Shih & 
Cashman, 1983).
In the present study, no significant change in PGI2-M production from 
A23187-stimulated PMN’s within the active group itself was seen throughout the 
treatment period. However, in comparison with the placebo group, a significant fall in 
PGl2-M’s was observed at 6  months. This may have been due to a tendancy for CO 
products, including PGl2-M’s, to rise in the placebo group during attempts to reduce or 
stop NSAID’s from 3 months onwards. If this was the case, then the EPO/fish oil 
treatment appears to have stabilized this increase during NSAID withdrawal in the active
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group. The “rebound” of PG^-M ’s during the placebo phase in this group is further 
evidence that such a suppressant effect may have been occurring.
Results from this study, therefore, appear to be in contrast to those of others 
where EPA/DGLA was shown to maintain or increase levels of PGI2 -M’s in vivo. 
However, our study is different in that another factor affecting PG production 
(withdrawal of NSAID’s) is in operation. The effect of this in combination with the 
dietary supplementation is difficult to assess. It may also be the case that the potentiation 
of PGI2 -M production in PMN’s during EPO/fish oil supplementation is dependent on 
inhibition of LTB4 production thereby diverting AA substrate to the CO pathway. 
Results have shown that a significant reduction in LTB4 was not achieved until late in the 
study and was comparatively small.
In retrospect, measurement of plasma PGl2-M’s may have been a better way 
to assess the effect of EPO/fish oil.
7.3 (i) (iv) Effect on TXB2 production
There exists in the literature extensive evidence which suggests that dietary 
EPA has an anti-thrombotic effect both in man and animals (Siess et al., 1980; Dyerberg 
et al., 1978; Lorenz et al., 1983; Culp et a l, 1980). Part of this anti-thrombotic effect 
may be attributed to the synthesis of TXA3 which is a less potent platelet aggregant than 
TXA2 (Fisher & Weber, 1983), however the main mechanism whereby it occurs, is via 
direct competition of EPA with the conversion of AA by CO thereby decreasing platelet 
TXA2 synthesis (Needleman et al., 1979). Several studies have demonstrated decreased 
TXA2 and reduced platelet aggregation after dietary supplementation with EPA (Lorenz et 
al., 1983; von Schacky et a l, 1985). In the latter of these studies a reduction in serum 
TXA2 of 50% was observed in normal volunteers after 12 weeks on an EPA diet.
Although the effect of DGLA on TXA2 synthesis has not been so 
extensively studied it would appear that this also has the potential to reduce platelet TXA2 
synthesis both in animals (Kirtland et al., 1986) and in man (Belch et al., 1986). Another
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component of the Efamol supplement used in this study, DCHA, has also been shown to 
reduce TXA2 formation in platelets (Srivastava, 1985).
The observed effects of the EPO/fish oil supplement on serum TXB2 
generation in the present study were again complicated by the fact that patients taking the 
supplement were simultaneously reducing their NSAID intake. Although there had been 
no significant difference in TXB2 levels between the two groups at the start of the study, 
by 6  months, levels in the placebo group were significantly higher than those in the active 
group. It would appear, therefore, that while a reduction in NSAID’s in the placebo 
group caused an increase in serum TXB2 , the same effect did not occur in the active 
group even though the numbers of patients reducing/stopping NSAID’s was 
approximately equal in both groups. The increase in TXB2 observed after the 3 month 
placebo phase in the active group (non-significant) is a further indication that the EPO/fish 
oil supplement may have been having a suppressant effect.
7.3 (i) (v) Conclusion
In conclusion, this study failed to demonstrate that NSAID’s could be 
discontinued in PA patients treated with 12 Efamol Marine capsules daily, However, 
with respect to eicosanoid production, the dietary supplement did appear to stabilize the 
effects of NSAID withdrawal. Larger doses may be required to produce a clinical 
improvement in this condition.
239
CHAPTER 8  
GENERAL DISCUSSION
8 .1  M ethodology
8.1 (a) Measurement of PGl2-metabolites
It is now generally accepted that PGI2 does not function as a circulating 
hormone, nevertheless, it’s role as a local hormone may be crucial in maintaining 
haemostasis. Undoubtedly, absolute values of 6-keto-PGFia , the stable metabolite of 
PGI2 normally used as an index of PGI2 production, can be best measured by GCMS. 
However, it has also become apparent that PGI2 is metabolized to a range of metabolites 
in vivo (both by 15-PGDH and by non-enzymatic means) and that estimates of PGI2 
generation by a tissue may be misleading if 6-keto-PGFia is used as the sole index of 
PGI2 production.
The method used in this work for the estimation of circulating PGI2 levels 
takes account of this by carrying out RIA on unextracted plasma, thereby measuring 
“PGl2-metabolites” rather than 6-keto-PGFia . This method has been validated 
elsewhere (McLaren et al, 1985) and the values obtained (low pg/ml range) are now 
generally accepted as reflecting circulating levels of PGI2 in vivo.
8.1 (b) Measurement of TXB2
Several different approaches to the measurement of TXB2 have been adopted 
over the years. It is now recognized that attempts to measure circulating levels of TXB2 
(as an index of TXA2), by measuring plasma levels, simply reflected platelet activation 
during venepuncture. Since, like PGI2, TXA2 is not a circulating hormone, but is 
produced in response to local stimuli, a better approach would seem to be measurement of 
TXB2 generation by platelets for a given stimulus. Consequently, the measurement of 
TXB2 after in vitro clotting (the stimulus being endogenous thrombin) was the method 
used in this work. However, it has since become apparent that this method is only truly
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reproducible when the incubation time and temperature are standardized usually 37°C for 
at least 1 hour.
In this work, one of the studies (HSP) which employed measurement of 
serum TXB2 was carried out before the modified methodology was introduced and 
therefore, the results from this study must be treated with some reservation. However, 
results using the old procedure are not necessarily negated if the samples are collected and 
prepared as they were in this study, in a consistent manner.
8.1 (c) Measurement of LTB4
The method of PMN stimulation used in this work, maximal stimulation with 
calcium ionophore A23187, is assumed to reflect the total LTB4 -synthesizing capacity of 
the cells. It is always possible, of course, that a different metabolic capacity could exist 
under conditions for stimulation occurring in vivo. However, the Cal method is still 
probably the best in vitro method, as it has the advantage of using endogenous AA and 
gives rise to levels of LTB4 which are easily measured by RIA. The values of LTB4 
obtained in this work for normal, maximally stimulated PMN’s are similar to values 
reported elsewhere (Lewis, 1985).
The measurement of LTB4 by RIA directly in cell supernatants has been 
validated elsewhere (Salmon et al, 1982a) and the LTB4 assay has been shown in this 
work, to be sensitive and reproducible.
8 .2  R aynaud’s Phenomenon
8.2 (a) PGI2 in Raynaud’s phenomenon
The discovery of PGI2 and TXA2, two potent mediators with opposing 
actions in the cardiovascular system, provided Monacada and Vane with a rationale for 
describing the control of normal haemostasis and the development of vascular disease. 
However, not surprisingly, the concept of a decreased PGI2/TXA2 ratio in ischaemic 
vascular disease is proving to be more complex than at first envisaged and it is now
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apparent that in many inflammatory vascular conditions where an inadequate production 
of PGI2 may have been postulated, the opposite is in fact true. The work presented here 
has found that this is the case for patients with secondary Raynaud’s disease and has also 
shown that the phenomenon may be related to decreased platelet sensitivity to PGI2 in 
these patients. It is still not entirely clear what the mechanism of desensitization is in 
vivo, but it may be due to a loss of specific receptors upon chronic exposure to PGI2. If 
this is is the case then the lack of feedback inhibition via receptor-mediated increase in 
cAMP may not occur allowing this “futile” PGI2 generation to proceed unchecked. If the 
decreased sensitivity to PGI2 is a generalized phenomenon in the cells of these patients 
then this may explain some of the other manifestations of this condition, such as 
increased collagen production.
As is often the case in inflammatory disease states, it is difficult to present a 
unified theory of pathogenesis in which cause and effect are clearly distinguishable. 
However, since increased plasma levels of PGI2 were not observed in patients with 
primary Raynaud’s disease, it seems likely that sufficient vascular damage to produce an 
initial compensatory elevation of PGI2 had not yet occurred in these patients.
8.2 (b) LTB4 in Raynaud’s phenomenon
Although the role of platelets and the PGI2 /TXA 2  balance in the development 
of digital ischaemia has been well studied, relatively little attention has been given to role 
of leukocytes. Results from the study reported here have shown that isolated PMN’s 
from patients with Raynaud’s disease secondary to PSS and VWF have an increased 
capacity for LTB4 production. Since LTB4 has been shown to play an important role in 
many aspects of PMN behaviour including chemotaxis, aggregation and adhesion, this 
finding of increased LTB4 may well be relevant to the development of digital ischaemia in 
these patients. PMN aggregates (like platelet aggregates) may physically obstruct blood 
flow and, futhermore, such activation of PMN’s is likely to result in the release of 
lysosomal enzymes and oxygen free radicals and so perpetuate the cycle of vascular 
damage and PMN activation.
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The finding of increased LTB4 production from PMN’s of patients with 
secondary Raynaud’s disease is also consistent with the hypothesis that a generalised loss 
of cell sensitivity to the inhibitory effects of PGI2 occurs in this condition. However, it 
must be stressed that this is merely a hypothesis and no work has been done here to 
confirm this.
Vibration-induced white finger (VWF) is increasingly being shown to be very 
similar in nature to the more classical types of secondary Raynaud’s disease. The 
observation that LTB4 production from PMN’s is also increased in VWF would seem to 
support this idea and suggests an overlap in their pathophysiology. Although the initial 
source of vessel damage may differ in PSS and VWF, the self-perpetuating cycle of PMN 
activation and vessel damage which ensues may lead to development of systemic disease 
long after the initial damaging stimulus has ceased. Despite the fact that the increased 
production of LTB4 and other markers for inflammation increasingly depict VWF as a 
true secondary Raynaud’s disease, it has, since the work for this thesis was done, been 
removed from the prescribed list of diseases eligible for compensation.
8.2 (c) Studies with iloprost
The effectiveness of PGI2 and it’s stable analogue iloprost in treating RP has 
stimulated investigation into less obtrusive methods of delivery, such as transdermally. 
Although much of the effectiveness of iloprost can be attributed to it’s anti-platelet effects, 
more evidence is emerging which suggests that some of it’s effects on the circulation are 
mediated via it’s inhibitory action on leukocytes. In this work, clinical studies with 
transdermally applied iloprost provided the opportunity to investigate the effect of iloprost 
on LTB4 from PMN’s ex vivo.
There was a suggestion from the results that LTB4 production from PMN’s of 
normal volunteers receiving transdermal iloprost was decreased. However, the doses 
used in this pilot study were cautious and in the dose-pair receiving the highest dose 
(even higher doses are used therapeutically in RP patients) a clear decrease in LTB4 was 
observed. The initial “spike” of increased LTB4 production in the first 3 hours of
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transdermal iloprost remains unexplained. However, similar effects in other studies with 
iloprost are not unknown and PGI2 is recognized as having a dual character with respect 
to development of the cardinal signs and its (later) inhibitory effects on cell function. 
Further investigation of this phenomenon is obviously required.
A longer term study of transdermal iloprost in Raynaud’s patients showed 
that, in terms of disease activity, iloprost was successful in reducing the frequency and 
duration of spasm attacks. Although the treatment did appear to decrease the LTB4 
synthesizing capacity of PMN’s, this decrease did not co-incide with the clinical 
improvement. It may still be the case that LTB4 inhibition made some contribution to the 
clinical improvement, however it seems likely that anti-platelet and vasodilatory properties 
of iloprost were most important. An earlier study in this work showed doses of PG were 
able to normalize platelet sensitivity to PGI2, however, the PMN is a less responsive cell 
to PGI2 and higher levels may be required to overcome resistance in RP PMN’s if it 
exists.
Although LTB4 levels were increased in RP, these did not significantly 
correlate with subjective measures of disease activity such as frequency and duration of 
spasm attacks. LTB4 could not therefore be used as any kind of diagnostic predictor in 
RP, and in this sense, would appear to be simply a general marker for inflammation. 
However, the patient numbers in this study were small, and more extensive work with 
larger patient groups is required to clarify the extent to which inhibition of LTB4 can 
improve blood flow in RP.
Despite the results of the two ex vivo studies described above, inhibition of 
LTB4 production by iloprost in vitro (although it has been reported by other authors) 
could not be demonstrated using the maximal stimulation method employed in this work.
8.2 (d) Other therapies
The fact that many factors are involved in the control of vascular tone is 
reflected in the number of different theories regarding the pathogenesis of RP and the
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many different approaches to therapy. The serotonin antagonist, ketanserin is another 
drug used in the treatment of RP whose effectiveness can most easily be attributed to it’s 
inhibitory effects on platelet aggregation and vasoconstriction. However, results from the 
study of oral ketanserin in Raynaud’s patients suggested that it was also having an effect 
on the LTB4-synthesizing capacity of PMN’s. It is most likely that this effect of 
ketanserin was secondary to it’s effects in reducing the frequency and duration of spasm 
attacks thus diminishing the effect of spasm on PMN activation and the potentiation of 
LTB4 production.
The effectiveness of the anabolic steroid stanozalol in RP has been attributed 
to it’s fibrinolytic effect. However, there is some evidence to suggest that it does not 
operate solely through this mechanism. The in vitro study described in this work, 
showed that, at concentrations which are compatible with the therapeutic dose, stanozalol 
causes a clear inhibition of LTB4 production from stimulated PMN’s. This may therefore 
be an additional mode of action contributing to it’s effectiveness in the treatment of RP. It 
would obviously be desirable to confirm that this effect occurs ex vivo in patients 
receiving stanozalol treatment. It would also be of interest to establish whether stanozalol 
inhibits the 5-LO enzyme in a cell-free system or whether another enzyme is involved. 
The effect of stanozalol on PG production also requires clarification since only subjective 
evidence that it has no effect exists at present.
8 .3  Henoch-Schonlein P urpura
Henoch-Schonlein purpura, like the haemolytic uraemic syndrome, would 
appear to be an inflammatory condition in which there is a deficiency of vascular PGI2 
production. Results from the preliminary study presented here indicate that probably 
more than one mechanism contributes to inadequate PGI2 production and this is certainly 
an area in which a more thorough investigation could be carried out. Measurement of 
serum TXB2 in patients with HSP suggested that platelet activation was not enhanced in 
this condition. However, the methodology which was used has since been modified and
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repetition of the TXB2 measurements using the standardized method for serum collection 
would confirm whether this observation is correct.
It is not suggested either in the case of RP or HSP that the disturbance of 
PGI2 metabolism is the primary factor in pathogenesis. Rather, the disturbance is 
secondary to endothelial damage initiated by other factors, as yet unknown.
8 .4  LTB4 in Inflammatory Joint and Skin Disease
It has been known for several years that LTB4 is one of the many 
inflammatory mediators which can be detected in the synovial fluid from rheumatoid 
joints. This is mainly derived from unfiltrating PMN’s which accumulate at inflammatory 
loci. The results from the study reported here have illustrated that the LTB4-synthesizing 
capacity of PMN’s from RA patients is increased compared to that of normal controls and 
that this does not appear to occur merely as a result of NSAID therapy. If these results 
reflect the true in vivo situation, then the concern that NSAID’s may inhibit the cardinal 
signs of inflammation, but potentiate the cell-mediated aspects of inflammation via an 
increase in 5-LO products may be unfounded. Nevertheless, the increased LTB4- 
synthesizing capacity of RA PMN’s entering the synovium is likely to intensify the 
inflammatory response and the use of dual CO and 5-LO inhibitors is likely to have a 
significant advantage over NSAID therapy.
The finding that PMN’s from PA patients also have an increased capacity for 
LTB4 production but that (in this case) LTB4 levels do not significantly correlate with 
indices of skin or joint disease activity reinforces the hypothesis that LTB4 is as much a 
product of inflammation as a cause - a so-called “inflammatory marker”. Interestingly, 
although LTB4 production from PMN’s was found to increase in both RA and PA, 
another report in the literature suggests that there is no such increase in patients with 
psoriasis alone. This may mean that LTB4 is more associated with inflammatory joint 
disease than inflammatory skin disease, however, it is more likely that raised LTB4 
simply reflects the presence of a more severe inflammatory condition in psoriatic 
anthropathy. The fact that the other authors found 20-hydroxylase products of LTB4 to
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be increased in psoriasis may indicate that LTB4 production is increased, but not beyond 
the capacity of the 20-hydroxylase enzyme. It should be noted that 2O-OH-LTB4 does in 
any case, retain significant chemotactic activity (Ford-Hutchinson et al, 1983).
There seems to be general agreement in the literature (Simmons et al, 1983; 
Clancy & Hugli, 1985) that LTB4, even where it is increased probably does not have an 
initiating patho-physiological role in inflammatory disease, but is more likely to amplify 
and modulate an inflammatory response which is already present. It is also usual in the 
literature to find that in diseases where increased production of LTB4 has been detected, 
generally, no significant correlation or only a weak correlation, has been found between 
LTB4 and disease activity (Maurice et al, 1986; Nielsen et al, 1987). This supports the 
idea that LTB4 is a general rather than a specific marker for inflammatory disease and that 
it’s inhibition is likely to produce a reduction in inflammatory symptoms, but would not 
have a disease-modifying effect. In a model proposed by Clancy and Hugli (1985), the 
suggested initiating chemotactic stimulus at the inflammatory locus is complement 
fragment C5a. The fact that C5a can only stimulate LTB4 synthesis in PMN’s when 
exogenous AA is provided means that firstly, it is able to migrate to a site of tissue injury 
without the elaboration of chemotactic factors such as LTB4 en route and secondly, the 
amount of LTB4 released at the locus would initially be proportional to the amount of free 
AA available and hence, to the degree of tissue damage. In this model, LTB4 would then 
serve to amplify the inflammatory response once it had been initiated.
It is evident that a deeper knowlege of the mechanims controlling LTB4 production in 
normal cells, and those leading to increased LTB4 production in disease, is required. The 
recent identification and isolation of a 5-LO activating protein (FLAP), (Miller et a/,1990; 
Dixon et al, 1990) in the membranes of various leukocyte lines that synthesise LT’s, is 
likely to lead to a greater understanding of the mechanisms of LT production and may 
also provide a new target for therapeutic manipulation.
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8 .5  Dietary Studies
There is, at present, a growing consumer enthusiasm for “alternative” 
medicine, and the use of dietary supplements of diverse nature, many of which have 
dubious scientific validity, is currently in vogue. However, the use of Evening Primrose 
oil, (a source of DGLA) and fish oil, (a source of EPA and DCHA) in the treatment of 
inflammatory disease has a sound scientific basis.
Horrobin (1980) has hypothesized that chronic inflammatory disease as a 
whole may be due to an imbalance in the AA/DGLA ratio in the modem Western diet 
leading to an inadequate production of PGEi which may be essential for the normal self­
regulation of PG synthesis to occur. In this model, NSAID and corticosteroid therapy 
would merely aggravate the problem by having very little effect on production of the more 
prominent 2-series PG’s, but significantly inhibiting the PGEi deficiency. If this is the 
case, then only treatment with agents which enhance PGEi synthesis could correct the 
imbalance.
The beneficial effects of EPA on the eicosanoid balance are also well 
recognized and, in addition, epidemiological evidence exists to suggest that a high dietary 
intake of fish leads to low incidence of inflammatory disease.
The influence of diet on RA (exclusion diets, fasting etc) has always been 
controversial and there is now an increasing volume of literature involving dietary studies 
with EPO and fish oil in RA. An overall assessment of these studies and comparisons 
with the work presented here are difficult for several reasons, i) a wide variation in dose 
(especially EPA) has been used, 2) the length of these studies has varied considerably, 3) 
different RA patient populations have been studied, 4) in most cases the study has been 
carried out against a stable background of NSAID and/or corticosteroid therapy, whereas 
in our study, NSAID’s were being withdrawn, 5) in some cases general diet was also 
altered and 6 ) the studies were not always placebo controlled.These factors have made an 
overall assessment of the effectiveness of the dietary supplements difficult. On the whole, 
however, both DGLA and EPA do seem to be of some benefit in the treatment of RA.
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One possible factor contributing to their effectiveness is decreased production of LTB4 
from PMN’s and indeed, decreased LTB4 after dietary EPA at least, has now been 
demonstrated on several occasions.
In this work, the clinical aim was to see if the EPO or EPO/fish oil 
supplements could be substituted for NSAID’s without deterioration in objective markers 
for disease activity, and, in this respect, the study was successful. However, the fact that 
NSAID’s were being withdrawn made interpretation of the LTB4 results more difficult. 
Although conventional wisdom would have predicted, if anything, a decrease in LTB4 
synthesis as NSAID’s were withdrawn, results from the placebo and EPO/fish oil groups 
suggested the opposite.
In terms of LTB4 inhibition, the EPO treatment appeared to be more effective 
than the combined therapy. The effect of the EPO and fish oil together did not appear to 
be additive, far less synergistic. More studies are required to clarify the situation with 
respect to combined therapy.
The substantial placebo effect on subjective measures of disease observed in 
the RA study stresses the need for placebo-controlled studies and casts some doubt on 
un-controlled studies which have reported improvement in the more subjective aspects of 
RA (eg grip strength, morning stiffness) with EPO and fish oil. A positive placebo effect 
may be even more likely where patients view the treatment as being a “natural” therapy 
rather than a “drug”. In addition, the use of olive oil as placebo in some studies is 
dubious, since, although thus mono-unsaturate is inert in terms of eicosanoid synthesis, it 
does have effects on membrane fluidity and cholesterol metabolism (Jantti et al, 1989) 
and certainly has the potential to affect disease activity via these other mechanisms, thus 
possibly obscurring any positive effect of the active EPO or fish oil treatment (Darlington 
& Ramsay, 1987).
Although EFA’s have obvious effects on eicosanoid metabolism in PMN’s, it 
should be appreciated that manipulation of EFA’s will alter eicosanoid biochemistry in 
other cell types and systems. As previously mentioned, an increase in production of
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PGEi in the brain could be responsible for the “anti-depressant” effect of EPO. In 
addition, EFA’s have properties which are independent of their role as eicosanoid 
precursors and which could contribute to their anti-inflammatory effects. One of their 
major roles is in the maintenance of cell membrane structure (Crawford, 1983). The 
unsaturated fatty acid content of a membrane determines it’s degree of fluidity, which in 
turn effects it’s permeability and the behaviour of membrane-bound enzymes and 
receptors, thus, conceivably altering the cell’s response to inflammatory stimuli. 
However, there is evidence to suggest that unsaturated fatty acids per se are not anti­
inflammatory since in rats, Safflower oil (a rich source of linoleic acid) does not have an 
anti-inflammatory effect whereas EPO does (Tate et al, 1988).
In the psoriatic arthritis study, the EPO/fish oil supplement did appear to have 
some inhibitory effect on LTB4 production and was able to stabilize prostanoid levels 
during NSAID withdrawal. Despite this, the PA patient group as a whole were not very 
successful in discontinuing NSAID’s, and the active group were no more successful than 
the placebo group. The reason for the number of placebo responders being lower in the 
PA patient group than the RA patient group is not known.
In conclusion, the evidence from these and other studies, taken together, 
suggests that EPO and fish oil may be useful treatments in the suppression of the 
symptoms of inflammatory joint disease in some cases. However, where there is benefit, 
the exact mechanism is still not completely understood due to the complex role of EFA’s 
in human biochemistry. It is likely, therefore, that investigation into dietary manipulation 
as one of the many approaches to inflammatory disease therapy, will continue to be an 
active area of research and may well reveal useful information regarding the role of 
dietary EFA’s in normal health as well as in disease.
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PLATELET SENSITIVITY TO A PROSTACYCLIN
ANALOGUE IN SYSTEMIC SCLEROSIS
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Infirm ary, 10 A lexan dra  P arade, G lasgow  G31 2E R , U K
S U M M A R Y
Vascular prostacyclin (P G I2) regulates p latelet function and b lood  flow. In system ic sc lerosis (SS) there  
is increased p latelet aggregation (P A ) but no inform ation is available on the p late le t/P G I2 relationship . 
W e evaluated  p late let sensitivity to a P G I2 analogue Z K 36374 in 17 SS patients and 18 controls. T he  
percentage (% )  inhibition o f  P A  was m easured at tw o doses o f Z K 36374 with saline giving the 100%  
b aseline. In the SS group 2n g  Z K 36374 produced a percentage inhibition o f 19 +  14 com pared  to  a 
control value o f  60 +  21, and 3 ng a percentage inhibition o f 47 +  21 in the SS group and 82 +  20 in the  
controls. In 11 SS patients treated  with either prostaglandin E or nifedipine the sensitivity approached  
norm al. T hese data suggest that SS p latelets are less sensitive to the inhibitory effect o f  P G I2 on P A . 
This m ay contribute to the vascular lesions o f  SS. O ther cells are resistant to the effects o f  P G I2 and our  
findings support this p icture o f  cellu lar resistance.
K e y  w o r d s : System ic sc lerosis, R aynaud’s syndrom e, Prostacyclin, P latelets.
S y s t e m ic  sclerosis (SS) is a connective tissue disease characterized by fibrotic changes 
involving predominantly skin and blood vessels (1). Raynaud’s syndrome (RS) is often the 
presenting feature in this group of patients and can be a persistent management problem for 
the physician. Although it is well recognized that hand and digital blood flow is diminished 
(2) the pathogenesis of the Raynaud’s is still incompletely understood, thus treatm ent has 
been unsatisfactory in the past.
Recent work, however, has shown that prostaglandin E, (PGE,) (3 )  and prostacyclin 
(PGI2) (4) may be useful in the management of this disorder. Intravenous infusions of these 
prostaglandins (PGs) have been shown to increase blood flow to the hands and to elevate 
hand temperatures for up to six weeks. These clinical and laboratory improvements seen 
following PG treatment might suggest that SS patients either produce inadequate amounts 
of vasodilator PGs or that they are resistant to the actions of normal or even increased 
amounts. A resistance to the effects of the PGs seems most likely as both our group (5) and 
H orrobin’s group (6) have found increased levels of PGI2 and PGE metabolites, respec­
tively. Furthermore, Whicher et al. (7) demonstrated a diminished acute-phase response 
after PGE, infusion in SS, suggesting either a hepatocyte or macrophage resistance, and 
Kirby et al. (8) postulated a PG resistance of the cyclic nucleotide responsiveness of the SS 
lymphocyte.
The possibility of PG resistance in the SS platelet has not yet been explored. Should this 
resistance be found then it may explain the formation of circulating platelet aggregates (9) 
and occlusion of the microcirculation that occurs during a Raynaud’s spasm.
The aim of this study was to evaluate the prostacyclin sensitivity of SS platelets 
compared to age- and sex-matched controls. As PGI2 is unstable, therefore presenting 
difficulties in standardizing dose, a stable carbacyclin analogue of PGI2, ZK36374 (Schering 
Chemicals Ltd.), was used (10). In addition the effect on the PGI2 sensitivity of platelets of
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patients treated with CL115,347, a transdermally absorbed PGE analogue (Cyanamid 
International), and oral nifedipine was observed.
METHODS
Patients
Twenty-four patients (mean age 45 ± 11 years) with classical SS, as defined by the
A .R .A . criteria, were enrolled in the study. Seventeen of these patients were on no drug 
therapy known to interfere with PG metabolism. Four patients subsequently received 
CL115,347 1000 pg/24 h transdermally and were therefore sampled twice. One further 
patient was also sampled whilst receiving the transdermal PG and six were taking oral 
nifedipine 10 mg t.i.d. After informed consent had been obtained the patient sat in a warm 
waiting room for at least |  h to ensure that no blood sample was taken during a Raynaud’s 
attack.
Eighteen matched controls (mean age 44 ± 9 years) were also studied.
Blood tests
Blood (9 ml) was drawn from the antecubital fossa and anticoagulated with 3.2% 
sodium citrate (9:1, v : v). The blood was carefully mixed, and centrifuged for 7 min at 150 g 
at room temperature to obtain platelet rich plasma (PRP). Platelet poor plasma (PPP) was 
prepared by centrifuging the remaining blood at 2000 g for 15 min. PRP platelet count was in 
general about 250 x 109/1.
Platelet aggregation (PA) was studied in 200 pi of PRP according to the method of Born 
(11) using a two-channel Malin’s aggregometer. Following 3 min incubation at 37°C with 
100 pi of saline and two different dilutions of ZK36374 (2 ng/ml, 3 ng/ml), 3 pi of 2 pM 
adenosine 5-diphosphate (ADP) was added. The change in light transmission was recorded 
graphically and expressed as a percentage inhibition of saline control. Care was taken to 
standardize the procedure as suggested by Siess et al. (12). The doses of ZK36374 were 
compatible with those intended for therapeutic use of the drug (10).
RESULTS
As can be seen from Fig. 1, when 100 pi of 2 ng/ml ZK36374 is added to normal PRP, 
59 ±  17% (mean ± SD) of platelet aggregation to ADP is inhibited. However, when the 
same amount of ZK36374 is added to the platelets of SS patients on no treatm ent only 18 ±  
13% of PA is inhibited. The same pattern is repeated at the higher dose of ZK36374 (3 
ng/ml)—85 ± 1 1 %  inhibition of PA for normals and 49 ± 19% for SS. These results are 
statistically significant (p<0.001, Mann Whitney).
In contrast, the platelet sensitivity of ZK36374 in SS patients on either nifedipine or 
CL115,347 is in the normal range (68 ±  18%, 85 ±  15%) (Fig. 2). In an effort to show that 
this difference was not due to a difference in SS population, four of the patients originally on 
no treatm ent were given a 2-week course of CL115,347 and then retested. As can be seen 
from Fig. 3 the initial abnormal sensitivity is normalized by treatment.
The baseline (saline only) rate of aggregation measured in the conventional way 
(% change optical density/s) demonstrated no significant difference between SS patients and 
normal controls (mean 12.9 ±  4.2, 12.8 ±  3.6, respectively).
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DISCUSSION
This study demonstrates that the platelets of patients with SS are resistant to the anti­
aggregatory effects of the synthetic PGI2 analogue, ZK36374. As PG I2 sensitivity decreases 
even further at cold temperatures (13), platelet clumping in the microcirculation with release 
of vasoconstrictor substances could play a part in the development of Raynaud’s syndrome. 
The platelets of patients with other thrombotic disorders have been shown to have a similar 
resistance to PGI2 (14,15) and it is thought that this contributes to the clinical manifestations 
of ischaemia.
Furthermore it seems likely that the SS macrophage (7), lymphocyte (8) and now the 
platelet are resistant to effects of PGs. Why is this? PGI2 resistance develops physiologically 
in pregnancy as the plasma levels of PGI2 increase (15). We have found increased levels of 
PGI2 metabolite in these SS patients (5) and it may be that a ‘tachyphylaxis’ or ‘down 
regulation’ is occurring. Receptor binding studies would be required to evaluate this 
hypothesis. Recently conducted clinical studies (unpublished observations) have shown that 
chronically administered PG therapy, given in pharmacological doses, produces a similar 
fall-off in effect. Platelet aggregation, initially decreased by the PG, returns to baseline over 
a period of 6-8 weeks, as does the improved blood flow and clinical response. Chronic 
exposure to increased levels may desensitize the cells to the action of PGs and even higher 
levels obtained by pharmacological doses may be required to allow the cells to respond 
normally, at least for a time. Support for this can be seen with leucocytes (8) where normal 
cyclic nucleotide responsiveness to isoprenaline was restored after infusion of PG I2. 
Similarly in our study the addition of the transdermally absorbed PG E seems to normalize
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the response of the platelet to PGL. Oral nifedipine, via its calcium channel blocking 
activity, will decrease the platelet release reaction therefore inhibiting release of the vaso­
constrictor thromboxane A2 (TXA2). TXA2 is antagonistic to the action of PGL and 
therefore any decrease in this substance will enhance the action of the available PGs.
In conclusion therefore, we have demonstrated a resistance of the SS platelet to the 
anti-aggregatory effects of PGI2 and suggest that this may be important in the development 
of digital ischaemia.
These observations also support the hypothesis of a generalized cellular resistance in 
SS. If this is extrapolated to other cells some additional manifestations of SS could be 
explained, for example, in SS there is augmented growth of collagen-producing fibroblasts 
(16) which are normally inhibited by PG. If the fibroblasts are resistant to the negative effect 
of PG, this might explain the excess collagen production seen in this disease.
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jtal Effectiveness o f Occlusal Splint Therapy Lamev and Barclay
: height of the appliance by excessive wear. Four 
jents, who were asked to discontinue the use of the 
®t for one m onth suffered a relapse of their symptoms.
tussion
dentate patients with symptoms of classical migraine on- 
ling, or within hours of waking, occlusal splint therapy is 
jctive. The success of treatm ent is also achieved without 
(medication. The aetiological relationship of classical 
jaine to TM J dysfunction syndrom e rem ains speculative 
[dental aspects of migraine seem to be im portant in 
tcted patients. O ther advantages of this means of 
iapy in selected patients are that there  are no contraindi- 
ions and drug therapy with its associated side effects in 
iepatients is avoided.
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ABNORMAL BIOCHEMICAL AND CELLULAR PARAMETERS IN THE BLOOD OF PATIENTS WITH
RAYNAUDS PHENOMENON
J.J.F . Belch, J. Drury, K. M cLaughlin, A . O ’Dowd, J. Anderson, R .D . Sturrock, C .D . Forbes
University Department o f M edicine.
Roval Infirmary.
10 Alexandra Parade, G lasgow. G31 2ER.
Abstract. Finger b lood flo w  is decreased in Raynauds Phenom enon (R P ). This m ay be due not only to 
vasospasm, but also to blood abnormalities. 40 patients with Raynauds Disease (R D ), 28 with suspected R P  
(SS) and 42 with secondary Raynauds syndrom e (RS) were enrolled and com pared to 50 controls. Results 
from  base-line samples show  that those with R P  have abnorm al haemostasis and rheology whereas those with 
mild Raynauds, R D  do not. B lood sam pled after cold challenge in 15 R S  patients and  15 controls show  that 
both groups exhibit platelet activation after emersion. The degree o f  activation how ever was much m ore  
marked in the R S  patients. We have shown that abnormalities o f  haemostasis and rheology are fo u n d  in 
patients likely to have endothelial damage (RS). These changes are probably a consequence rather than a cause 
o f the disease. A fter  cold challenge the results become more abnorm al and correlate with severity o f  disease.
IlS established that hand and digital blood flow is 
jminished in p a tien ts  su ffering  from  R ay n au d ’s 
Wienon (RP)- H ow ever, the mechanism by which this 
W ed  flow is produced is unclear. M any suggestions 
Ming the pathophysiology of R P have been studied, for 
®ple increased sym pathetic to n e ( l) , local arterial sensi- 
|to cold, and deposition of im m une complexes in the 
jtl wall. A n association has been found between 
«uds Syndrom e (RS) and im m une complexes in vinyl 
Me disease. In addition , increased levels of phagocy- 
 ^immune com plexes in circulating PMN leucocytes 
: been dem onstrated  and the levels of complexes 
Mte with systemic involvem ent and severity of vase­
'll].
]1 the above are concerned with vessel wall and the
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developm ent of spasm . M ore recently how ever, attention 
has focused on the contribu tion  to decreased flow m ade by 
biochemical and cellular abnorm alities in the blood. This 
study deals with the m easurem ent of these abnorm alities in 
patients with R P, and assessm ent of w hether these p ara ­
m eters can be used as a judge of severity of disease, and to 
m onitor im provem ent during  trea tm ent.
Patients
In 1932. A llen and Brown (2) em phasised the wide spectrum o f disorders 
that may be associated with RP, and they classified patients with 
associated disease as having Raynauds Syndrome (RS) and those without 
as having Raynauds D isease (R D ). In recent years the developm ent o f  
more sophisticated and sensitive laboratory procedures has revealed that 
greater than one half o f  patients with RP have an associated systematic 
disease. Furthermore, long term studies have shown that RD  may be a 
precursor of systemic illness by many years. This had led to the delineation  
o f a third subdivision o f patients with RP, that is “suspected secondary 
(SS)” whereby patients have som e, but not all, o f the criteria required for 
diagnosis of a connective tissue disorder.
The data in this study obtained from 40 patients with R D , 28 patients 
with SS and 42 patients with RS. Results are compared to 50 age, sex and 
smoking matched controls.
j Drury, M cLaughlin, O ’Dowd, Anderson, Sturrock and Forbes Blood Abnormalities in Raynauds Phenomenon
Table 1
jne Plasma levels obtained from patients with RP and normal 
mils (mean ±  SD )
Normals RD SS RS
li nogen ( g / 1 )  2 . 5 1 0 . 9  2 . b ± 1 . 0  3 . 7 1  1 . 2 * 4 . 7 1 0 . 9 * *
diinouen activator
l i t y ( m m ' )  8 6 1 1 5  8 3  ±  1 2  6 5 1 2 0 *  5 6 + 1 4 * *
j i r V I I I . ' C  ( % )  9 3 1 2 0  9 2 1 1 8  1 2 6 ± 2 0  1 S 0 ± 4 2 *  *
| , m ( p g / m l )  1 3  ± 4  1 0 ± 2  3 6 1 7 * *  5 5 1 6 * *
* p().05, ** pO.Ol (Mann W hitney)
lise-line Abnormalities 
libronogen and flbrinoiysis
lability of the RP patient to digest fibrin may be impaired, and it has 
jisuggestcd that this may aggravate the disease through deposition and 
((clearance o f vascular endothelial fibrin (3).
b normal subjects, fibrin is rem oved by enzymatic degradation 
dated by plasmin. Piasmin is produced by cleavage o f its inactive 
cursor Plasminogen, and the rate o f this reaction is determined by the 
jlive proportion of activators and inhibitors o f fibronolysis present.
Hus a decrease in plasminogen activator production from the endothe- 
jwall would lead to increased fibrinogen (m ethod o f Clauss) (4) and 
sninogen activator activity (P A A ) (fibrin plate) (5) in the above group 
patients and control subjects. Results are displayed in Table 1, and 
y a decrease in P A A  and increase in fibrinogen level in patients with 
i Those with RD show no abnormality and this suggests that the 
teased fibrinolysis is a response to endothelial dam age, that is a 
sequence rather than a cause o f the disorder. The increase in plasma 
wsity and decrease in red cell deformability produced by the elevated  
sna fibrinogen, in com bination with fibrin deposition round the vessel 
imay contribute to the severity o f  the sym ptoms o f RS.
Other endothelial products
iddition to plasminogen activator, factor VIII and prostacyclin (PG I2) 
(also released by the endothelium . Factor VIII:c (measured by RIA) is 
jated in patients with RS and normal in those with R D  (Table I). This 
ztase probably again reflects endothelial dam age, but may contribute to 
ihypercoaguable state seen in patients with RS.
Plasma prostacyclin metabolite levels (PG I2M) (6 ) (R IA ) show the 
uepattern, being elevated in patients with RS and normal in those with 
D(Table I). It is known that noxious physical and chemical stimuli, such 
vessel spasm or infusion o f hypertonic dextrose, will promote 
liothelial release o f PGI2. The PG I2 thus formed has a potent 
sxlilator. anti-platelet effect preventing thrombosis in the affected 
set. One might expect therefore that elevated levels o f PGI2 in RS 
«ild ameliorate the symptoms of digital ischaemia. Unfortunately, the 
nelopment o f cellular resistance (7) to these elevated PGI2m lebels 
bws the activation of platelets.
IRed and white blood ceils
iepart played by the red cell has also been studied. Its diameter of 7p is 
tater than that o f the capillaries, so flow in the microcirculation may be 
dcally dependent o f red cell hardness. R ed cell deformability measured 
|afiltration technique (8 ), is decreased in patients with RS (Table III), 
dd temperatures reduce red cell deformability further, as does the 
ddosis present in cold ulcerated fingers, so hard red cells may contribute 
Hhe decreased blood flow. In addition, Kovacs et al showed that the red 
dlsfrom patients with RS were more adherent to the endothelium  than in 
total persons (9 ), and found a similar pattern for PMN leucocytes, 
lese adherent cells could further impair blood flow, 
t Platelets
platelets are activated in the circulation they aggregate and circulate in 
>mps, releasing vasoconstrictor substances such as thromboxane A 2 
ItAj) and serotonin. These two features allow good haemostasis in the 
ftence of tissue lacerations. If. how ever, platelet activation occurs in the 
tonce of haemorrhage, then inappropriate thrombosis will occur and it 
®been suggested that platelet activation may play a part in producing 
Symptoms of RS. We have measured the rate o f platelet aggregation to 
MADP (Malins photometric aggregom eter) (10), and found it to be 
toased in patients with RS.
Table 2
'tolinc r e d  c e ll  a n d  p l a te l e t  r e s u l t s  o b t a in e d  f r o m  p a t ie n t s  w ith  R P  a n d
'total c o n tro ls  ( m e a n ± S D )
Normals RD SS RS
fell deformability 
toire (ratio) l.(K)±().I 1.1010.11 1.35+0.20* 1.4510 .5 5* '**
fetaggregation to ADP 
•change optical densitv/sec) n ± y  12110 1S±6 25 ±6 *
fenboglobulin (pg/ml) 2 0 I X  1S± 11 3 6 1 1 0 * 5 6 1 9 *
* p < 0 .0 5  ( S t u d e n t ’s  te s t )
In addition, we have found elevated levels o f the platelet release 
product B-thromboglobuiin (R IA ) in these patients (Table II). No 
abnormality was detected in patients with R D , suggesting that the 
activation seen in severe disease occurs as a result o f platelet contact with 
damaged endothelium . It is important to note that this activation occurs 
despite elevated plasma PGI2m levels. This is explained on the basis o f the 
platelet resistance to the effects o f PGI2 seen in (7) RS.
Sum m ary (I)
Patients with the severest form  of R P , i.e. those with RS, 
have changes in biochem ical and cellular param eters which 
might contribute to the decreased blood flow seen in this 
group of patients.
It is im portant to note how ever, because of the large 
standard deviations seen in the results, that it is not possible 
to use these m easurem ents to diagnose the type of R P in 
individual patients. In addition, although the most severe 
group (RS) dem onstrate  the abnorm alities, there  is no 
correlation with any of these m easurem ents with duration  
or frequency of spasm  attack  (diary cards) o r with 
hand-tem perature (therm ocouple probe), o r plethysm ogra­
phy (cold challenge, M edim atic SP2) results. H ow ever, we 
can use these abnorm alities to m onitor response to 
treatm ent; O ur results from  previous studies (11) show that 
those subjects given PG I infusion, who dem onstrate 
greater than 20% im provem ent in duration and frequency 
of spasm attacks, have significantly decreased p latelet 
activation and decreased white cell adhesion com pared to 
non-responders.
B. Abnorm alities after cold-challenge
A fter stabilizing for one hour in a tem pera tu re  controlled 
room  (24±1°C ), 15 patien ts with RS im m ersed gloved 
hands into w ater at 37°C for 10 m inutes. A  baseline blood 
sam ple is draw n from the antecubital fossa of one arm . 
T hereafter the hands are im m ersed in cold w ater (10°C) for 
a further five m inutes and  again blood is draw n, this time 
from the o ther arm . R esults were com pared with 15 age and 
sex m atched controls.
Platelet Behaviour
The rate of p latelet aggregation to  2uM  A D P was m easured 
as before, as were B -throm boglobulin  levels and serum  
T xB2, the stable m etabolite  of T xA 2 (R IA ) (11). R esults 
show that p latelet activation takes place even in norm al 
subjects; how ever, the changes are m ost m arked in those 
with RS (Table III). A n increase in red cell hardness has 
also been shown to occur after cold challenge.
Sum m ary (II)
A s with the baseline m easurem ent, cold challenge results 
show an increase in p la telet activation in patients with RS, 
which may contribu te to the decrease in blood flow. It is 
interesting tha t, in contrast to the baseline findings, a 
correlation is obtained  betw een duration  and frequency of 
attacks and the p latelet release products BTG  (r= 0 .65) and 
T xB2 (r= 0 .72). F u rtherm ore , the decrease in p latelet 
release of T xA 2 seen after trea tm en t with nifedipine 
correlates well with the  degree of im provem ent on 
treatm ent, (unpublished observations)
Table 3
Platelet behaviour before and after cold challenge in patients with RS and 
controls (m ean ± S D )
Raynauds Controls
Pre Post Pre Post
Platelet aggregation to A D P  
(% change optical density/sec) 2 4 ± 6 3 3 1 5 1516 2 3 1 6
B-thrombogloubulin (pg/ml) 49 ± 10 7 2 1 9 120117 163122
T xB2 (pg/ml 5 9 1 1 2 103120 120117 163122
* p < 0 .01  (Mann W hitney)
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i c l u s i o n s
/(Iteration in blood biochem istry and cell behaviour 
might contribu te  to decreased blood flow.
Most m arked abnorm alities are in those with endo the­
lial dam age (RS vs R D ). These changes are probably a 
consequence ra ther than a cause of the disease.
Baseline sam pling not useful for individual patient 
diagnosis o r for assessm ent of severity. However, they 
can be used as an assessm ent of response to certain 
drug treatm ents.
tPre and post cold challenge results are also abnorm al in 
RS and the results correlate with severity of disease 
and im provem ent on certain  drug treatm ents.
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INPATIENT CARDIOLOGY IN A RURAL D ISTRICT GENERAL HOSPITAL
J .A . Tulloch 
S tracathro Hospital
Sum m ary: The pattern o f  cardiac admissions to a rural district general hospital has been analysed. Coronary 
artery disease is the m ajor disorder, both as an acute and chronic problem . O ther fo rm s o f  heart disease are 
relatively uncom m on. The absence o f  hypertension and hypertensive heart disease is striking. The deaths were 
m ainly related to coronary artery disease.
Key w ords: Cardiac adm ission pattern , coronary artery  disease.
''HANGING patterns of disease over the years create 
/one of the long term  challenges to medicine. D uring 
s century and in this country, cardiac disease has 
Jergone a great transform ation. D iphtheritic heart dis- 
sehas d isappeared and acute rheum atic fever almost so, 
lerculous pericarditis and its sequel of constrictive 
(icarditis are very rare, rheum atic heart disease is no 
lger the scourge it was and hypertension is now so 
gently discovered and relatively successfully treated  by 
Jeral practitioners that hypertensive heart disease is 
iom seen. O n the o ther hand, coronary artery disease 
iemerged as an ever increasing th rea t, to become the 
ijor cardiac problem  in this country today. Congenital 
art lesions are b e tte r understood , m ore readily diagnosed 
dmore radically and m ore successfully treated  at earlier 
is. Cardiom yopathies of viral and other causes are 
iognised. A e tio lo g ies  are  b e tte r  u n d ersto o d  and  
atments are m ore rational and m ore fundam ental so that 
'he future the pattern  may slowly change. Taking stock at 
irvals is thus of great im portance and this paper 
Resents such an exercise in a small rural district general 
spital.
Serial
lr>ng a 6 m onth  period (A pril to Septem ber 1985) 104 
and 161 fem ales were adm itted  to the medical wards
Jess for correspondence: Dr. J. A . Tulloch, Parklands. Edzcll, Angus
of Stracathro H ospital under one consultant. Forty th ree 
males and 31 fem ales w ere adm itted for a prim arily cardiac 
reason —  the ‘acu te ’ cardiac group, while 61 males and 130 
females had a non-cardiac illness. H ow ever 30 males and 36 
fem ales in the non-cardiac group had a history of a past 
cardiac problem  o r had a co-existing cardiac disorder.
T a b l e  I
A ge Distribution o f the non-cardiac and cardiac admissions. The first 
group is subdivided into the ‘non-acute cardiac group’ and those totally 
non-cardiac. D eaths are given in brackets.
M a l e F e m a l e
Age Totally Non Total Acute Overall Totally Non Total Acute Overall
In Non Acute Non Cardiac Total Non Acute Non Cardiac Total
Years Cardiac Cardiac Cardiac Cardiac Cardiac Cardiac
Under
20 0 0 0 0 0 8 0 8 0 8
20-29 2 0 2 0 2 7 0 7 0 7
30-39 11 0 11 0 11 9 1 10 0 10
40-49 3 2(1) 5(1) 3 8(1) 12 0 12 1 13-
50-59 3 5 8 8 16 13(1) 4 17(1) 3 20(1)
60-69 3 6 9 15(2) 24(2) 9 6 15 6 21
70-79 7(1) 12(3) 19(4) 12(2) 31(6) 24(3) 12 36(3) 13(4) 49(7)
80-89 2 3(1) 5(1) 5(3) 10(4) 11(1) 12(2) 23(3) 8(1) 31(4)
90+ 0 2(1) 2 d ) 0 2(1) 1 KD 2(1) 0 2(1)
Total 31(1) 30(6) 61(7) 43(7) 104(14) 94(5) 36(3) 130(8) 31(5) 161(13)
Annals o f the Rheumatic Diseases, 1988; 47, 96-104
Effects of altering dietary essential fatty acids on 
requirements for non-steroidal anti-inflammatory 
drugs in patients with rheumatoid arthritis: a double 
blind placebo controlled study
J J F  B E L C H , D A N S E L L , R M A D H O K , A O ’D O W D , A N D  R D S T U R R O C K  
From the Centre for Rheumatic Diseases, University Department o f Medicine, Royal Infirmary, Glasgow
s u m m a r y  In rheum atoid arthritis (R A ) benefit from  non-steroidal anti-inflam m atory drugs 
(N SA ID s) is m ediated through inhibition of the cyclo-oxygenase enzym e, thereby decreasing 
production of the 2 series prostaglandins (PG s). The lipoxygenase enzym e is intact, how ever, 
allowing leucotriene (LT) production, e .g ., LTB4 (an inflam m atory m ediator). T reatm ent with 
evening prim rose;oil (E PO ) which contains y-linolenic acid (G LA ) leads to production of the 1 
series PG s, e .g ., P G E ,, which has less inflam m atory effects. Also LT production is inhibited. 
E icosapentaenoic acid (E PA , fish oil) treatm ent provides a substrate for PG s and LTs, which are 
also less inflam m atory. In this study 16 patients with R A  were given 540 mg G LA /day (E P O ), 15 
patients 240 mg E PA  and 450 mg G LA /day (EPO /fish oil), and 18 patients an inert oil (placebo). 
The aim of this study was to determ ine if EPO  or EPO /fish oil could replace N SA ID  treatm ent in 
R A . The initial 12 m onth treatm en t period was followed by three m onths of placebo for all 
groups. Results at 12 m onths showed a significant subjective im provem ent for EPO  and EPO/fish 
oil com pared with placebo. In addition, by 12 m onths the patients receiving E PO  and EPO /fish 
oil had significantly reduced their N SA ID s. A fter 3 m onths of placebo those receiving active 
trea tm en t had relapsed. D espite the decrease in N SA ID s, m easures of disease activity did not 
w orsen. It is suggested that EPO  and EPO/fish oil produce a subjective im provem ent and allow 
som e patients to  reduce or stop treatm en t with N SA ID s. There is, how ever, no evidence that 
they act as disease modifying agents.
Key words: evening prim rose oil, fish oil, prostaglandins, leucotrienes.
Inflammation is a process which occurs in tissues 
after sublethal injury. This is followed by production 
of inflammatory mediators. One such group of 
mediators is the eicosanoids. These are formed from 
precursor essential fatty acids (EFAs). The most 
abundant EFA in the Western diet is arachidonic 
acid (AA), which forms the 2 series prostaglandins 
(PGs), e.g., PGE2, and the 4 series leucotrienes 
(LTs), e.g., leucotriene B 4 .1 2 In general these PGs 
and LTs have pro-inflammatory effects.3 The inges­
tion of a diet rich in evening primrose oil (EPO) will 
increase levels of y-linolenic acid (GLA).4 GLA is
Accepted for publication 1 July 1987.
Correspondence to Dr R D Sturrock, Centre for Rheumatic 
Diseases, University Department of Medicine, Royal Infirmary, 10 
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metabolised to dihomo-y-linolenic acid (DGLA), 
which produces the monoenoic PGs, e.g., PGE,.5 
PGE, has been shown to have important anti­
inflammatory effects.5 DGLA cannot itself be con­
verted to LTs but can form a 15-hydroxyl derivative 
that blocks transformation of AA to LTs.6 Dietary 
DGLA may therefore act as a competitive inhibitor 
of 2 series PGs and 4 series LTs. Animal studies 
have shown that such a diet can both decrease 
inflammatory cell function and suppress inflam­
mation.7-9
High dietary levels of another EFA, eicosapentae­
noic acid (EPA), would provide a substrate for 
production of the 3 series PGs and LTs of the 5 
series.3 10 The potency of LTB5 in inducing leuco­
cyte aggregation is 10% of the potency of LTB4.n
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Again, animal studies have suggested that an anti­
inflammatory effect can be obtained by increasing 
dietary EPA .12 13 The effect of altering EFAs in the 
diet of humans with inflammatory disorders has, 
however, been less well studied. Wright and Burton 
have shown a significant clinical improvement in the 
manifestation of eczema in patients treated with 
EPO ,14 and Baker, Krakauer, and Zurier have 
demonstrated a reduction in human synovial cell 
proliferation in vitro by addition of DGLA.15 Two 
clinical studies of EPO in rheumatoid arthritis (RA) 
proved disappointing.16 17 The respective doses of 
EPO were low and the study periods short, 
however.
Payan et al have shown a decrease in leucocyte 
activity in humans after treatment with EPA,10 and 
Kremer et al suggested that patients with RA had 
obtained benefit after such treatment.18
Another benefit might be expected from manipu­
lating essential fatty acids in the diet of patients with 
RA. ‘First line’ treatment for RA is with non­
steroidal anti-inflammatory drugs (NSAIDs). These 
drugs act by inhibiting the cyclo-oxygenase enzyme 
and therefore decreasing the production of pro- 
inflammatory prostaglandins from AA. AA, how­
ever, is also metabolised by another enzyme, the 
lipoxygenase enzyme, into the LTs.3 Treatment 
with NSAIDs may therefore ameliorate the PG 
mediated aspects of inflammation, but will allow 
those dependent on lipoxygenase action to proceed 
unchecked. Furthermore, NSAIDs may produce 
side effects, e.g., gastric irritation, as a result of 
decreased PG production. Theoretically it should be 
possible to substitute EPO or EPA for NSAID 
treatment; this would allow a decrease in the pro- 
inflammatory PGs and LTs metabolised from AA 
and, as other less inflammatory PGs (e.g., PGE,) 
would be increased, there should be no gastric side 
effects from this therapy.
The aim of our study, therefore, was to determine 
whether EPO or an EPO/fish oil combination 
containing EPA could be substituted for NSAID 
therapy without any deterioration in clinical symp­
toms. The study was double blind and placebo 
controlled.
Patients and methods
P A T I E N T S
Forty nine patients with classical or definite RA as 
defined by American Rheumatism Association 
criteria were enrolled in the study after informed 
consent had been obtained. Permission for the study 
had been received from the regional ethical com­
mittee. All patients required first line (NSAID) 
therapy for control of their symptoms, but none was
considered severe enough to warrant second line 
therapy. Sixteen patients received EPO treatment 
taken as 12 capsules/day, providing a total daily dose 
of 540 mg GLA; 15 received EPO/fish oil capsules 
(12/day), providing a total daily dose of 450 m g. 
GLA and 240 mg EPA; 18 patients received 12 
capsules/day of placebo (liquid paraffin). In addition, 
all capsules contained vitamin E as an antioxidant 
(dose 120 mg/day). As it was considered that 12 
capsules at one time might be inconvenient the 
patients were instructed to take them intermittently 
throughout the day. Most selected four capsules 
three times/day, though some patients took six 
twice/day or three capsules four times/day.
C A P S U L E S
All three types of capsules were supplied by Efamol 
Ltd and were visually identical. They were issued to 
the patients in a randomised double blind fashion.
S T U D Y  D E S I G N
The duration of study was 15 months. For the first 
three months of the study the patients were in­
structed to take the 12 capsules of oil a day, plus 
their full dose of NSAID. From three to six months 
in particular, but also up to 12 months, the patients 
were instructed to decrease or stop their NSAID. 
From 12 to 15 months they were told to maintain, if 
possible, the current dose of NSAID. Patients were 
only to decrease or stop NSAIDs if this could be 
done without exacerbation of RA symptoms. At 12 
months all patients received placebo capsules 
(12/day) without vitamin E. As this was part of the 
study design investigators were aware of the treat­
ment in all patients from 12 to 15 months; the 
patients, however, remained blinded. The aim of 
this placebo phase was to assess whether any 
improvement was due to the antioxidant and radical 
scavenging effect of the vitamin E ,19 and also to 
monitor relapse. The patients attended the clinic at 
monthly intervals for the first six months and 
thereafter at three-monthly intervals.
C L I N I C A L  A S S E S S M E N T
Full metrological assessment was carried out before 
the start of the study and at 3, 6, 12, and 15 months. 
The duration of morning stiffness in minutes, the 
grip strength of left and right hands (mmHg, mean 
of three readings), and the Ritchie articular index20 
were noted. The patients also completed a 10 cm 
visual analogue pain scale, and the occurrence of 
side effects was recorded. In addition, the patients 
were asked to record whether they obtained benefit 
or otherwise from the treatment.
B L O O D  T E S T S
Blood was sampled before the start of the study and
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again at 3, 6, 12, and 15 months. The erythrocyte 
sedimentation rate (ESR) was measured, as were C 
reactive protein (CRP) levels. Haemoglobin (Hb) 
and rheumatoid factor estimation were also carried 
out. Samples from month 0, 6 months, and 12 
months were stored at — 70°C for later analysis of 
plasma and red cell membrane EFA levels; this 
enabled a check of patient compliance.
S T A T I S T I C A L  A N A L Y S E S
Comparability between the treatment groups was 
analysed with the Mann-Whitney U test. Sequential 
analyses were carried out using the two tailed paired 
Wilcoxon test.
Results
Table 1 shows the comparability of the different 
treatment groups, both for clinical and laboratory 
measurements, at the start of the study. No signifi­
cant differences in the patient populations were 
witnessed. Table 2 shows the number of patients 
withdrawn from the study by 12 months. One 
patient in the EPO group and two in the EPO/fish 
oil group were withdrawn owing to increasing 
symptoms of RA, compared with 10/18 of the 
placebo patients (both p<0-001, Mann-Whitney).
The results from all patients who were withdrawn 
were analysed throughout the study on an intention 
to treat basis. The subsequent results are expressed 
as a percentage of baseline so that the different 
group totals can be more easily compared.
EPO /  NSAID  DOSAGE
1 0 0 i------------------------------------------------------------------------------------------------------------------
9 0 -
8 0 -
1 2  M ONTHS6  MONTHS 
MONTHS
9  MONTHSS T A R T 3  MONTHS
V/7A RED U C EDF U L L  D O SE
□  NONE
Fig. la
Fig. 1 is a compilation of results showing the dose 
of NSAID in all three groups before the start of 
treatment and at 3, 6, 9, and 12 months. As one 
EPO and three placebo patients were not taking 
NSAIDs at the start of the study they have not been
Table 1 Comparability o f  groups*
Placebo EPO EPO1 
fish oil
Age (years) 48 46 53
(30-74) (35-68) (28-73)
Duration (years) 5 5 5
(1-20) (1-18) (1-25)
Sex M:F 1:17 1:15 4:11
Morning stiffness (min) 31 47 31
(0-240) (0-120) (0-240)
Grip strength 
(mmHg, right hand) 106 116 105
(53-260) (58-207) (50-300)
Articular index 6 5 7
(0-24) (0-14) (0-12)
Visual analogue scale (cm) 2-3 3-6 3-0
(0-8-0) (0-9-5) (0-7-3)
ESR (mm/h) 30 22 26
(3-75) (4-81) (4-55)
CRP (mg/1) 19 19 13
(8-76) (10-43) (10-38)
Hb (g/1) 118 126 138
(100-155) (88-149) (117-168)
RF (titre) 1/16 1/128 1/128
(0-1024) (0-1024) (0-1024)
'M edian (range).
ESR=erythrocyte sedimentation rate; CRP=C reactive protein; 
Hb=haemoglobin; RF=rheumatoid factor.
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included in these analyses. Eleven out of 15 EPO Table 2 Patients withdrawn fro m  the study by 12 m onths 
patients and 12 out of 15 EPO/fish oil patients 
reduced or stopped their NSAIDs by 12 months, 
compared with five out of 15 of the placebo patients 
(p<0-003, p<0-002, p<0-05 respectively, paired 
Wilcoxon).
Fig. 2 shows a compilation of results for the 
clinical measurements in all three groups. No 
significant change was seen over the study period.
Placebo EPO EPO/ 
fish oil
Increasing RA symptoms 10 1 2
Gastrointestinal upset 0 2 0
Total 10 3 2
EPO -M ARINE /  N SAID  DOSAGE
I I I
3  M ONTHS 6  MONTHS 9  MONTHS
MONTHS
■ ■  F U L L  D O SE  
□  NONE Fig. lb
PLACEBO /  N SA ID  DOSAGE
START 3 MONTHS 6  MONTHS 9 MONTHS 
MONTHS
FULL DOSE 
□  NONE
REDUCED
Fig. lc
Fig. 1 NSAID treatment in the 
three groups o f  patients.
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Fig. 3 shows the three sets of results from the 
laboratory measurements; again no significant 
change in results was noted over the study period, 
though, as with the clinical results, the EPO group 
appeared to fare better.
Fig. 4 shows the subjective response for the three
patient groups over the study period. As one would 
expect, the control group did show a marked 
placebo response of about 40% at six months. 
Surprisingly this persisted throughout the study, 
though it fell to about 30% at 12 months. Despite 
the absence of real change in objective measures of
EPO /  C L IN  RESPONSE
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Fig. 2a
EPO -M ARINE /  C L IN  RESPONSE
2 00
1 5 0
100
5 0
0  AM S T I F F N E S S  
S  V IS U A L  ANALOGUE
G R IP  ST R E N G T H  
A R T IC U L A R  IN O EX
Fig. 2b
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PLACEBO /  CLIN RESPONSE
Fig. 2 Clinical measurements in 
the three groups of patients.
M ONTHS
G R I P  ST R E N G T H
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disease activity, 94% of the EPO and 93% of the 
EPO/fish oil group felt a subjective improvement in 
their condition at 12 months. Most patients on active 
treatment recorded an increase in their general 
sense of wellbeing.
After the three month placebo phase all the EPO 
patients and 80% of the EPO/fish oil patients had 
either returned to baseline or become worse. This 
compares with a relapse rate of only 14% in the 
placebo group.
Four patients experienced side effects. Two in the 
EPO group, one with nausea and one with diarrhoea, 
required to be withdrawn from the study at two and 
one months respectively (Table 2). Two patients in 
the EPO/fish oil group also experienced side effects, 
nausea and headache, but neither patient required 
to be withdrawn from the study.
Estimation of fatty acid levels by high perfor­
mance liquid chromatography in plasma and red cell 
membranes confirmed compliance in all subjects 
apart from one EPO/fish oil patient. This patient 
was one of the two from the group who were 
withdrawn because of increasing RA symptoms.
Discussion
There are good theoretical reasons for suggesting 
that altering dietary EFA may produce anti-inflam­
matory effects similar to cyclo-oxygenase inhibition 
by NSAIDs.5 7 8 9 13 Indeed, additional effects 
might be expected because of the alteration in leuco­
triene production not seen with NSAIDs.6 Further­
more, fewer gastric side effects would be expected 
as PGs of other series, though less inflammatory, 
would be available for gastric cytoprotection.5
In this study we have shown that it was possible 
for some patients with RA to decrease or stop 
NSAID treatment when EPO or EPO/fish oil was 
given. This was achieved with no deterioration in 
clinical or laboratory measures of RA activity. A 
decrease in NSAID dose was also seen in the 
placebo group, though this was much less marked. 
In combination with the 30% placebo subjective 
response, this stresses the importance of placebo 
controlled studies in RA. Four patients (three 
placebo and one EPO) were not receiving any 
NSAID at the start of the study. These patients had 
stopped NSAID treatment without medical advice, 
having developed dyspepsia since their last clinic 
visit. Because of the severity of the gastrointestinal 
symptoms it was decided to enrol them into the 
study.
It was interesting that, despite the lack of ob­
jective improvement in symptoms on the active oils, 
there was a very definite subjective improvement. 
The mechanism of this is unclear, but two alter­
native explanations are possible. EPO has had some 
success in treating premenstrual tension and cer­
tainly it is known to alter brain PG production.21 22 
PGEj may have an antidepressant effect,23 and the 
increase in PGEj after EPO treatment may be 
responsible for the subjective response witnessed in
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the study. An alternative explanation could be that 
decreasing NSAID therapy may remove some nega­
tive effect of these drugs on the patient’s wellbeing.
The relapse in response witnessed after substitu­
tion with placebo capsules was interesting. The fact 
that only 14% of the placebo group relapsed makes 
it very likely that spontaneous remission had oc­
curred in the other placebo patients; all the patients 
in the EPO group either felt worse or returned to
pre-study level symptoms. Interestingly, although 
almost 80% of the EPO/fish oil group relapsed on 
placebo, 20% maintained their improvement. It 
may be that loss of EPA from the cell membrane 
takes longer to occur than with DGLA. Unfor­
tunately, fatty acid analyses of the 15 month samples 
were not carried out so this hypothesis remains 
unchecked. The results from our work appear to be 
in contrast with those obtained by Brown et al16 and
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Fig. 3 Laboratory measurements 
in the three groups of patients.
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Fig. 4 Subjective response in the 
three groups of patients.
Hansen et a l}1 Both these studies used a lower 
dosage regimen of EPO and in both the study period 
was only three months. As can be seen from our 
data, improvement is most marked from six months 
onwards. In addition, their patients stopped 
NSAIDs abruptly before the start of the studies. 
This may have caused a flare in the patients’ 
symptoms in the first weeks as it is unclear how long
EFA treatment should be undertaken before alter­
ation in PG and LT production occurs. This 
combination of NSAID withdrawal and short treat­
ment period may explain the authors’ negative 
findings. It is also possible that these two studies 
looked at different patient populations. All of our 
patients had mild RA as shown by the clinical and 
laboratory values in Table 1. In contrast, these other
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two groups appeared to study patients with more 
severe disease; in particular the group studied by 
Hansen et al had markedly higher ranges of ESR 
and much lower ranges of Hb.
Kremer et al showed benefit in RA with EPA 
treatment18; our work cannot be compared with this 
study, however, as we used EPA only in combina­
tion with EPO. Nevertheless, he did show an 
improvement at three months and certainly this 
agrees with our data, where the combined therapy 
did seem to produce an earlier response. There did 
not, however, appear to be any other differences 
between the EPO and the EPO/fish oil groups. It is 
possible that the addition of EPA had no effect and 
the lower dose of EPO was sufficient to allow 
NSAID withdrawal; it is also possible that the fish 
oil contributed to the effect of the EPOs, thus 
making the two groups indistinguishable. In retro­
spect a more suitable study design would appear to 
have been EPO versus fish oil versus placebo; 
previous work, however, had suggested a synergism 
between the two EFAs24 which we wished to 
investigate.
In conclusion, therefore, we have shown that it is 
possible to decrease or stop NSAIDs in some 
patients with RA by introducing EPO or EPO/fish 
oil treatment. It should be noted, however, that, 
although the patients claimed a subjective improve­
ment, there was no change in any of the measure­
ments conventionally used to measure disease 
activity. It is unlikely, therefore, that long term 
therapy with these EFAs would alter the course or 
prognosis of the disease. It would seem that these 
oils may be best used in clinical situations where 
NSAID therapy should be avoided, for example in 
patients with peptic ulceration or renal impairment.
We would like to thank Dr Charles Stewart of Efamol Ltd for 
providing the capsules for the study. This work has been supported 
by a grant from Action Research for the Crippled Child, and their 
help is gratefully acknowledged.
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Leukotriene B4 Production by Peripheral Blood 
Neutrophils in Rheumatoid Arthritis
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Belch JJF, O ’Dowd A , Ansell D , Sturrock RD. Leukotriene B4 production by peripheral 
blood neutrophils in rheumatoid arthritis. Scand J Rheum atology 1989; 18: 213-219.
Leukotriene B4 (LTB4) is an activator o f  white blood cells (W BC) and it has been suggested  
that its inhibition may be useful in rheumatoid arthritis (RA). Its production by peripheral 
WBC has not yet been investigated. We measured LTB4 production in 105 patients with 
RA and compared it with 59 matched controls. C-reactive protein (CRP) and ESR  were 
measured in 90 patients and correlated with LTB4 values. Ten millilitres o f blood were 
drawn. Separation was undertaken to obtain polym orphonuclear leukocytes (PM N) which  
were stimulated with calcium  ionophore, and the supernatant was frozen for radioimmuno­
assay o f  LTB4. Results show that RA patients produce significantly higher levels o f  LTB4. 
It has been suggested that blockage o f  the cyclo-oxygenase enzym e by non-steroid anti­
inflammatory drugs (N SA ID ) leads to increased production o f  LT via the lipoxygenase  
enzym e. Twenty-one patients not taking N SA ID  were compared with 84 on therapy. There 
was no significant difference. A linear regression was used to obtain Pearson’s correlation  
coefficients. With LTB4 and CRP, r= 0 .3  (p<0.003). With LTB4 and E SR , r= 0.25 (p < 0.02). 
Low but significant correlations with CRP and E SR  were obtained.
Key w ords: leukotriene B4, rheumatoid arthritis, polymorphonuclear leukocytes, erythro­
cyte sedimentation rate, C-reactive protein.
J. J. F. Belch, D epartm en t o f  M edicine , N inew ells H osp ita l an d  M edica l School, D undee  
DDI 9SY, Scotland.
The polyunsaturated essential fatty acid (EFA) arachidonic acid (AA) plays a unique role 
as a precursor molecule for potent mediators with far-ranging effects. The best recognised 
of these are the prostaglandins (PG) (1). Recently, however, the discovery of another 
group of biologically active derivatives of AA, the leukotrienes (LT), has provoked much 
interest (2). These compounds, formed via the action of the 5-lipoxygenase enzyme, have 
pronounced biological effects which are related to immediate hypersensitivity responses 
and inflammation. LTB4 in particular would appear to play a significant role in the 
inflammatory process (3). Polymorphonuclear leukocytes (PMN) present the first line of 
defence against foreign and pathogenic stimuli. As such they have to perform several 
functions. LTB4 has been shown to promote chemokinesis, chemotaxis, aggregation and 
degranulation of the PMN, so we know that LTB4 plays a part in the general picture of 
inflammation. However, there is little evidence to support a hypothesis that excess LT 
production contributes to states of excess pathological inflammation such as rheumatoid 
arthritis (RA). Klickstein et al. (4), using high-performance liquid chromatography 
(HPLC), detected excess lipoxygenase products in the synovial fluid of patients with RA 
compared with osteoarthritic controls. These findings were supported by Davidson et al. 
in 1983 (5). However, these studies do not clarify whether excess LTB4 was being 
produced by the PMN or whether the increased amounts of LTB4 merely reflected an 
increased PMN population within the synovial fluid.
The aim of our study was therefore to determine the amount of LTB4 produced by 
peripheral PMN after maximal stimulation in patients with RA compared with normal
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controls. The results obtained were correlated with three conventional markers for RA 
disease activity: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels 
and the Ritchie articular index (Al).
METHODS
P atien ts
One hundred and five patients with classical or definite RA (ARA criteria) (7), were enrolled in the 
study after informed consent had been obtained. O f these, 84 patients were taking standard d oses o f  
non-steroidal anti-inflammatory drugs (N SA ID ). The N SA ID  used by these patients were various, all 
being taken at or near the maximum dose for the drug. Tw enty-one patients were not on N SA ID . 
They had stopped their N SA ID  therapy at least 2 weeks prior to sampling (median 6 w eeks, range 
2-24 weeks). N o  patient was taking any disease-m odifying drug. Ethical perm ission for the study was 
obtained from the regional Ethical Com m ittee.
A ssessm en t
All patients attended the out-patient department, where 90 out o f  105 had a Ritchie articular index 
calculated (6).
B lood  sam pling
Twenty millilitres o f  blood were drawn from the anticubital fossa o f  these 90 RA patients. Five 
millilitres, anticoagulated with EDTA, were taken for m easurement o f ESR (W estergren method). 
Five millilitres o f  clotted blood were also taken for later analysis o f  serum CRP (pg/ml). The final 10 
ml was anticoagulated with heparin (10 p/ml) for m easurement o f  LTB4 production from PM N. A  
further 15 patients, making a total o f  105 RA subjects, had only the LTB4 levels measured.
UBi, assay
PM N cell separation was carried out by F icoll-H ypaque centrifugation (8). The PM N were counted  
and then incubated at 37°C for 5 min with the calcium ionophore A23187 (1 pg/ml). A liquots o f  the 
supernatant were then taken and stored at — 70°C for later radioimmunoassay (RIA) o f  LTB4 using a 
m odification o f  the method devised by Salmon et al. (9). This RIA was carried out using [3H]LTB4 
from Amersham International, Am ersham , U K , and the results were expressed as ng/106 cells. In our 
laboratory this assay has an intra-assay variation o f  6 .6 % and an inter-assay variation o f  8.5% . The 
minimum detection limit is 7.8  pg. The non-specific binding o f  the antibody is shown in Table I.
Controls
Fifty-nine age- and sex-m atched normal volunteers also had blood sampled for estim ation o f  PM N  
production o f  LTB4 and CRP levels.
Table I. Cross-reactivity o f assay antibody
%  Cross-reactivity
Compound (50% B /B 0 replacement)
LTB4 100
LTC4 0.03
LTD4 0.03
Diastereoisom ers o f  5,12-dihydroxy-6,8,10- 
trans- 14-ci.s-eicosatetraenoic acid 3.3
Diastereoisom ers o f  5 ,6-diH E TE 1.6
5(S), 12(S)-diH ETE 0.14
5-HETE 0.03
12-HETE 2.0
11-HETE 0.04
15-H ETE < 0 .03
PGE2 and other prostaglandins < 0 .03
Arachidonic acid < 0 .03
LTBS 17.0
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RESULTS
Table II shows the comparability between the RA patients and the controls. There were no 
significant differences in age between the two groups. The medians and ranges for the 
clinical and laboratory results from RA patients are also shown in this table.
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Fig. 1 shows the L T B 4 produced by PMN in both patients and controls. The levels from 
RA cells are elevated (p<0.002, Mann Whitney U).
Fig. 2 shows the RA patient population divided for drug therapy. As can be seen, there 
is no significant difference between those on or off NSAID.
With a linear regression, the Pearson’s correlation coefficient between LTB4 and 
articular index has an r value of 0.08 (p=0.49). The correlation between LTB4 and ESR has 
an r value of 0.25 (p<0.02) and the correlation between LTB4 and CRP is r=0.3 (p<0.003) 
(Figs. 3 and 4).
DISCUSSION
Klickstein et al. (4) and Davidson et al. (5) have previously demonstrated increased levels 
of LTB4 in synovial fluid from RA patients. However, these findings did not differentiate 
between increased production by the RA cell and increased amounts secondary to in­
creased cell numbers. We have shown that LTB4 production from a standard number of 
peripheral PMN is increased, suggesting a real difference between RA cells and those from 
normal controls.
Table II. Clinical and laboratory measures on RA patients and normal volunteers (median 
range)
RA Controls
A ge (years) 48 (28-68) 35 (22-60)
Articular index 3 (0-20) -
ESR (mm/h) 31 (3-99) -
CRP (ng/ml) 17 (10-88) All < 1 0
LTB4 (ng/106 cells) 28 (12-44) 20 (3-37)
LTB4 on N SA ID  (n = 84) 28 (13-44) -
LTB4 o ff N SA ID  (n= 2\) 26 (18-42) -
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The reason for this increased LTB4 production is not yet clear. It had been suggested 
that the use of NSAID might be a contributing factor (1). NSAID inhibit the cyclo- 
oxygenase enzyme and PG production. Thus, larger amounts of A A could be available for 
LT production via the 5-lipoxygenase enzyme. However, our results show no difference 
between those who took NSAID and those who did not. It is unlikely therefore that 
diversion of the substrate plays a major role in the finding of increased LTB4 production in 
RA.
More recently assay systems have been devised to measure the enzymes involved in AA 
metabolism. An excess of either phospholipase A2 or the 5-lipoxygenase enzyme could 
increase the metabolism of AA to LTB4. Work is currently under way to assess this 
hypothesis and could be extended to family studies.
Even though we do not yet fully understand the mechanism of this increased LTB4 
production, such an increase may produce pro-inflammatory effects (3). In addition to the 
effect of LTB4 on the PMN, there are effects on other cell types. Recently LTB4 has been 
implicated in the chemotaxis of eosinophils and the release of peroxidase from these cells. 
LTB4 may also be a mediator of lymphocyte responses. A number of workers (10, 11) have 
suggested that products of the 5-lipoxygenase pathway inhibit lymphocyte activities in 
vitro, in particular that LTB4 reduce the lymphocyte response to mitogen. This field of 
study, however, has not been fully explored and reports are conflicting (12). Nevertheless 
it is probable that LTB4 plays a role in modulating lymphocyte behaviour. In addition 
LTB4 can interact and augment the action of other inflammatory mediators (13, 14, 15). 
These interactions may be important in the development and persistence of inflammation 
in RA.
Whether excess LTB4 is a cause or a consequence of inflammation is unknown. It is 
interesting to suggest, however, that whether the excess is primary or secondary, a 
decrease in LTB4 production may allow improvement in the clinical symptoms of inflam­
matory diseases. Our results show only a weak correlation with three conventional 
measures of disease activity, so it is unlikely that decreasing LTB4 production will have 
any disease-modifying effect. However, such therapies may decrease the inflammatory 
symptoms in the same way as NSAID do via cyclo-oxygenase inhibition. The results from
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our recent study of evening primrose oil (EPO) as a treatment for RA (16) may be 
secondary to a decrease in LTB4 production. EPO contains the EFA gamma-linolenic acid 
(GLA). In contrast to AA, GLA’s metabolites are far less inflammatory; indeed GLA 
cannot itself be converted to LT but forms an inert 15-hydroxyl derivative that blocks 
transformation of AA to LT (17). LTBj produced from another EFA, eicosapentaenoic 
acid, is only 10% as potent as LTB4 (18). This is found in fish oil, and Kremer et al. (19) 
have suggested that such a treatment might be useful in RA, perhaps mediating its 
beneficial effects through decreased LTB4 production.
A more straightforward approach to therapy would be the development of a specific 5- 
lipoxygenase inhibitor. However, there are only a few compounds available and they are 
only now reaching the stage of clinical trials. Most of the known compounds are not 
selective and also inhibit the cyclo-oxygenase enzyme. It has been suggested that such a 
dual effect might produce the clinical benefit seen with corticosteroids (which inhibit the 
action of phospholipase A2) without producing steroid-like side effects (20).
In conclusion, therefore, we have demonstrated that LTB4 production is increased in 
patients with RA. This finding does not appear to depend on NSAID therapy. There are 
weak but significant correlations with two conventional measures of disease activity. 
Although there is no evidence to suggest that inhibition of LTB4 would have a disease- 
modifying effect, in view of its pro-inflammatory effects we suggest that inhibition of its 
production might improve the clinical symptoms of RA.
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BLOOD COAGULATION AND RHEOLOGY IN PATIENTS WITH 
VIBRATION W H ITE FINGER DISEASE
J F Belch, FRCP,MD. M McLaren, PhD. M Chopra, PhD.
A ODowd, BSc. G D O Lowe, FRCP, MD. C D Forbes, FRCP, MD.
A bstract
In vibration white finger (VWF) the abnormal response of blood vessels to cold has been 
clearly documented. Less fully explored has been the potential abnormalities in blood 
coagulation and rheology. We have investigated these in 35 patients with VWF grade III 
(Taylor Pelmear scale) compared to 25 matched controls. Forty-two patients with secondary 
Raynaud’s syndrome and systemic sclerosis were used as positive controls. VWF patients had 
less deformable red cells than controls [1.25 (0.86-2.0) vs 1.00 (0.56-1.5), p<0.05 MW], 
white blood cells released more leukotriene B4  [26.0 (14.4-39.4) vs 17.2 (6.0-38.0), p<0.01
MW] VWF patients had lower plasma thiols [450 (417-510) vs 480 (418-555), p<0.01 MW] a 
trend towards brisker platelet aggregation to collagen [17 (6-32) vs 11 (3-32), p=0.05 MW] 
higher fi  thromboglobulins levels [37 (20-55) vs 23 (12-41), p<0.01 MW] elevated whole 
blood viscosity at low shear rate [20.0 (15.3-26.2) vs 17.9 (11.8-20.3) p<0.01 MW] higher 
fibrinogens [3.1 (2.1-4.8) vs 2.6 (2.0-4.0), p<0.01 MW] lower plasminogen activator activity 
[6 8  (45-95) vs 106 (64-151), p<0.01 MW], and higher plasma factor VIII von Willebrand 
factor [175 (72-242) vs 100 (38-195) p<0.01 MW]. Results in systemic sclerosis were similar 
to those of the patients with VWF.
We have demonstrated that VWF is a true secondary Raynaud’s syndrome with abnormalities 
in blood clotting and rheology. Although the tests are not specific enough to be used as a 
diagnostic test they may contribute to decreased blood flow, and provide a rationale for the use 
of antithrombotic drugs in VWF.
Key words: Vibration white finger. Red blood cells.
Leukotriene B4 . 
Platelet aggregation. 
Blood viscosity.
Free radicals.
B thromboglobulin. 
Fibrinolysis.
Factor VIII von Willebrand factor.
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In troduction
Operators of hand-held vibrating power tools have long complained of tingling and numbness 
in their hands and of their fingers blanching. These episodes of vibration white finger (VWF) 
were first reported in the literature between 1911 and 1920 (1,2) and the link with VWF and the 
episodic digital ischaemia in response to cold reported by Raynaud in 1862 was quickly 
recognised (3). VWF is now known to be one of the secondary causes of Raynaud's 
Syndrome (RS).
The pathophysiology of VWF is still not fully known. Most hypotheses involve vibration 
induced damage to the blood vessel wall (4,5). In patients with secondary RS caused by other 
clinical conditions, such as connective tissue disorders (C/T), blood coagulation and rheology 
may be abnormal (6). It is generally agreed that these changes are not a primary phenomenon 
but develop later, probably as a result of blood passing over damaged blood vessels. No 
matter whether cause or consequence of the initial vessel damage, the resultant effects of 
disordered coagulation and rheology is to worsen blood flow and augment the clinical 
symptoms of secondary RS.
The aim of this study was to investigate aspects of blood cell and plasma behaviour in patients 
with VWF compared to matched controls and to patients with secondary RS and an associated 
C/T disorder.
Patients and Methods
Thirty-five patients with VWF were enrolled in the study. All had grade III VWF as described 
by Taylor et al (7), thus all had marked blanching of the digits and the condition significantly 
interfered with their activities at work and play. All were or had been employed as 
boilermakers exposed to vibrating machines such as chippers, grinders and buffs. Results 
were compared to 25 age, sex and smoking matched workers not exposed to vibration. As a 
positive control 42 patients with secondary RS associated with systemic sclerosis (SS) were 
also studied. Clinical details of these patients are shown in Table 1. As VWF is predominantly 
a disease of men and SS of women, these 2 groups could not be matched for sex. However, in 
this age group there is not thought to be a difference between the sexes in the tests measured.
None of the patients had taken aspirin or other medications known to interfere with the tests in 
the previous 2 weeks. Smokers were asked to refrain from smoking from 12 midnight prior to 
the day of testing. All samples were taken at the same time of day after a standard light
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breakfast. Blood was taken through a 19 gauge butterfly needle with minimal venous 
occlusion. The following tests were performed:
Red cell deformabilitv. 5 ml of blood were anticoagulated with edetic acid (EDTA 1.5 mg/ml) 
and red cell deformability was measured by a positive pressure filtration method (8 ). A syringe 
containing Tris-saline buffer solution was connected to a disposable polycarbonate filter 
(nucleopore, pore diameter 5 p). A constant flow rate of 1.5 ml/min was applied and filtration 
pressure measured via a pressure transducer and recorded for 6  min. Washed red blood cells 
were suspended in buffer (haematocrit 0.05) and were then filtered the same way through the 
same filter. Red cell deformability was assessed by the ratio of the pressure generated by the 
flow of the cell suspension to the pressure generated by the flow of buffer.
Leukotriene B/\ (LTB4 ). 10 ml of blood were anticoagulated with sodium heparin (10 u/ml). 
The polymorphonuclear leukocytes (PMNs) were separated over Ficoll Hypaque and 
stimulated with calcium ionophore A23187 (1 p/ml). The resultant supernatant was aspirated 
and stored for later radio-immunoassay (RIA) for LTB4  (9). As this assay was developed later
than the others 25 VWF patients, 34 SS patients and 30 controls were sampled for this test.
Plasma thiols (PSH). PSH was estimated as a measure of free radical (FR) activity. This was 
measured using a photometric analysis using a technique first described by Ellman (10). As 
this assay was also a later development, 12 VWF patients, 15 SS patients and 16 normals were 
studied.
Platelet aggregation. 10 ml of blood were anticoagulated with 3.8% Trisodium citrate (9:1 v:v) 
The rate of platelet aggregation (PA) to 2 pmol adenosine 5-diphosphate (ADP) in platelet rich 
plasma (PRP) was measured using the turbidimetric technique described by Bom (11) (Malin 
photometric aggregometer). Aggregation to 1 pg of collagen was also measured.
ft thromboglobulin fftTG). This platelet release product was measured by RIA using an 
Amersham kit.
Blood viscosity. Blood viscosity was measured in a Contraves LS30 rotational viscometer at 
37°C at high shear rate (9.45 s- *) and low shear rate (0.95 s~l) both corrected to a standard 
microhaematocrit of 0.45 (Hawksley, 13,000 g for 5 min) using regression equations derived 
from 2 0 0  samples (1 2 ).
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Fibrinogen and fibrinolysis. 10 ml of blood was anticoagulated with 3.8% Trisodium citrate 
(9:1, v:v) Fibrinogen was measured using an automated coagulometer (method of Class) (13). 
Plasminogen activator activity was measured by estimating the area of lysis on a fibrin plate 
(14).
Factor VIII von Willebrand factor (fVIII vWF). Citrated blood was again used to measure 
fv n i vWF using the Laurell rocket technique (15).
R esults
Red cell deformability. Using the pressure ratio Pi/Pb the red cells in both patient groups were 
harder than the cells from the controls (p<0.05, Mann-Whitney U) (Table 2).
Leukotriene Bq LTB4  production from stimulated WBCs was increased in both VWF and SS 
(p<0.01, p<0.05 respectively, Mann-Whitney U). This suggests a degree of activation of the 
WBCs and supports the hypothesis of an inflammatory element in VWF (7) (Table 2).
Plasma thiol. PSH was lower in both patient groups (p<0.01, Mann-Whitney U) suggesting 
an excess of free radical generation (Table 2).
Platelet aggregation. There was no significant difference between the groups for PA to 2 pm 
ADP. However, there was a trend towards brisker PA to 1 pg collagen in the VWF group and 
a statistical difference between the SS patients and controls (p=0.05, p<0.02 respectively, 
Mann-Whitney U) (Table 3).
B thrombolglobulin. Despite there being no statistical difference in PA in VWF there is still 
evidence of platelet activation, as demonstrated by the increased levels of BTG in VWF 
(p<0.01, Mann-Whitney U). BTG is also increased in SS (p<0.01, Mann-Whitney U) 
(Table 3).
Blood viscosity. Whole blood viscosity at low shear rate (0.95s-*) is significantly increased in 
both patient groups (p<0.01, Mann-Whitney U). There is no difference between the groups at 
high shear rate (9.45s-*) (Table 3).
Fibrinogen and fibrinolysis. As expected from the whole blood viscosity results plasma 
fibrinogen levels are significantly increased in both VWF and SS (p<0.01, Mann-Whitney U). 
Plasminogen activator activity was significantly decreased in both patient groups (p<0 .0 1 , 
Mann-Whitney U) (Table 3).
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fVIII vWF. Both VWF patients and SS patients showed a statistically significant increase in 
plasma fVIII vWF reflecting a degree of vascular damage in both patient groups (PcO.Ol, 
Mann-Whitney U) (Table 4).
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DISCU SSIO N
In this study we have shown abnormalities of blood coagulation and rheology in VWF similar 
to those found in secondary RS. These findings may be relevant. The diameter of the red 
blood cell is greater than some of the capillaries, so flow in the microcirculation may be 
critically dependent on red cell hardness. The white cell is being increasingly recognised as 
being important, not only in inflammation and immunity, but also in thrombosis (16). Hard 
white cells or clumps of aggregated WBCs may impede the circulation. Activated WBCs are 
less deformable and aggregate. LTB4  is a WBC release product which promotes WBC
activation (17) and we have shown this to be increased in VWF. WBCs also release noxious 
products, such as free radicals (FRs). FRs are prethrombotic (18) via their ability to damage 
the endothelium and by selectively increasing production of the platelet aggregant thromboxane 
A2 . As short lived species they are difficult to measure directly. However, plasma thiol levels
(PSH, mainly albumin thiol) shows the degree of oxidation of the plasma. Albumin 
conformation is altered by FR generation and therefore PSH is a good measure of FR activity. 
The decreased levels of PSH seen in VWF reflect increased FR production. Similarly, if the 
blood platelet is activated it aggregates and releases. We have shown increased plasma BTG in 
VWF. Bovenzi et al (19) also failed to show an increase in platelet aggregation in VWF 
patients between grade ON and grade I (Taylor Pelmear scale) (7). A more sensitive measure 
of platelet activation may be the BTG release into the plasma. Our results suggest, therefore, 
that there is an early degree of platelet activation which is not manifest by a frank increase in 
aggregation rate.
In a normal subject fibrin is removed by the enzymatic degradation mediated by plasmin. 
Plasmin is produced by cleavage of its inactive precursor plasminogen under the control of 
plasminogen activators. A decrease in activator activity, as shown here, may aggravate VWF 
through poor clearance of vascular endothelial fibrin. Fibrinogen is increased which will 
contribute to the elevated whole blood viscosity at low shear rate, witnessed here and also by 
Okada et al (20). FVIII vWF is released from the endothelium and levels have been shown to 
be increased in diseases in which there is vascular damage (21). It may also predispose to 
thrombosis by its effects on platelet aggregation and in the clotting cascade.
It is easy to diagnose VWF during an attack but it is difficult to be sure of a diagnosis when the 
patients are seen between attacks. As VWF is now recognised as an occupational disease, 
eligible for compensation, it is desirable to devise tests that will establish the diagnosis clearly. 
Although statistical differences are seen between the controls and patients with VWF in our 
tests, the degree of overlap of the results is such that disappointingly they cannot be used as a
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means of diagnosis. Nevertheless, these findings may have considerable importance, as not 
only may they contribute to the worsening of the VWF symptoms via their deliterious effects 
on blood flow, but they may contribute to diseases elsewhere in the body. Elevated blood 
pressure and electrocardiogram abnormalities are more frequently reported in VWF patients 
than in controls (2 2 ) and the abnormalities described here by us may contribute to decreased 
coronary flow. The majority of VWF patients also suffer from a degree of industrial deafness 
thought to be due to noise exposure. There is, however, a synergistic effect of vibration and 
noise on this deafness (23) and the explanation may be that vibration produces constriction in 
the cochlear vessels with a contribution to the decreased flow from the rheological and blood 
clotting abnormalities (24). Furthermore, most of the recent advances in the treatment of 
Raynaud's Phenomenon have come from drugs which affect blood clotting and rheology (25). 
It may be, therefore, that the delineation of these abnormalities in this group of patients may 
give a rationale for these drugs to be studied in VWF.
In conclusion, therefore, we have demonstrated that VWF is a true secondary RS with 
abnormalities in blood clotting and rheology. Although the tests are not specific enough to be 
used as a measure of diagnosis for this disorder, they may contribute to the decreased blood 
flow and provide a rationale for the use of antithrombotic drugs as a treatment for severe VWF.
TABLE 1 - Clinical data and comparability of Groups
VWF* SS** Controls
Numbers 35 42 25
Median age in years (Range) 49 (27-65) 43 (28-68) 44 (25-63)
Sex M/F 35:0 5:37 25:0
Smokers 23 25 19
Median duration of symptoms in years 5 9 -
(range) (3-20) (2-15) -
Median duration of vibration exposure (years) 29 - -
(range) (5-49)
VWF* = Vibration White Finger 
SS** = Systemic Sclerosis
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Table 2 - Red cell deformability. WBC release of LTB^ and plama thiols
VWF SS Controls
Red cell deformability Median 1.25 1.25 1 .0 0
(pressure ratio) Range (0 .8 6 -2 .0 ) ( 1 .1-2 .8 ) (0.56-1.5)
LTB4  (ng/106  cells) Median 26.0** 23.5* 17.2
Range (14.4-39,4) (14.4-44.0) (6.0-38.0)
PSH (pML-1) Median 450** 445** 480
Range (417-510) (375-475) (418-555)
*p<0.05; **p<0.01 (Mann Whitney U)
Table 3 - Platelet aggregation to ADP and collagen, and plasma BTG
VWF SS Controls
Platelet aggregation to 2 pmol ADP Median 17 16 15
(% change optical density/sec) Range (7-30) (8-36) (9-30)
Platelet aggregation to 1 |ig collagen Median 17 19* 11
(% change optical density/sec) Range (6-32) (10-69) (3-32)
BTG (pg/ml) Median 3 7 ** 41** 23
Range (20-55) (15-69) (12-41)
*p<0.02; **p<0.01 (Mann Whitney U)
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Table 4 - Whole blood viscosity, fibrinogen, plasminogen activator activity and fV II I  vWF
VW F SS C o n tr o ls
V ic o s ity  0.95s" * M e d ia n 20.0* 20.1* 17.9
(in  P a .s) R a n g e (15 .3-26 .2) (15 .8-31 .9) (11.8-20.3)
V isc o s ity  9.45s" * M e d ia n 5 .71 5.92 5.79
(in  P a .s) R a n g e (5.21-6 .94) 3.2* (3.12-6.66)
F ib r in o g e n  (g /L ) M e d ia n 3 .1 * 3.2* 2.6
R a n g e (2 .1-4 .8) (1 .3-6 .8) (2.0-4.0)
P la sm in o g e n  activ a to r a c tiv ity  (% )M edian 6 8 * 61* 106
R a n g e (45-95) (3 1 -8 8 ) (64-151)
fV III vW F (%) M e d i a n 1 7 5 * 198* 100
R a n g e (72-242) (76-390) (38-195)
*p<0.01  (Mann Whitney U) 
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